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Abstract
Photodynamic therapy (PDT) has been widely used in recent years for the treatment of 
cancers. However the growing problem of drug resistance in bacteria has led to PDT 
being used to treat bacterial infections in a new type of therapy called Photodynamic 
Antimicrobial ChemoTherapy (PACT). In PACT a drug is administered and allowed to 
accumulate within the target molecules prior to irradiation with red light. This produces 
singlet oxygen and other reactive oxygen species which target multiple areas within the 
cell leading to a mode of therapy that is less susceptible to the emergence of bacterial 
resistance.
The development of an appropriate assay for use in PACT was undertaken, looking at 
various parameters which might affect cell kill. These parameters included incubation 
time, light dose (varying fluence and fractionating), drug concentration and methods of 
determining cell viability. The most important factor in achieving cell kill via a PDT 
effect was found to be the length of time with which the drug is allowed to incubate with 
the cells prior to irradiation. The optimum incubation time of bacterial cells with drug 
prior to irradiation was found to be 5 minutes.
Cationic photosensitizers are used in PACT due to their ability to interact with the 
negatively charged surface of the bacterial cell wall. Several different synthesis were 
attempted to produce multiply cationic porphyrins.
Initially the synthesis of four tetra cationic porphyrins bearing highly fluorinated side 
chains was attempted. Namely these were 5,10,15,20-tetra-(4-AT-(lH, 1H, 2H, 2H- 
perfluorohexyl)-pyridyl) porphyrin (66), 5,10,15, 20-tetra-(4-#- (1H, 1H, 2H, 2H- 
perfluorododecyO-pyridyl) porphyrin (67), 5,10,15, 20-tetra-(4-(^-(lH, 1H, 2H, 2H- 
perfluorohexyl)-dimethylanilinium) porphyrin (68) and 5,10,15,20-tetra-(4-(AT-lH, 1H, 
2H, 2H-perfluorododecyl)-dimethylanilinium) porphyrin (69). However it was found that 
the alkyl iodides would not couple to the porphyrins, even under severe conditions. The
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purification of reactions which had partially reacted, were found to be problematic due to 
the porphyrins sticking to silica.
The syntheses of several different octa cationic and dendritic porphyrins were attempted 
with varying degrees of success.
Amines at physiological pH are cationic and therefore it was decided to attempt the 
synthesis of 5,10,15,20-tetra-(4-(aminomethyl)phenyl) porphyrin (70). Several different 
methods were used in the attempted synthesis, however all proved problematic.
It was decided to utilise parallel synthesis to produce a number of cationic 
photosensitizers. These were successfully synthesised and contain phosphorus, nitrogen 
or arsenic cations. The R groups surrounding the cations vary in 2 ways; either the 
aliphatic chain length varies from methyl to butyl or the aromatic vs. aliphatic character
differs.
In total 11 compounds were synthesised and a further 3 were donated by Dr R Hudson to 
be screened in-vitro against both Gram negative and Gram positive bacteria in order to 
determine whether any structure activity relationships could be established.
The results of the bacterial assays for the compounds with phosphorus cations, showed 
that, with the exception of 5,10,15,20-tetra-(4 ((trimethylphosphomunryi)methyl) 
phenyl) porphyrin tetrabromide, PDT activity decreased as chain length increased. This 
was also found to be true in the case of the compounds with nitrogen cations, with the 
exception of both 5,10,15,20-tetra-(4-((trimethylamino)methyl)phenyl)porphyrin 
tetrabromide (92) and 5,10,15,20-tetra-(4-((triethylamino)methyl)phenyl)porphyrin 
tetrabromide (82), which gave no cell kill.
In general it was found that compounds with aromatic groups surrounding the cations 
have less activity than those with aliphatic groups. Differential activity was seen using 
the compounds synthesised and some idea of optimum structure derived, with 5,10,15,
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20-tetra-(4-((tripropylphosphoniumyl)methyl)phenyl) porphyrin tetrabromide (90) and 5, 
10,15,20-tetra-(4-((tripropylamino)methyl)phenyl) porphyrin tetrabromide (93) being 
the most active over a broad spectrum. Interestingly a difference was noted between the 
activities of S. Aureus and MRS A, possibly due to their different surface structures. 
Despite the limited range of compounds made, the results in this thesis show that 
porphyrins can be synthesised and optimized for use in PACT.
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Chapter 1. Introduction.
1.1 Aim
Antibiotics have commonly been used to control bacterial infections, however in recent 
years resistance is becoming more of a problem. The aim of this project is to look at a 
new way to treat bacterial infections. Photodynamic antimicrobial chemotherapy (PACT) 
is one way in which this could be addressed. The production of singlet oxygen by 
porphyrins means that multiple sites within the microorganism could be targeted in order 
to overcome the bacteria's ability to develop resistance. This project concentrates on the 
synthesis of a library of catiomc porphyrins substituted with either nitrogen or 
phosphorus-centred cationic groups. A bacterial assay has been developed for use in 
PACT and the compounds screened, using the optimised protocol, to test their potential 
for use in the photodynamic inactivation of bacteria.
1.2 Bacteria
1.2.1. The Problem of Bacterial Infection.
Although some bacteria are vital for our everyday health and well being they can also 
cause infection, and methods of eradicating them are needed. Bum victim's wounds are 
most commonly infected with bacteria such as Staphylococcus aureus (Gram positive 
bacteria), Pseudomonas aeruginosa and Klebsiella species (Gram negative bacteria). 
Once in the wounds the bacteria can spread and locally impede wound closure [1] or 
enter the vascular system. Sepsis and endotoxemia occur when bacterial infections 
overcome both antibacterial agents administered and the bodies' systemic immune 
responses. S. aureus can excrete several protein exotoxins which produce diverse 
systemic toxaemias, toxic shock syndrome toxin, and exfoliate toxin which causes 
scalded skin syndrome. The Gram negative bacteria produce strain-specific 
lipopolysaccharide endotoxins that can induce life-threatening endotoxic shock. 
Septicemia by any of these bacteria may be fatal [2],
1.2.2. Classification
There are two types of cells, eukaryotic and prokaryotic, and these differ greatly in size 
and structure. There are several groups of eukaryotic microorganisms and these include 
algae, fungi and protozoa, whilst bacteria are the only prokaryote. The major structural 
difference between eukaryotes and prokaryotes are their nuclear structures. The 
eukaryotic nucleus is bound by a nuclear membrane and contains several DNA 
molecules. In contrast to this the prokaryotic nuclear region has no membrane and is 
made up of a single DNA molecule. Table 1 shows the differences between prokaryotic 
cells and eukaryotic cells [3].
Eukarvotic ceils Prokarvotic cells
The chromosomes are enclosed within a sac- 
like, double-layered 'nuclear' membrane.
There is no nuclear membrane:
Chromosomes are in direct contact with
the cytoplasm.
Chromosome structure is complex; the DNA
is usually associated with proteins called
histones.
Chromosome structure is relatively 
simple.
Cell division involves mitosis or meiosis. Mitosis and meiosis are not involved.
The cell wall, when present, includes
structural compounds such as cellulose or
chitin, but never peptidoglycan.
The cell wall, when present, usually
contains peptidoglycan but never 
cellulose or chitin structural components.
Mitochondria are generally present; 
Chloroplasts occur in photosynthetic cells.
Mitochondria and chloroplasts are never 
present.
Cells contain ribosomes of two types; a 
larger type in the cytoplasm and a smaller 
type in the mitochondria and chloroplasts.
Cells contain ribosomes of only one size
Flagella, when present, have a complex 
structure.
Flagella, when present, have a relatively 
simple structure.
Table 1. The difference between eukaiyotic cells and prokaryotic cells [3].
All bacteria, with a small number of exceptions, fall into one of two categories. These are 
either Gram-positive bacteria or Gram-negative bacteria and can be distinguished from 
each other using the Gram stain test. The Gram stain test involves the bacteria being 
mixed with a purple dye (crystal violet), washed with alcohol, and then mixed with a pink 
dye (safarin). The Gram negative bacteria lose the crystal violet and retain the safarin so 
turn pink, whereas the Gram positive bacteria retain the crystal violet so turn purple.
Bacterial species differ from one another in many ways. These include size, shape and 
structure. The smallest bacteria are 0.2um (cells of Chlamydia) and the largest >600um 
(Epulopiscium fishelsonf), although in general they are between 5 and O.Sum. There are 
three main classes of bacterial shape and these are spherical - cocci, cylindrical or rod 
shaped - bacilli and helical - spirochaetes.
Bacteria can be classified through morphology, staining, cultural characteristics, 
biochemical reactions, antigenic structure and base composition (i.e. guanine to cytosine 
ratio of bacterial DNA). The most medically important genera are shown in tables 2 and 
3, classified based on Gram's stain, morphology and aerobic or anaerobic growth [4],
Cocci
Bacilli
Aerobes or 
facultative 
anaerobes
Anaerobes
Aerobes or 
facultative 
anaerobes
Anaerobes
Arranged in clusters
Arranged in chains
Arranged in clusters
Arranged in chains
Sporulating
Non Sporulating
Sporulating
Non Sporulating
Micrococcus
Staphylococcus
Streptococcus
Peptococcus
Peptostreptcoccus
Bacillus
Corynebacterium
Listeria
Lactobacillus
Nocardia
Mycobacterium
Clostridium
Actinomyces
Table 2. Classification of some Gram positive bacteria [4].
Cocci
Bacilli
Spirochaetes
Aerobes
Anaerobes
Aerobes
Aerobes or 
facultative 
anaerobes
Anaerobes
Aerobes
Anaerobes
Neisseria
Veillonella
Pseudomonas
Salmonella
Shigella
Klebsiella
Proteus
Escherichia
Yersinia
Bordetella
Haemophilus
Brucella
Pasteurella
Vibrio
Campylobacter
Bacteroides
Fusobacterium
Leptospira
Borrelia
Treponema
Enterobacteria
Parvobacteria
Table 3. Classification of some Gram negative bacteria [4].
1.2.3. Structure.
The general structure of a bacterium is shown in figure 1 [5].
Capsule
Cell wall
Plasma membrane
Cytoplasm
Ribosomes
Plasmid
Pili
Bacterial Flagellum 
Nucleoid (circular DNA)
Figure 1. The generalised structure of a bacterium [5].
1.2.3.1. Capsule
The capsule or slime layer can be found on both Gram positive and Gram negative 
bacteria (i.e. Streptococcus pneumoniae and Escherichia colt). It is a layer of acidic 
polysaccharides usually composed of 2-3 sugars which are characteristic of the particular 
organism. The purpose of the capsule is to prevent the cell drying out and to protect 
against phagocytosis (engulfing) by larger organisms.
1.2.3.2. Cell Wall.
The function of the cell wall is to provide rigidity to the cell and protect against osmotic 
damage. The structure of the cell wall is different in Gram positive and Gram negative 
bacteria and this is the reason that they stain differently in the Gram stain test. Figures 2a, 
2b and 2c show the structures of Gram positive and Gram negative cell walls.
Gram Positive Bacteria Cell Wall
Gram Negative Bacteria Cell Wall
Peptidoglycan (with teichoic acid) 
Cytoplasmic membrane
Outer membrane (with surface 
lipopolysaccharide)
Periplasmic space 
Peptidoglycan
Cytoplasmic membrane
Figure 2a. The different structures of Gram positive and Gram negative cell walls.
Figure 2b. Electron micrograph of Gram positive cell wall [6].
peptidoglycan outer membrane
penplasra
cytoplasm cytoplasrnic membrane 
Figure 2c. Electron micrograph of Gram negative cell wall [6].
The Gram positive cell wall is usually between 15 and 50 nm thick and lies on the outside 
of the cell membrane. Approximately 50% of the cell wall is made up of peptidoglycan. 
Peptidoglycan is composed of two sugar derivatives (JV-acetylglucosamine and N- 
acetylmuramic acid) and a small group of amino acids (L-alanine, D-alanine, D-glutamic 
acid and either lysine (GPB) or diaminopimelic acid (GNB)) to form a glycan 
tetrapeptide (see figure 3). These glycan chains are connected by peptide cross-links 
formed by the amino acids (see figure 4) and it is this cross Unking that gives the 
peptidoglycan its strength [6]. In Gram positive bacteria the cross linkage is via a peptide 
inter-bridge whereas Gram negative cross links are by direct peptide link from the amine 
group of the diaminopimelic acid (DAP) to the carboxyl group of the terminal D-alanine 
(See figure 5). Gram positive bacteria have acidic polysaccharides attached to their cell 
walls called teichoic acids. Teichoic acids are negatively charged and are partly 
responsible for the negative charge of the cell surface.
NH
HOOC
COOH
O
NH n
COOH
Figure 3. The glycan tetrapeptide.
M/G G
G' 
/
_— a 
/ M
G X
-7 = peptide cross-links 
M = A/-acetylmuramic acid 
G = A/-acetylglucosamine
Figure 4. Overall structure of peptidoglycan showing cross linkages between glycan chains.
a) G-M-G b) G-M-G
L-ala L-Ala
D-Glu D-Glu-NH2
DAP———D-Ala L-Lys——————.
II II
D-Ala DAP D-Ala Gly
D-Glu Gly
D-Ala Gly
—G-M-G— Gly
Gly 
D-Ala 
L-Lys 
D-Glu-NH2 
L-Ala 
—G-M-G—
Figure 5. a) Direct interbridge in Gram negative bacteria, b) Glycine interbridge in Gram positive bacteria.
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1.2.3.3 Outer membrane.
Unlike Gram positive bacteria, Grain negative bacteria are surrounded by an outer 
membrane. Embedded in the outer membrane are proteins called porins that facilitate 
transport across the membrane. The membrane is asymmetric and is made up of an inner 
phospholipid layer and an outer layer comprising lipopolysaccharide (LPS) molecules
(see figure 6 [7]).
Outeide
LPS
Inside Penplasmic space
Figure 6. Diagram of a Gram negative bacterium outer membrane adapted from [7].
The lipid part of the LPS, called Lipid A, is comprised of fatty acids (caproic, lauric, 
myristic, palmitic and stearic acids) which are connected by an amide link to a 
disaccharide composed of 7V-acetylglucosamine. The LPS molecules associate with the 
phospholipids to form the outer layer of the outer membrane. The inner layer is 
'anchored' to the peptidoglycan by lipoproteins.
The outer membrane acts as a permeability barrier. Small hydrophilic molecules do not 
pass through the LPS layer but instead they enter the cell via the porins.
11
1.2.3.4. Bacterial physiology.
The cytoplasmic membrane is made up of phospholipids and proteins and encloses the 
interior of the bacterium. It acts as an osmotic barrier and regulates the flow of materials 
in and out of the microorganism. It is also involved in electron transport and oxidative 
phosphorylation, energy production, motility and replication. Bacterial growth, 
metabolism and replication are carried out in the cytoplasm. The cytoplasm of bacteria is 
typically void of organelles except for ribosomes and some small membrane-bound 
structures (not always present). The chromosome is not encased in a nuclear membrane 
as it is in eukaryotic cells and is a single, continuous strand of DNA Many bacteria also 
possess small circular elements of DNA termed plasmids.
On the outside of the bacterial cell are the flagella. Flagella (singular: flagellum) provide 
locomotion for the organism so it can move away from toxins or towards nutrients. They 
are hair-like structures that are helically shaped and comprised of protein subunits. 
Locomotion is brought about by rotation of the flagella in a propeller like movement. 
There are two main types of flagella and these are peritrichous flagella or polar flagella. 
Peritrichous flagella have flagellum surrounding the whole organism whereas polar 
flagella have flagellum located only at one end. Pili are also found on the outside of the 
bacteria. Pilli (singular: pillus) are hair-like projections, comprised of protein building 
blocks that emerge from the outside of the cell surface. They assist the bacteria in 
attachment to cells, surfaces and can also assist the transfer of DNA between bacteria.
1.3 Antibacterial agents.
1.3.1. Introduction to antibacterial agents.
The range of bacteria or other microorganisms affected by a certain antibacterial agent is 
called its spectrum of activity. If an antibacterial agent is active against both Gram 
positive bacteria and Gram negative bacteria then it is said to have a broad spectrum of 
activity whereas if it only works on one or the other then it is said to have a narrow 
spectrum of activity. A limited spectrum of activity is when the drug only acts on a single 
organism. To be clinically useful an antibiotic must have the following characteristics: it 
must have a broad spectrum of activity, it must be non toxic to the host, it must be non 
allergenic to the host, it must not eliminate the host's natural flora, it must reach the
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infected part of the body, it must be inexpensive and easy to produce, it must be 
chemically stable and microbial resistance must be uncommon or unlikely to develop. 
Antibacterial agents can work in one of two ways and these are either bacteriocidal 
(bacteria-killing) or bacteriostactic (growth inhibiting).
1.3.2. p-lactams.
p-Lactam antibiotics include penicillins, cephalosporins, carbapenems, clavams and 
monobactams. The feature that they all have in common is a four-membered nitrogen 
containing ring called a p-lactam ring. Figure 7 shows the core structure of some 
common P-lactams.
H
-N. TH H
O
Penicillin 
1
COOH
H
R''
R1 - J, H H^n<f~ Y^HR"
COOH
Cephalosporin 
2
R"1 „ H H
Monobactam 
4
H COOH
Nocardicins 
3
COOH
Carbapenems 
5
Figure 7. The generic structures of some common p-lactams
The antibacterial effect of penicillin (1) was discovered by Alexander Fleming in 1929. 
p-Lactams are normally bacteriocidal however they require the bacteria to be growing in 
order to exert their toxicity. The different p-lactams vary in spectrum of activity, toxicity, 
stability, clearance rate, whether they can be orally taken or not, ability to cross the blood 
brain barrier and susceptibility to P-lactamases. However, despite all these differences, p- 
lactams have only one mode of action. Their mode of action is the inhibition of the final
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stages of peptidoglycan biosynthesis and their activity is dependent on having an intact P- 
lactam ring. p-Lactams bind to the penicillin binding proteins (PBP's) found in the outer 
leaflet of the cell membrane and to do this they must penetrate the cell wall and operate 
in the periplasmic space. The periplasmic space is accessible in Gram positive bacteria 
but in Gram negative bacteria the drugs need to cross the bacterial cell membrane or pass 
through the porin channels. The 3-D structure of p-lactams resembles the D-alanyl-D- 
alanine end of the pentapeptide in peptidoglycan just before final assembly. The enzymes 
that normally work on the D-alanyl-D-alanine end of the pentapeptide are called 
transpeptidases and the P-lactams bind to the active sites of these enzymes, preventing the 
assembly of peptidoglycan. The p-lactam bond can also be hydrolysed by enzymes called 
p-lactamases.
1.3.3. Glycopeptides.
The most common glycopeptide is vancomycin (6), although teicoplanin is also now 
available. Vancomycin (see figure 9) was first isolated in 1956, and is thought of as the 
last line of defence against pathogenic bacteria. Like P-lactams, it inhibits the synthesis of 
peptidoglycan. However the mechanism by which it inhibits peptidoglycan synthesis is 
different to P-lactams. Vancomycin binds to the D-alanyl-D-alanine end of the 
peptidoglycan pentapeptide chain rather than the penicillin-binding enzyme. By doing 
this it blocks access to the active site of the enzyme. Vancomycin is often used to treat 
multiple resistant infections and is thought of as the antibiotic of last resort. However 
resistance to this has emerged over the years since it was introduced. Vancomycin- 
resistant enterococci (VRE) were first reported in the UK in 1988 [8] and the first 
isolation of vancomycin-resistant Staphylococcus aureus (VRSA) was in Japan in 1997 
[9]. These discoveries mean that this antibiotic may in the future be less useful in the 
treatment of infections.
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NH
Figure 9. The structure of Vancomycin. 6.
1.3.4. Sulfonamides.
In 1935 Domagk discovered a group of synthetic chemicals, known as sulfonamides, 
which exhibited broad antimicrobial activity. They are competitive inhibitors that act on 
the folic acid synthetic pathway [10]. Folic acid is a cofactor in the synthesis of purines, 
thymidine and methionine which are necessary for the synthesis of RNA, DNA and 
proteins. Sulfonamides are analogues of /7-aminobenzoic acid 8 (see figure 10) and they 
competitively inhibit dihydropteroate synthetase which is the enzyme that condenses p- 
aminobenzoic acid with dihydropteroic acid in the early stages of folic acid synthesis.
SO2NH2
Sulfanilamide
7
COOH
p-Aminobenzoic acid 
8
Figure 10. Comparison of the structures of sulfonamides and PABA.
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Bacteria must synthesise folic acid however, mammalian cells uptake it as preformed 
folate. Despite this selectivity for bacteria over mammalian cells the sulfonamides have 
many side effects in the body including kidney damage due to sulfonamide crystals 
forming in acidic urine, allergic reactions such as rashes and drug induced fever, Stevens- 
Johnson syndrome (a rare, severe form of erythema multiforme), kernicterus 
(sulfonamides displace bilirubin from plasma protein binding sites), haemolytic anaemia, 
G.I. distress, nausea, vomiting, diarrhoea and photosensitivity [11].
1.3.5. Quinolones.
Quinolones are broad spectrum antibiotics that cause inhibition of the enzyme DNA 
gyrase. DNA gyrase is an enzyme involved in uncoiling supercoiled DNA prior to cell 
division. The prototype drug in this class was nalidixic acid (see figure 11) which was 
active against Gram negative bacteria. Many other analogues of this have been 
synthesised and it has been found that fluorination at the 6 position [i.e. in ciprofloxacin 
10 (figure 11)] gives better activity against a broader spectrum of bacteria.
COOH
COOH
Nalidixic acid 
9
Ciprofloxacin 
10
Figure 11. The structures of nalidixic acid and ciprofloxacin.
1.3.6. Tetracyclines.
Tetracyclines have a broad spectrum of activity against a number of both Gram positive 
and Gram negative bacteria and are made up of four, fused C6 rings (see figure 12). 
Tetracyclines are actively transported into bacterial cells where they act as protein 
synthesis inhibitors. They are bacteriostatic and prevent the binding of amino acyl-tRNA 
to the ribosome.
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11
Figure 12. The structure of tetracycline.
All of the antibacterial agents have different modes of action although they share the fact 
that they are all targeted to a specific process and this means the bacteria are often able to 
find a way of combating their toxic effects.
1.4. Bacterial resistance to antibiotics.
1.4.1. Clinical importance.
Antimicrobial agents have reduced the threats posed by bacterial infections and have 
saved millions of lives since their introduction in the early part of the 20th century. Many 
serious infectious diseases have been brought under control and they have contributed in 
large part to increasing life expectancy. These gains however may be jeopardised by the 
emergence and spread of bacteria which are resistant to first line drugs. The emergence of 
resistance is most evident in the bacterial infections that contribute most to human 
disease. Some important examples of this are penicillin-resistant Streptococcus 
pneumoniae, vancomycin-resistant enterococci, methicillin-resistant Staphylococcus 
aureus (MRSA), multi-resistant salmonellae and multi-resistant Mycobacterium 
tuberculosis [12].
The consequences of the emergence of antibiotic resistance in bacteria are severe. 
Bacterial infections that fail to respond to treatment result in prolonged illness and greater 
risk of death. An infection that is not successfully treated allows for greater spread within 
the community. When first line treatments are no longer viable, second or third line 
treatments must be used however these are often more expensive and / or more toxic to
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the patient. The major cause for concern however, is for organisms which are developing 
resistance to virtually all currently available drugs, necessitating the need for the 
development of drugs in which resistance will not occur (i.e. those that act on multiple 
targets).
There are a number of reasons why bacterial resistance is thought to have come about and 
these include the use and misuse of antimicrobial agents, increased use of invasive 
devices and procedures, a greater number of susceptible hosts, lapses in infection control 
practices leading to increased transmission of resistant organisms, and widespread use of 
antimicrobials in hospitals, for immunocompromised patients [13]. 
Most studies show a higher rate of resistance associated with noscomial pathogens, 
especially from intensive care units, than with community acquired organisms. Specific 
bacterial pathogens that are significant problems in hospitals today include MRSA, 
multidrug resistant Gram-negative bacilli, vancomycin-resistant enterococci (VRE) and 
oxacillin-resistant S. aureus.
1.4.2. Emerging resistance.
There are two general types of resistance and these are either intrinsic or acquired. 
Intrinsic resistance is inherent (chromosomal) whereas acquired resistance results from 
the alteration of the bacterial genome. This alteration of the genome can occur through 
one of two pathways, which are vertical evolution or horizontal evolution. Vertical 
evolution is thought to be linked to the selection of favourable mutations in a population 
and this gene is then passed on to the new cells. Horizontal evolution is by genetic 
transfer via plasmids which can occur through various mechanisms (see 1.4.3). Soon after 
each antibacterial agent was entered into clinical practice, resistance was reported by at 
least one organism (table 4) [14].
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Agent for which
resistance was
observed
Penicillin G
Streptomycin
Tetracycline
Penicillin and
tetracycline
combination
Methicillin
Nalidixic acid
Gentamycin
FDA apnroval
1943
1947
1952
1943 and 1952
1960
1964
1967
Resistance renorted
1940
1947
1952
1976-80
1961
1966
1969
Mechanism of
resistance.
Penicillinase
production
Mutation in
ribosomal protein
S12
Efflux
Plasmid coded broad
spectrum P-
lactamases and
tetracycline efflux
pump
MecA (Penicillin
Binding
Protein(PBP))
Topoisomerase
mutations
Aminogylcoside 
modifying enzyme.
Table 4. Reported resistance to new agents following approval for clinical use and mechanisms of
resistance.
1.4.3. Mechanisms of resistance.
1.4.3.1. Enzymatic inactivation of die antibiotic.
Resistance to p-lactams is common due to bacteria producing the pMactamase enzyme. P- 
lactamase inactivates the drug by acting on the pMactam ring. The overall reaction
scheme for this is shown in scheme 1 and the mechanism of action is shown in scheme 2.
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Scheme 1. The overall reaction scheme for (3-lactamase action on tfie p-lactam
ring.
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Scheme 2. Mechanism of p-lactamase action.
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1.4.3.2. Modification of the target (becoming insensitive)
The most common mechanism of resistance to macrolides involves modification of the 
target site on the ribosome. This is achieved by methylation of an adenine residue in 
domain V of the 23 S rRNA and it is carried out by a family of plasmid or transposon 
encoded M-methyltransferases [15].
Vancomycin resistance also occurs via modification of the target site. It targets the D- 
Ala-D-Ala termini of the UDP-N-acetylmuramyl-pentapeptide precursor of 
peptidoglycan. Resistance arises as a result of the synthesis of abnormal pentapeptide 
precursors which possess altered termini such as D-Ala-D-Lac or D-Ala-D-Ser and these 
have a lower affinity for vancomycin than D-Ala-D-Ala [15].
Another form of antibiotic resistance via modification of the target site has arisen with 
fluoroquinolones. This involves a mutation affecting the fluoroquinolone targets, the 
DNA gyrase and topoisomerase IV enzymes. Alterations can be made in either the GyrA 
or GyrB subunits of DNA gyrase. In Gram negative bacteria, the most common 
mutations in the GyrA subunit cause resistance through decreased drug affinity for the 
altered gyrase-DNA complex. The GyrB subunit modifications are less common and their 
effect on drug binding is not clear. Topoisomerase IV alterations due to mutations in 
ParC or ParE also occur in Gram negative bacteria but appear to be of less importance. 
The situation is reversed in Gram positive bacteria where the topoisomerase IV acts as 
the primary target over DNA gyrase.
1.4.3.3. Impermeability.
Antibiotics must be able to enter the cell in order to reach their intracellular targets. To 
enter the cell they must cross the Gram negative bacterial outer membrane. This, in part, 
explains why Gram negative bacteria are harder to kill than Gram positive bacteria. 
Acquired resistance to p-lactams in a number of Gram negative bacteria had been 
attributed to outer membrane changes that correlate with reduced permeability, however 
the outer membrane as a resistance mechanism is only significant in context of additional 
resistance mechanisms. A more general example of impermeability leading to resistance 
is found in biofilms [16]. A biofilm is a population of cells growing on a surface enclosed
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in a polysaccharide matrix and, according to the National Institute of Health "more than 
60% of all microbial infections are caused by biofilms" [16]. It is harder to kill bacterial 
cells in a biofilm than in planktonic populations. Although penetration of antibiotics into 
a biofilm may be important for some antibiotics this is unlikely to be the mechanism of 
resistance (persistence) for the majority of antibiotics.
Mutational impermeability is important in resistance to carbapenems and arises via the 
loss of OmpD, a porin that forms narrow transmembrane channels that are accessible to 
carbapenems but not other 0-lactams [17].
The major porin from a wild type strain and a resistant strain of Enterobacter aerogenes 
were characterised and analysed. The findings showed that the OmpC / OmpF-like 
protein from the resistant stain had single-channel conductance 70% lower than the wild 
type, it was three times more selective for cations and had a lack of voltage sensitivity. 
These results indicated that the clinical strain was able to synthesise a modified porin that 
decreased the permeability of the outer membrane [18].
1.4.3.4. Efflux mechanism to pump out the antibiotic.
Tetracycline resistance, discovered in 1953, has arisen due to bacteria having an efflux 
mechanism which pumps the antibiotic out of the cell. Efflux proteins transport 
tetracycline molecules out of the cell, reducing the concentration of drug within the cell 
so that it is below the MIC for the inhibition of protein synthesis. The proteins are 
encoded by genes in bacteria called tet (from tetracycline) or otr (from oxytetracycline). 
The tet genes that encode efflux pumps, code for energy dependent membrane-associated 
proteins (46KDa in size) which export tetracycline out of the cell. See figure 13 for a 
diagram showing the structure of an efflux pump.
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Figure 13. Diagram adapted from [4], shows efflux machinery used to pump tetracycline out of the
bacterial cell in P. aeruginosa.
The mechanism by which the efflux pump works is by the active trans locator * catching' 
the drug in the cytoplasmic area. The efflux proteins then exchange a proton for a 
tetracycline cation complex against a concentration gradient. The bound molecule is 
transported out of the cell via a change in configuration of the protein and is then released 
into the surroundings [19]. Bacterial drug efflux pumps are classed into five families 
which are the major facilitator superfamily (MFS), the adenosine triphosphate (ATP)- 
binding cassette (ABC) superfamily, the small multidrug resistance (SMR) family, the 
resistance-nodulation-cell division (RND) superfamily and* the multidrug and toxic 
compound extrusion (MATE) family [20]. Of these families the first two are very large 
whilst the others are smaller. Efflux pumps can be further classified into single 
component or multi component pumps. In most cases multidrug efflux pumps are 
chromosomally encoded and therefore not readily transferable between bacteria. 
However examples can be found in both Gram positive and Gram negative bacteria 
where the genes are on mobile elements.
23
1.4.3.5. Enhanced production of the target to compensate.
Glycopeptide antibiotics such as vancomycin inhibit cell wall synthesis by binding to the 
D-Ala-D-AIa end of the peptidoglycan precursors. However, vancomycin resistant 
S.aureus (VRSA) was first isolated in Japan in 1997. When compared to control stains 
these bacteria show a number of changes in their cell wall structures. Specifically, there is 
a two-fold increase in the thickness of the cell wall, there is an increased proportion of 
peptidoglycan stem peptides containing non-amidated glutamine residues and reduced 
peptidoglycan cross-linking [21]. The thicker cell wall with its multiple binding sites for 
vancomycin has been shown to trap antibiotic molecules, reducing the number of 
vancomycin molecules that reach the cytoplasmic membrane where the transglycosylase 
targets are located.
1.4.3.6. By-pass of target, using alternative insensitive route.
Bacteria can produce a new enzyme that is not inhibited by the antimicrobial. 
Trimethoprim-sulphamethoxazole resistance is due to bacteria that produce a new 
dihydrofolate reductase not inhibited by trimethoprim and a new dihydropteroate 
synthetase not susceptible to sulfonamides. These new enzymes are plasmid coded 
whereas the chromosomally determined enzyme is the target for sulphonamides [22]. The 
R-plasmid enzyme binds sulphonamides 10,000 times less tightly than the chromosomal 
enzyme while the Km for the substrate, p-aminobenzoic acid, is the same for both 
enzymes.
1.4.4 Self promoted uptake
Self promoted uptake is a process by which cationic antimicrobial compounds can enter a 
bacterial cell. There is a high net negative charge on the outside of the bacterial cell wall 
which is partly neutralised by Mg2"1" and Ca2+. Polycationic drugs can interact with the 
divalent cation binding sites. They have a higher affinity for the site so either chelate or 
displace the divalent cations. In doing so the bulkiness of the polycation leads to a 
distortion of outer membrane structure. Gaps then appear in the membrane allowing the 
drug to diffuse into the cell.
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1.4.5. Programmed cell death.
Bacteria live in colonies and when conditions become overcrowded or food is scarce 
some of the population commit suicide. This is done when a bacterial protein or peptide 
triggers a 'death signal' that causes the microbe to disintegrate. Many antibiotics are 
thought to exploit this signal and cause bacterial cell suicide. It has been shown that many 
bacterial species undergo programmed cell death [23]. In one of these, Streptococcus 
pneumonia, a sensor protein called VncS together with VncR form a suicide signalling 
pathway. VncR controls the amount of autolysin, which is an enzyme that hydrolyses 
components of a biological cell in which it is released. If VncS activity is triggered it 
chemically modifies VncR so that it releases autolysins to destroy the cell wall. The 
signal that stimulates VncS is a peptide of 27 amino acids called Pep. It is thought that 
antibiotics can increase the production of Pep until it reaches a concentration that the 
sensors can see, triggering the VncS-VncR-autolysin suicide pathway [24]. 
E. coli has also been shown to undergo programmed cell death when treated with 
antibiotics [25]. This occurs through a system called an "addiction module". An addiction 
module consists of a pair of genes, a stable toxin and an unstable antitoxin that prevents 
the lethal action of the toxin. The E. coli mazEF module consists of two adjacent genes 
called mazE and mazF and it has been found that this module has the properties of an 
addiction module. MazF is toxic and long lived whilst MazE is antitoxic and is a labile 
protein degraded in-vivo by the ATP dependent ClpPA serine protease. MazE and MazF 
interact with each other and are co-expressed. E. coli was treated with low concentrations 
of antibiotics known to inhibit transcription and / or translation. From this study it was 
found that the antibiotics can trigger mazEF-mediated cell death by reducing the levels of 
MazE.
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1.5. Porphyrins.
1.5.1. Structure.
Porphyrins are an important class of compound in biological systems and are central to 
the roles of photosynthesis, biological oxidation and reductions and the transport of 
oxygen by haemoglobin. Porphyrins are aromatic tetrapyrrolic macrocycles which follow 
HiickeFs rule of 4n+2 n, electrons, where n = 4, 5 or 6. The structure and numbering of 
the porphyrin nucleus is shown in figure 14.
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Figure 14. The porphyrin nucleus.
The porphyrin core is numbered from 1 to 20 where the 5, 10, 15 and 20 positions are 
known as the meso positions and the 2, 3, 7, 8, 12, 13, 17 and 18 positions are the B- 
positions. Porphyrins have a planar ring system which allows maximum overlap of the p 
orbitals. They are thermally stable and have an anisotropic ring current which is shown in 
a typical NMR spectrum. The inner protons on the nitrogen atoms are shielded by the 
ring current from the external magnetic field and so are found at the unusually low 
position of between -2 and -3 ppm. The outer protons on the backbone of the pyrrole 
rings, known as the p-protons, have a higher then usual resonance as they are deshielded 
by the ring current from the external magnetic field and appear between 8 and 9 ppm. 
Porphyrins are tetradentate ligands which strongly chelate metal ions and this is an 
important property for haemoglobin in the transport and delivery of oxygen to cells. 
Porphyrins have four nitrogen atoms pointing to a central cavity of 2.01 A (from N to N).
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Two of these nitrogen atoms exhibit pyridine character in that they are basic and 
protonate in acid to give mono- and di- cations whereas the other two have pyrrolic 
character in that they are acidic and deprotonate in base to give mono- and di- anions. 
Porphyrins are intensely coloured and absorb light in the visible part of the spectrum. 
Absorptions in the blue and green regions of the spectrum mean that porphyrins appear 
red. In the absorbance spectrum of tetraphenyl porphyrin, the largest band at ~ 400 nm is 
known as the Soret or B band and the smaller bands between -500 nm and 650 nm are 
the Q bands. On metallation the Q bands collapse to leave two rather than four. This is 
due to an increase in symmetry of the molecule from D2h to D4h.
1.5.2. Excited states of porphyrins.
Porphyrins are photosensitizers which means they can absorb light and use it to perform 
chemical reactions. All photochemical reactions of porphyrins occur in their excited 
states and the generation and fates of these excited states can be explained using the 
Jablonski diagram shown in figure 15.
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Figure 15. The Jablonski diagram showing the generation and fetes of excited states.
Photosensitizers in their singlet ground state can absorb a photon of light and in doing so 
are excited to their singlet excited states. The singlet excited states of the photosensitizer
27
can then either undergo radiative decay back to the ground state, a process known as 
fluorescence, or it can undergo intersystem crossing (a radiationless crossing between 
different spin states) to the triplet excited state. The radiative decay from the triplet 
excited state to the singlet ground state is a spin forbidden process because it involves a 
net change of spin. Oxygen, unusually, has a triplet ground state and can react with the 
triplet excited state to produce ground state photosensitizer and singlet oxygen.
1.5.3. Synthesis of porphyrins.
5, 10, 15, 20-tetraphenyl porphyrin (12) was synthesised by Rothemund in 1936 for the 
first time. He reacted benzaldehyde (13) and pyrrole (14), in pyridine, in a sealed bomb at 
150 °C for 24 hours. However the yields were low and the conditions severe, so only a 
few substituted benzaldehydes could be made in this way. Adler and Longo altered these 
conditions by reacting benzaldehyde with pyrrole in propionic acid for 30 mins at reflux, 
in a system that was open to the air. Scheme 3 shows a typical reaction scheme for an 
Adler reaction. The milder conditions of the Adler-Longo reaction meant that many more 
substituents on the benzaldehydes can be converted to their corresponding porphyrins in 
yields of up to 20% and multigram quantities can be produced [26]. Unsymmetric 
porphyrins can also be made in this way by using two or three different benzaldehydes; 
however extensive column chromatography is needed in order to separate the products. If 
acid sensitive functional groups on the benzaldehyde are present, porphyrins can't be 
made in this way and this problem was addressed by Lindsey et al in 1987.
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Scheme 3. A typical Adler reaction showing the condensation between pyrrole and a substituted
benzaldehyde in propionic acid.
The Lindsey method relies on the formation of porphyrinogen as an intermediate in 
porphyrin synthesis [27]. Pyrrole and benzaldehyde form an equilibrium under mildly 
acidic conditions with tetraphenyl porphyrinogen (see scheme 4). After equilibrium has 
been reached a chemical oxidant is added to convert the porphyrinogen to the 
corresponding porphyrin. The advantages of this method are that it allows functional 
groups that are acid sensitive to be introduced, as well as allowing more facile 
purification and higher yields. However, higher dilution conditions are needed, in the 
order of 10"2M, and this means it is not easily scaled up. In a typical Lindsey reaction 
equimolar concentrations of pyrrole and benzaldehyde are reacted with boron trifluoride 
at room temperature, under an inert atmosphere, for 1 hour in dichloromethane, using a 
water scavenger (triethyl orthoacetate). This is followed by addition of 2, 3, 5, 6-
•
tetrachlorobenzoquinone, which is then refluxed for a further hour to produce the desired 
porphyrin.
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oScheme 4. Lindsey method. Equilibrium formed between pyrrole and benzaldehyde with porphyrinogen
and then porphyrinogen oxidated to porphyrin.
1.6. Photodynamic therapy.
The photodynamic effect was demonstrated in 1913 when Meyer-Betz intravenously 
injected himself with 200 mg of haematoporphyrin. He subsequently exposed himself to 
light, which resulted in massive swelling and blistering. In 1970 Lipson and Schwartz 
found that a polymeric derivative of haematoporphyrin (HpD) was selectively taken up 
and retained by rapidly dividing cells and it was this observation that prompted 
investigations into the photodynamic therapy (PDT) of cancer. HpD is derived from 
acerylating haematoporphyrin (Hp) then neutralising it prior to alkaline hydrolysis. The 
resulting mixture contains haematoporphyrin, hydroxyethylvinyldeuteroporphyrin (HVD) 
and protoporphyrin (Pp), as well as a mixture of complex dimeric and oligomeric 
fractions containing ester, ether and carbon-carbon linkages of haematoporphyrin. HpD is 
~ 45% monomeric/dimeric porphyrins and ~ 55% oligomerit material. This has been 
partly purified in Photofrin® to ~ 85% oligomeric material. Since the discovery of these 
compounds, the PDT of cancer has been well developed and compounds such as 
Photofrin® and Foscan® are regularly used in clinics for the treatment of cancers and 
many other second and third generation photosensitizers have been developed [28]. PDT, 
as shown in figure 16, involves the injection of a non-toxic dye called a photosensitizer 
(PS) into the patient. This PS must then selectively accumulate in the tumour site and, on
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irradiation with red light, produce singlet oxygen and other reactive oxygen species 
which selectively destroy the tumour leaving the healthy patient.
light
Figure 16. Photodynamic therapy of cancer. Involves injection of photosensitizer, localisation in tumour 
site and irradiation to produce singlet oxygen which leaves a healthy patient [29]
Although singlet oxygen is the main cytotoxic molecule produced by the photochemical 
excitation of the photosensitizer in the cells, other reactions can occur. The reactions of 
the excited photosensitizer can be classed into two types, type I reactions and type II 
reactions, and examples of both of these are given in figure 17 [30]. Type II reactions are 
characterised by dependence on oxygen concentration and include the production of 
singlet oxygen whereas type I reactions are characterised by dependence on target- 
substrate concentrations. In an anoxic environment, the excited photosensitizer can react 
with organic substrates (S) by electron exchange to produce an oxidised substrate (S+) 
and a reduced PS (PS"). In hypoxic conditions (low levels of oxygen) the reduced PS 
(PS") can react with oxygen (Cb) to form superoxide anions (02"). This can then form the 
highly reactive hydroxyl radical ('OH).
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Type I photoreactions 
3p*+s ——— *" P-+S+ 
P- + O ——— *• P + 02-
3p*+o2-
Type If photoreactions
3P* + 3O2 ——— *• 1 P + 102 
102 + S ———— S(0)
Figure 17. Photochemical reactions [30].
PDT relies on the production of singlet oxygen for its cidal effects and the production of 
singlet oxygen was discussed in section 1.5.2. Singlet oxygen can react with more than 
one target within a cell, as shown in figure 18, including DNA bases, proteins, and 
cholesterol found in cell membranes [31].
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Figure 18. Targets for singlet oxygen reaction within a cell.
There are five factors which are necessary in order to produce a good PDT agent and 
these are:
1) Chemical purity
2) Minimal dark toxicity
3) Significant absorption at wavelengths that penetrate tissue deeply
4) High selectivity for target tissue
5) Rapid clearance from normal tissue.
Photofrin® fulfils these in that it has minimal dark toxicity and reasonable selectivity for 
target tissue. However it does not achieve chemical purity or significant absorption at 
wavelengths that penetrate tissue deeply and it is for this reason that it can not be used for 
deep-seated tumours and questions have arisen about the identity of its active
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components. Tissue penetration is optimal with red light and mis is shown pictorially in 
figures 19 and 20. Figure 19 shows the light absorption spectra of red blood cells overlaid 
with the light absorption spectra of a porphyrin based photosensitizer (a benzoporphyrin 
derivative, BPD). Red blood cells block the absorption of blue and green light though 
tissue and so the optimal wavelength to excite the porphyrin derivative is between 650- 
700 nm (red light).
0
Photoactivation of BPD at 688rnn
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Figure 1 9. Light absorption spectra, for red blood cells and a benzoporphyrin derivative (BPD) [32]
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Figure 20. Light absorption through tissue is optimal with red light rather than white light [32]
Although red light must be used for PDT there are many types of light sources mat can be 
used and these include argon / dye lasers, metal vapour lasers, KTP:YAG / dye lasers, 
diode lasers and other non laser light sources including light emitting diodes (LEDs) and 
these have been reviewed by Mang in some detail [33], There are also many different 
types of photosensitizers in use for PDT as reviewed by Allison et al [34].
1.7. Photodynamic Antimicrobial ChemoTherapy (PACT).
1.7.1 Introduction to PACT.
PDT in cancer therapy is now well established and various groups have moved on to look 
at other areas to which the principles of PDT can be applied. Areas that have been looked 
at include age-related macular disease [35], inactivation of yeasts [36], inactivation of 
viruses [37], blood product disinfection [38], infected burn wounds [39] and ulcers
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caused by bacteria. Photodynamic antimicrobial chemotherapy, or PACT, is potentially 
very useful in the treatment of chronic wounds or ulcers which are resistant to healing on 
their own or using conventional therapies, and this is a growing problem in the elderly 
(see figure 21).
Figure 21. An example of an ulcer showing inflammation and immune response- this is likely to contain at
least 10 different species of bacteria. [40].
The emergence of bacterial resistance to conventional antibiotics has left a gap in the 
market where new therapies are needed to cope with the demands of multiple drug 
resistant bacteria and the diseases that they cause. Many strains of bacteria are no longer 
susceptible to antibiotics due to the problem of developing resistance. PACT however is a 
therapy to which bacteria are less likely to build up a resistance to due to the nature of the 
singlet oxygen produced and the fact that it can attack multiple targets within the cell. 
The compounds can also potentially target anaerobic microorganisms through type I 
reactions. PACT is, however, limited to local, rather than systemic, infections because the 
body's natural flora needs to remain unaffected. There can also be problems with light 
delivery to internal sites, although deep-seated infections can now be treated due to the 
development of optical fibre technology.
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1.7.2 Photosensitizers used in PACT.
There are a number of different types of photosensitizer that have been used in PACT and 
these include acridines, azines, macrocyclic photosensitizers such as porphyrins and 
phthalocyanines, naturally occurring sensitizers such as psoralens and polylysine 
conjugates attached to chlorins.
1.7.2.1 Acridine.
Adrien Albert, an Australian chemist worked with acridines 15 (shown in figure 22) and 
it was his work that lead to the understanding of their mode of action. He set the 
following parameters for antibacterial activity: 1) cationic ionization, 2) high levels of 
ionization at neutral pH and 3) planar molecular surface area >38A2 . This hypothesis 
explained the activity against bacteria of many fused aromatic compounds.
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Figure 22. Generic structure of acridines.
Albert showed that aminoacridines with electronic conjugation between the ring nitrogen 
and amino group were most active because of increased ionization of these compounds. 
Nucleic acids are the established sites of action of simple aminoacridine derivatives in 
bacteria. This is because, the planar area of the tricyclic acridine nucleus is ideally suited 
to intercalation between nucleotide base pairs in the helix and the positive charge aids 
targeting. DNA intercalation forms the basis of opposition to me use of acridines owing 
to the nucleic acid site of action resulting in positive mutagenicity testing in-vitro.
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1.7.2.2 Azines
Figure 23 shows the generic structure of the azine photosensitizers with some specific 
examples [41]. The first synthetic antibacterial compounds were azine derivatives. They 
have a simple tricyclic skeleton. Methylene blue is an efficient nucleic acid intercalator 
and is relatively non-toxic to humans. It has been used for the inactivation of various 
pathogens contained in blood plasma and for the treatment of methaemoglobinaemia. 
Methylene blue and its related phenothiazinium structures are relatively easy to 
synthesize but are easily reduced to the neutral amine that is ineffective as a 
photosensitizer. The fact that the phenomiazine derivatives associate with nucleic acids 
suggests that the dyes would be more specific for pathogen reduction and cause less 
damage to red blood cells. However some of the phenothiazine is associated with red 
blood cells and the bound form of the dye is responsible for photo induced haemolysis. 
Photo treated red cells exhibit high rates of potassium efflux, which is indicative of 
membrane damage [42]. Small pores are produced which are permeable to ions but not 
haemoglobin. At ionic equilibrium, the internal osmotic pressure in ion permeable red 
cells is greater than the external osmotic pressure because haemoglobin contributes as an 
osmoticum. This imbalance in pressure leads to water influx, cell swelling and ultimately 
lysis.
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Figure 23. Azine photosensitizer structure with specific examples of some common azine based
photos ensitisers.
1.7.2.3. Porphyrins and Phthalocyanines.
Many groups have shown porphyrins to be efficient photosensitizers for use in PACT. 
While both naturally occurring and synthetic porphyrins can be used, the former are at a 
disadvantage due to similarities in their absorption spectra to endogenous porphyrins. 
PACT studies by Orenstein et al showed lhat it was possible to kill Staphylococcus 
aureus, a Gram positive bacteria, using deuteroporphyrin [43] but Gram negative bacteria 
such as Escherichia coli and Pseudomonas aeruginosa could not be inhibited using 
deuteroporphyrin alone. Malik et al [44] overcame this problem by pre-treating the cells 
with either ethylenediaminetetraacetic acid (EDTA) or polymyxin B nonapeptide 
(PMBN). They found that cells pre-treated with EDTA lost up to 50% of their LPS into 
the medium due to an increased electrostatic repulsion between LPS molecules caused by 
the removal of the divalent cations. Cells pre-treated with PMBN did not cause the
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release of LPS into the medium as with EDTA. The polycation bound tightly to the 
highly negatively charged surface and displaced the divalent cations. In doing so, they 
caused an expansion in the outer leaflet of the outer membrane which, in turn, caused the 
hydrophobic molecules to become less crystalline and allowed the partition of 
hydrophobic molecules from the external medium.
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Figure 24. Zinc phthalocyanine used by Scalise etal [45] to inactivate KColi.
The use of phthalocyanines in PACT has been studied by several groups who have 
looked at the types of charge needed in order to inactivate bacteria. Scalise et al [45] 
synthesised a tetracationic zinc phthalocyanine derivative 17 (see figure 24) and 
compared this to the analogous non-charged phthalocyanine 18. They found that it was 
sossible to photoinactivate E. coli using the charged derivative (0.01% survival) but not 
he neutral one and that neither derivative produced any dark toxicity. A similar effect 
las been shown by Minnock et al [46] who tested the effect of different charges on the 
)hotoinactivation of Gram positive Enterococcus seriolicida and Gram negative E. coli 
ind P. aeruginosa using the molecules shown in figure 25.
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Figure 25. Cationic pyridinium phthalocyanine 19, anionic tetra-sulphonated phthalocyanme 20 and 
neutral tetra-diethanolamine phthalocyanine 21.
The results showed that the cationic compound could photoinactivate both Gram positive 
and Gram negative bacteria whilst the anionic and neutral molecules did not induce any 
appreciable decrease in cell survival.
Other studies, conducted using meso substituted porphyrins, have also shown that the 
molecules need to be cationic in order to photoinactivate both Gram positive and Gram 
negative bacteria. Several studies have been conducted using 5, 10, 15, 20-tetra-(4-N 
methylpyridyl) porphyrin (22) (TMPyP) shown in figure 26.
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Figure 26. 5,10,15,20-tetra (4-N-methylpyridyl) potphyrin 22 (TMPyP)
Nitzan and Ashkenazi [47] showed that 22 could be used to photoinactivate E. coli (Gram 
negative) and A. baumannii (Gram positive). Different light sources and different 
wavelengths were compared in this study. Using either red, green or blue light they 
found that green and red light needed a 8 to 16 or 20-fold higher light intensity, relative 
to blue light, for the total eradication of both bacteria at a concentration of 29.4 umol/L. 
However despite their findings the use of blue light clinically would be irrelevant as it 
would have minimal transmission through tissue, conversely, the use of red light 
produces maximal tissue penetration and is more clinically relevant. 
Merchat et al [48] compared the photodynamic activity of two cationic /weso-substituted 
porphyrins, namely 5, 10, 15, 20-tetra (4-JV-methyl-pyridyl) porphyrin tetraiodide (22) 
and 5, 10, 15, 20-tetra (4-N, N, Af-trimethyl-anilinium) porphyrin (23) and compared then- 
activity to the tetra anionic compound 5, 10, 15, 20-tetra(4-sulphonatophenyl) porphyrin 
(24) (Structures shown in figure 27). They found that the anionic compound had no 
appreciable photosensitizing activity against the Gram negative bacteria, but that all three 
compounds tested photo-inactivated Gram positive bacteria. The two cationic compounds
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were both found to have good photosensitizing activity against Gram negative bacteria 
with no appreciable differences between the two compounds tested. Salmon-Divon et al 
[49] studied the mechanistic aspects of E. coli photo-inactivation using TMPyP. They 
suggested that TMPyP-dependent PDI of E. coli is primarily dependent on DNA damage 
rather than on protein or membrane malfunctions. However other authors have concluded 
that, although DNA damage does occur, it may not be the prime cause of bacterial cell 
death. The mechanisms of cell damage have been reviewed by Hamblin et al [50] who 
quoted studies using Dinococcus radiodurans, which is known to have a very efficient 
DNA repair mechanism and is easily killed by PDI, as a reason for DNA damage not 
being the prime cause of cell death. Instead they point the reader towards believing that 
damage to the cytoplasmic membrane is the main cause of bacterial cell death, quoting 
the alteration of cytoplasmic membrane proteins shown by Valduga et al and the 
disturbance of cell wall synthesis and appearance of a multilamellar structure near the 
septum of dividing cells, along with the loss of potassium ions from cells as reported by 
Salmon-Divon et al [49].
Several authors have started investigating the structure-activity relationships between 
various different cationic porphyrins [51, 52, 53, 54, 55]. Lazzeri et al [51] studied a 
series of asymmetrically meso-substituted cationic porphyrins shown in figure 28 and 
their activity against E. coli. They found that compounds 26 and 27 (Fig 29) produced ~ 
5.5 log decrease in cell survival when treated with 10 uM solution whereas compound 25 
gave ~ 4 log decrease and compound 28 (Fig 29) gave no significant decrease. From 
these results they concluded that the addition of the trifluoromethyl group made the 
molecule more amphiphilic and that it wasn't simply the cationic character mat was 
important but the amphiphilic character also played a role in. the PDI of Gram negative 
bacteria. Another study by the same authors [52] uses the compounds shown in figure 30.
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Figure 27. Structures of compounds used by Merchat el al [48] to compare photodynamic activity against
Gram positive and Gram negative bacteria.
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25 R1 = R" = N+(CH3)3I- R1 " = R"" = CH3 M = H2
26 R' = R" = R"1 = N+(CH3)3I- R"" = CF3 M = H2
27 R1 = R" = R" 1 = N+(CH3)3 I- R"" = CF3 M = Pd(ll)
28 R' = R" = R1" = CH3 R"" = COOH M = H2
Figure 28. Series of asymmetric porphyrins synmesised by Lazzeri etal [51] and tested against/?, coh.
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30 R' = R" =
R1"
MeO
OMe
MeO
31 R1 = R" = R"1 =
Figure 29. Series of porphyrins synthesised by Spesia et al [52] and tested against E. coli.
From these compounds it was found that the mono and di-cationic (29 and 30) 
compounds only photo-inactivated E. coli when the cells were irradiated without being 
washed, but that the tri-cationic porphyrin 31 gave promising results even with washing 
the cells prior to irradiation. The authors concluded from this, that photoinactivation of E. 
coli increases with increasing cationic charge.
Merchat et al [53] conducted a structure-activity relationship study using Enterococcus 
seriolicida, a Gram positive bacteria, Vibrio anguillarum and E. coli, both Gram negative 
bacteria. They used a series of mono-, di-, tri- and tetra-cationic porphyrins as shown in 
figure 30.
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Figure 30. Series of porphyrins synthesised and assayed against Enterococcus seriolicid. Vibrio 
anguillarum and E. coli by Merchat et al [53].
Merchat et al [53] showed that all the porphyrins in figure 30 had a very similar affinity 
for Gram positive and Gram negative bacteria, which was reduced when the porphyrin 
was incorporated into liposomes prior to incubation. The tetra-cationic isomers (22, 33,
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37) exhibited a nearly identical photosensitizing activity, both showing a ~ 4 log decrease 
in cell survival. This compared to ~ 6 - 7 log decrease for the tri- and di-cationic 
porphyrins (34, 35). The results from this study show that /weso-substituted cationic 
porphyrins efficiently photosensitize the inactivation of both Gram positive and Gram 
negative bacteria, and this property appeared to be independent of the number or position 
of positive charges in the meso substituents. Merchat et al [53] proposed that the presence 
of one or more positively charged groups plays an essential role in orientating the 
photosensitizer toward sites which are critical for the stability of cell organisation and / or 
cell metabolism.
Reddi et al [54] conducted a structure activity relationship study looking at TMPyP (22) 
and its derivatives when one of the methyl groups are replace with longer carbon chains 
of C6, CIO, C14, CIS and C22. These compounds were assayed against E. coli and S. 
aureus and the results are shown in table 5. It was found that the CIO, C14 and CIS 
chains were the most efficient photosensitizers and the authors concluded mat a limited 
increase in hydrophobicity of the photosensitizer enhances its affinity for bacterial cells.
Porphyrin
22TMPyP
38 C6
39 CIO
40C14
41 CIS
42C22
Concentration (uM)
8.3
0.4
8.3
0.4
0.8
0.4
0.8
0.4
0.8
0.4
0.8
Growth inhibition 
(%)E.coli
29
5
99
46
96
82
100
26
58
-
3
Growth inhibition 
(%) S.aureus.
96
47
-
74
-
73
-
42
59
27
70
Table 5. Percentage inhibition of growth forE. coli and S. aureus. Structure-activity relationship study by
Reddi et al [54].
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Trannoy et al [55] conducted a structure-activity relationship study in which they 
compared the cationic porphyrins as shown in figure 31 and they used these porphyrins to 
treat pathogens in red blood cells.
R1
23 R' = R" = R"1 = R"" =
22 R' = R" = R'" = R"" =
43 R- = R-" =
44 R1 = R" =
45 R" = R- = R»» =
46 R' = R" = R" 1 = R"" =
A
N 
N— R" = R"" =
N—
//N— R' =
//N ,OH
Figure 31. Structures synthesised and assayed [55]
(\ /)
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They found that the mono-phenyl-tri-(JV-methyl-4-pyridyl) porphyrin 45 was the best 
sensitizer against the vesicular stomatis virus (VSV).
1.7.2.4. Poly-lysine conjugates.
Tom6 et al [56] have reported the synthesis of new conjugates of poly-L-lysine (PL) with 
either neutral or cationic /weso-tetra-substituted porphyrins (see figure 32) and tested their 
activity against 5. aureus, MRSA and E. coli. They found that the phototoxic effect was 
more pronounced in the presence of a polylysine moiety, because the polylysine chain 
can interact with the outer wall structure of Gram negative bacteria, thereby increasing its 
permeability. No dark toxicity was seen for either conjugate and both killed MRSA and 
5. aureus up to >6 log cell survival. The cationic compounds 48 and 49 (Fig 32) were the 
only ones to photo-inactivate the E. coli with a 4-5 log cell survival at a concentration of 
1-5 uM.
50
47 Ar =
48 Ar = N— x = NH2
49 Ar= — x = N+(CH3)3 l-
Figure 32. Poly lysine conjugates with either neutral or carionic charge.
Porphycenes are electronic isomers of porphyrins and Polo et al [57] have conjugated 
them to polylysine moieties of different chain lengths. The polylysine chains were either 
1000-4000 MW (1-4 lysine monomers, average MW = 2900) or 15000-30000 (15-30 
lysine monomers, average MW = 20700). Porphycene when neutral has no PDI effect but 
on binding to a polylysine chain, which is cationic at physiological pH, significant 
toxicity against Gram negative bacteria was reported. The 14-30 lysine chain exerted 
bacteriostatic action in the dark whereas the 1-4 polylysine (PL) chain showed no such 
effect. At a concentration of 1 uM both the 1-4 chain and the 15-30 chain gave significant 
photosensitivity, although E. coli was less susceptible than S. aureus and on increasing 
the concentration to 10 uM it was possible to achieve a 95% loss in cell viability for E. 
coli.
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Soukos et al [58] have tested the hypothesis that polymeric conjugates between PL and 
Cee 50 (see figure 33 for structures) selectively target bacteria for photodestrucrion. They 
varied the charge of the conjugates from cationic through neutral to anionic and 
investigated the selectivity they showed towards two oral bacteria and an oral epithelial 
cell line (HCPC-1). They found that conjugation of €& to PL promotes the uptake of C^ 
by the bacteria and HCPC-1 cells and that the uptake is concentration-dependent. The 
bacteria tested were P. gingivalis and A. viscosus and they both showed the highest 
uptake for the cationic conjugate. HCPC-1 cells accumulated 30 to 100 times less C«e 
from the cationic conjugate than the bacteria did. Photodynamic treatment showed no 
dark toxicity in either bacteria or the HPCL-1 cells at a concentration of 5 uM and the 
results for the photoinactivation are summarized in table 6. The mammalian cells will 
accumulate the C^ conjugate 51, as do the bacteria, however the former are spared due to 
the mammalian cells needing time to internalize the PS.
HOOC
COOH 
COOH
50
COOH 
COOH
. s^ Lys-Lys Lys Lys-Lys-Lys-LysLystys 
\ys-Lys-Lys-Lys-Lys-Lys-Lys-Lys-Lys
51
Figure 33. Structures of free chlorin and polylysine conjugate used by Soukos et al [58].
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Photosenstitizer
Cationic conjugate
Anionic conjugate
Neutral conjugate
Free C^
Mixture (PL and Cee)
% survival for organism or cell line.
P.gingivalis
1,1 ±0.9
23.9 ±3.3
9.3 ±2.6
39.6 ±2.3
8.1 ±1.8
A.viscosus
<0.01
24.3 ±3. 4
21.2 ±1.5
52.9 ±5.9
2 ±0.1
HCPC-1
102 ±2.1
127 ±2.9
108 ±4.2
126 ±2.7
100 ±2.5
Table 6. Results of Soukos et al photoinactivation of P. gingtvatis, A. viscosus and HCPC-1 cells [58].
Hamblin et al [59] developed this study to investigate the effects of PL chain lengths and 
Gram classification on the photodynamic inactivation of bacteria. They used two 
polylysine chain lengths of 8 and 37 lysines respectively and found that S. aureus and E. 
coli took up comparable amounts of the conjugates, but only S. aureus took up the free 
Cee 50. The photoinactivation of the Gram positive S. aureus was fluence dependent for 
the free C^, the 8 lysine conjugate and to a lesser extent with the 37 lysine conjugate. In 
contrast to this it was only the 37 lysine conjugate that inactivated the Gram negative 
E.coli at concentrations of 4uM, and much higher concentrations of 100 fiM were needed 
for photoinactivation using the 8-lysine conjugate. Again in this study the incubation time 
was found to be important as the survival fraction after illumination decreased fairly 
sharply with increasing incubation time for both species.
Although compounds have been tested in-vitro for their ability to photoinactivate 
bacteria, very few studies have been completed in-vivo. Two in-vivo studies have been 
conducted by Hamblin et al [60] and Gad etal[6l]. The first of these studies reports on 
the use of optical techniques to monitor and treat Pseudomonas aeruginosa wound 
infections in mice [60]. The PL-Ce6 conjugate used in the in-vitro studies by the same 
authors [59, 60] was topically applied to a wound and this was followed by illumination 
with red light. The bacteria used were genetically engineered to emit bioluminescence 
which can be detected using an intensified charge-coupled device (CCD) camera. The 
mice used were all males of between 20 and 25g, their backs were shaved and they were 
anesthetized prior to surgery. Wounds were made down to, but not through the
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panniculus carnosu so that there was no bleeding within the wound. 40 mice were used 
and they were split into 4 groups as follows: untreated controls (bacteria alone), bacteria 
plus light, bacteria plus conjugate and bacteria, light and conjugate. Because 
Pseudomonas aeruginosa is invasive, only the PDT-treated wounds could be monitored 
until healing occurred as all the control mice died of systemic sepsis whereas 90% of 
treated mice survived. PDT treatment produced a fluence dependent loss in 
bioluminescence until only a trace remained at a light dose of 240 J/cm2 . The second m- 
vivo study by Gad et al [61] involved the treatment of established bacterial infections in 
mice rather than treatment 30 minutes after infection as in the previous study. Although 
mice have been used as animal models of bacterial infection they are not particularly 
susceptible to developing established soft-tissue infections. In this study S. aureus were 
genetically modified to emit bioluminescence. The mice, again all male and weighing 
between 20 and 25 g, were pre-treated with two doses of cyclophosphamide in order to 
create a temporary state of neutropenia which will allow the infection to take hold. A 
slight reduction in bacterial bioluminescense was observed after initial injection of the 
PL-Ce6 conjugate and this was further reduced after 30 minutes incubation in the dark. On 
illumination there was a light dose dependent reduction in bioluminescense after each 40 
J/cm2 increment. After 160 J/cm2 bioluminescense had decreased to the limit of detection 
and no re-growth of bacteria occurred.
The studies reported thus far in the literature have concentrated on a limited range of 
structures. It has been suggested that the amphiphilic character as well as the cationic 
character of porphyrins is important in the PDI of bacteria. A new route to cationic 
porphyrins is needed in which the amphiphilic character of the molecule can be altered 
relatively easily and this it should make it possible to produce a library of compounds 
which can be screened to assess the PDI of bacteria.
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Chapter 2. Photosensitizer synthesis. Tetra-cationic compounds. 
2.1. General synthetic routes to cationk porphyrins,
2.1.1. Quatemisation of 5,10,15, lO-tetra-^V-methylpyridyl) porphyrin and 5, 10, 
15,20-tetra-(4-.Y, JV, /V-trimetbyl-aniUniiim) porphyrin.
The commercially available 5,10, 15,20-tetra-(4-JV-methylpyridyl) porphyrin 22 and 5, 
10, 15, 20-tetra-(4-JV; N, N-trimethyl-anilinium) porphyrin 23 have been widely used in 
PACT studies and one reason for their popularity is that they can be synthesised 
relatively easily. The 5,10,15, 20-tetra-(4-J\r-methylpyridyl) porphyrin 22 is synthesised 
as shown in scheme 5. The first step in the synthesis is an Adler reaction, where pyridine- 
4-carboxaldehyde 52 and pyrrole 14 are refluxed in propionic acid for 30 minutes, men 
allowed to cool to room temperature. The precipitate is then filtered off and washed with 
methanol to afford 5, 10,15,20-tetra-(4-pyridyl) porphyrin 53 as a purple solid. The 5, 
10,15,20-tetra-(4-pyridyl) porphyrin is then treated with methyl iodide to produce 5, 10, 
15,20-tetra-(4-A/r-methyl-pyridyl) porphyrin 22 as its tetra iodide salt.
O Propionic add  N
14 <-,
53 22
Scheme 5. Synthetic route to 5,10,15,20-tetra-(4 -tf-methyl-pyridyl) porphyrin 22.
Similarly the 5,10,15,20-tetra-(4-^ N, ^-frimethyl-anilinium) porphyrin 23 (scheme 6) 
is made by means of an Adler reaction between 4-dimethylaminobenzaldehyde 54 with 
pyrrole, the product of which 55, is men treated with methyl iodide to produce 5,10,15, 
20-tetra-(4-JV; JVj JV-trimethyl-anilinium) porphyrin 23.
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14
Scheme 6. Synthetic route to 5,10, is, 20-tetra-(4-N, N, N-trimethyl-anilinium) porphyrin.
R-N
-R
56
57
58
59
60
61
62
63
,OH
Figure 34. Compounds made by Dancil et al [62].
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5, 10, 15, 20-tetra-(4-A/-methyl-pyridyl) porphyrin has been derivatized by Dancil et al 
[62] in order to systematically determine the influence of W-alkyl chain length, JV-alkyl 
chain functionality and peripheral charge distribution on the self-association of cationic 
porphyrins. A series of compounds were synthesised which are shown in figure 34. The 
general procedure for alkylation of 5, 10, 15, 20-tetra-(4-pyridyl) porphyrin 55 was to 
heat the starting porphyrin in DMF to 100°C and slowly add the alkylating agent, in this 
case alkyl bromides. The solution was then refluxed for 4 hours, cooled and the product 
collected by filtration.
2.1.2. Quaternisation of 22 using perfluorocarbon chains.
Perfluorocarbons (PFCs) have attracted much attention due to their unusual properties 
[63, 64, 65, 66]. PFCs can dissolve large volumes of respiratory and other non-polar 
gases and Lowe's review [67] gives examples of the uses which PFCs have found in 
medicine and cell biotechnology. The comparison of oxygen solubility in water (2.2 
mmol/1) with that of oxygen solubility in PFCs (35-44 mmol/1) [67] suggested that this 
property could be used to enhance the effect of PDT. We hypothesised, that the addition 
of highly fluorinated groups, to cationic porphyrins, would increase oxygen 
concentration. On irradiation with red light, this would then yield an increased yield of 
singlet oxygen, and hence lower drug concentrations would be needed. We therefore 
decided to attempt the synthesis of molecules bearing highly fluorinated side chains. In 
order to achieve this analogues of the commercial compounds, 5,10,15,20-tetra-(4-AT, N, 
JV-trimethyl-anilinium) porphyrin (23) and 5, 10, 15, 20-tetra-(4-pyridyl) porphyrin (22) 
were used. Namely, the syntheses of 5, 10, 15, 20-tetra-(4-N-(lH, 1H, 2H, 2H- 
perfluorohexyl)-pyridyl) porphyrin (66), 5, 10, 15, 20-tetra-{4-JV- (1H, 1H, 2H, 2H- 
perfluorododecyl)-pyridyl) porphyrin (67), 5, 10, 15, 20-tetra-(4-(#-(lH, 1H, 2H, 2H- 
perfluorohexyl)-dimethylamlinium) porphyrin (68) and 5, 10, 15, 20-tetra-(4-(JV-lH, 1H, 
2H, 2H-perfluorododecyl)-dimethylarn'linium) porphyrin (69) were attempted. The 
structures of these compounds are shown in figure 35. The synthesis followed the 
methods of Dancil et al [62], except that alkyl iodides were used rather than alkyl 
bromides. However the synthesis and purification of these molecules proved to be 
problematic.
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Figure 35. 5, 10, 15, 20-tetra-(4N- IH, IH, 2H, 2H-perfluorohexyl-pyridyl) porphyrin (66X 5, 10, 15, 20- 
tetra-(4N- IH, IH, 2H, 2H-perfluorododecyl-pyridyl) porphyrin (67), 5, 10,15, 20-tetra-(4N- IH, IH, 2H, 
2H-perfluorohexyl-anilinium)porphyrin (68), 5, 10, 15, 20-tetra-(4N- IH, IH, 2H, 2H-perfluorododecyl- 
anilinium)porphyrin (69).
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It was found that under the conditions used by Dancil et al [62] no change was seen from 
the starting material even on refluxing for up to 3 days. Thin layer chromatography 
(TLC) in 90/10/0.5 chloroform: methanol: 25% NH3 in H2O indicated that a cationic 
product was formed which was not a porphyrin. It was deduced that the 
iodoperfluorohexane and iodoperfluorododecane were reacting with decomposition 
products of the solvent, dimethylformamide (DMF), instead of the nitrogen atoms on the 
porphyrins. Dioxane was used instead of DMF but again no change was seen from the 
starting materials, possibly due to the boiling point of dioxane lowering the reaction 
temperature. Purification of the compounds, from a reaction which had gone partly to 
completion, was problematic due to the porphyrins sticking to the amberlite ion exchange 
resin.
Tjahjono et al [68,69] have synthesised octa-cationic porphyrins bearing diazonium 
rings, as shown in figure 36, and these were used to study their interaction with calf 
thymus DNA. They were synthesised via an Adler reaction between either 1- 
methylimidazole-2-carboxaldehyde or l-methylpyrazole-4-carboxaldehyde and pyrrole, 
followed by quaternisation with methyl iodide.
R =
\
N
R =
Figure 36. Tjahjono's octa-cationic porphyrins bearing diazonium rings.
These porphyrins were then metallated with Mnra, Nin, Cun or Znn and it was found that 
he nickel and copper porphyrins intercalated into the 5'GC3' step of ctDNA, in which
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the 2 positively charged N, W-dimethylpyrazolium rings were located in the major groove 
and the 2 others were located in the minor groove. The manganese porphyrin was bound 
edge-on at the 5'TA3' step of the minor groove of ctDNA and the zinc porphyrin was 
bound face-on at the 5'TA3' step of the major groove of ctDNA
2.1.3. Attempted synthesis of 5,10,15,20-tetra (4-(aminomethyl) phenyl) porphyrin
(70).
Amines at physiological pH are cationic and therefore photosensitizers with multiple
amine groups can be used in PACT. It was decided to attempt the synthesis of the 5,10,
15,20-tetra-(4-(aminomethyl)phenyl) porphyrin (70), shown in figure 37.
Figure 37. 5,10,15,20-tetra-(4-(aminomethyl)phenyl) porphyrin.
It has been reported that the aminomethyl groups can be synthesised by the reduction of a 
nitrile group [71, 72, 73, 74, 75]. 5, 10, 15, 20-tetra-(4-cyanophenyl) porphyrin (71) was 
synthesised via an Adler reaction between 4-cyanobenzaldehyde (72) and pyrrole (14) in 
propionic acid. Several attempts were then made to reduce the nitrile groups although all 
these attempts proved fruitless. 5, 10, 15, 20-tetra-(4-cyanophenyl) porphyrin (71) was 
stirred with lithium aluminium hydride in THF in the dark for 4 days, but no change was 
seen relative to the starting material by TLC. Reduction using borane-THF complex was
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attempted by refluxing 71 with this reagent for 18 hours, but no porphyrin was left in the 
reaction mixture after this time as determined by UV-visible spectroscopy. It was 
concluded that the borane-THF complex had attacked the macrocycle. Milder conditions 
of stirring the reaction at room temperature were attempted, but no change was seen from 
the starting materials. Finally, reduction of the nitrile groups was attempted by 
hydrogenation using palladium on carbon catalyst in THF / EtOH (3:1). The reaction was 
carried out at 40 psi overnight with shaking but again there was no change from the 
starting material and the majority of the porphyrin stuck to the palladium carbon catalyst. 
Zhang and Lippard [76] have employed the Gabriel synthesis on porphyrins to convert 
bromomethyl groups into aminomethyl groups. Brunner and Schellerer [74] have also 
used a modified version of this reaction in order to produce the phthalimide group via a 
Mitsunobu methodology [77] using triphenylphosphine, potassium phthalimide and 
diethyl azodicarboxylate (DEAD). The advantage of this method is that it has one less 
step in the synthetic route to the amine. It bypasses the bromination of the hydroxymethyl 
groups prior to conversion to phthalimido groups. It was decided to attempt a modified 
Gabriel synthesis [78] from 5,10,15,20-tetra-(4-(hydroxymethyl)phenyl) porphyrin (73) 
using DEAD, PPhs, and potassium phthalimide, in order to produce 5,10,15,20-tetra-(4- 
(phthalimidomethyl)phenyl) porphyrin (74), as shown in figure 38. 74 was successfiilly 
made in a 54% yield, and so the hydrolysis of 5, 10, 15, 20-tetra-(4- 
(phthalimidomethyl)phenyl) porphyrin was attempted, using NaOH and HCL, as 
described by Lavallee et al [79]. However the hydrolysis proved problematic. The 
reaction did not go to completion, by TLC, and purification proved problematic due to 
the solubility's of both compounds in aqueous work up (both stick to silica / alumina and 
so column not possible).
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Figure 38. 5,10,15,20-tetra-(4-(phlhalimidomethyl)phenyl)porphyrin
2.1.4. Alternative route to tetra-cationic porphyrins.
Cationic porphyrins are usually derived from 5, 10, 15, 20-tetra-(4-pyridyl) porphyrin or 
5,10, 15, 20-tetra-(4-aminophenyl) porphyrin and in using these types of compounds the 
nitrogen atoms are already attached to the porphyrin precursor prior to quaternisation to 
cationic centres. This methodology limits the number and type of cationic compounds 
that can be made to the amount of halo-alkanes that are available. Ideally what is needed 
is a synthetic route that can be manipulated in order to give as diverse a range of cationic 
centres as possible with the minimal amount of steps involved in the synthesis. One such 
route was developed by Jin el al [80, 81]. They produced water soluble cationic 
porphyrins containing different phosphonium and ammonium cations derived from one 
precursor, namely, 5, 10, 15, 20-tetra-(4-(chloromethyl)-phenyl) porphyrin (80). Initially 
they had to make the starting benzaldehyde, 4-chloromethylbenzaldehyde (79), as shown 
in Scheme 8. This was achieved by protection of the aldehyde as an acetal, reduction of 
the methyl ester group to the hydroxyl group, chlorination, and finally deprotection of the
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acetal to give the desired aldehyde. 79 was then reacted with pyrrole under Lindsey 
conditions to afford 80 in a 47% yield. 80 was reacted with either excess 
triphenylphosphine or triethylamine in DMF to produce the compounds shown in figure 
39.
80
Scheme 8. Synthetic routes to 79 and 80 [80, 81]. i) glycidyl methyl ether (excess), tetrabutylammonium 
bromide (cat), 80°C,3 days; ii) a. LiAfflL, in THF, 70°C, 16hrs b. NI^C^ iii) PPh3, CCl,, reflux, 3hrs iv) 
EtOH, 2M HCI room temp, 1 hr; v) a. BF3-Et2O, CHC13, room temp, Ihr. b. chroranil, NH3, CHC13, reflux,
Ihr.
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81 82
Figure 39. The structures of 81 and 82 [80, 81].
2.2. Synthetic route used.
Mthough some structure-activity relationship studies are available in the literature most
lave been conducted on commercially available porphyrins. A new series of compounds
lave been synthesised to study the effect of lipophilicity, aromatic vs aliphatic groups
iround the cation, and whether the analogous phosphorous cations show significant
lifferences in photo-inactivating bacteria compared with their nitrogen analogues.
The synthetic route devised by Jin et al [80] has been adapted to allow a parallel
ynthesis, from one intermediate compound, in which numerous compounds can be made
imultaneously and their structure-activity relationships compared in-vitro. The
strosynthetic analysis is shown in figure 40 and the synthetic route chosen for use, is
hown in Scheme 9. Retrosynthetic analysis showed two possible routes to the
itermediate compound 5, 10, 15, 20-tetra-(4-(bromomethyl)phenyl) porphyrin (83).
etrosynthetic route 1 shows a two step method where 5, 10, 15, 20-tetra-(4-
icthylphenyl) porphyrin (84) is synthesised via an Adler reaction from pyrrole (14) and
 methyl benzaldehyde (85). Bromination of 5, 10, 15, 20-tetra-(4-methylphenyl)
jrphyrin (84) would then afford the desired intermediate, Bromination reactions using
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NBS and a radical initiator have been used for this however the [i-positions could also be 
brominated, and this would result in extensive chromatography in order to isolate the 
desired compound. Although retrosynthetic route 2 has more steps than route 1 they are 
widely used and afford high yields hence this was the chosen route to 83. The initial step 
in the synthesis was an Adler reaction between 4-formyl-benzoate (86) and pyrrole (14). 
The 5, 10, 15, 20-tetra-(4-(carboxymethyl)phenyl) porphyrin (87) was then reduced using 
LiAlH, in dry THF to 5, 10, 15, 20-tetra-(4-(hydroxymethyl)phenyl) porphyrin (73). 
Bromination, using PBrs in dioxane, gave the intermediate compound 5, 10, 1.5,20-tetra- 
(4-(bromomethyl)phenyl) porphyrin (83). It was decided to use 83 rather than 80 because 
the bromide ion is a better leaving group than the chloride ion, and hence reactions 
should be more facile and an increased number of compounds could be made for the 
library. 83 was spilt into batches and the parallel synthesis of cationic porphyrins was 
conducted by heating 83 in DMF and adding the appropriate phosphine, amine or arsine. 
Purification of final compounds was achieved by precipitation between methanol and 
iiethyl ether followed by microfiltration.
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OH
Figure 40. Retrosynlhetic analysis of 5,10,15,20-tetra-(4-(bromomethyl)phenyl) porphyrin (83).
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14
LiAIH4
87
PBr3
Scheme 9. Synthetic route used for the library of catiomc porphyrins.
2.3. Parallel synthesis vs step-wise synthesis.
It was decided to use a parallel synthesis rather than a stepwise synthesis in order to 
minimise the amount of reaction steps needed and hence to improve the yield. The 
intermediate 5, 10, 15, 20-tetra-(4-(bromomethyl) phenyl) porphyrin was produced and 
was subsequently split into batches for the parallel production of the final library of 
compounds.
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2.4. Library of compounds made.
Figure 41 shows the combinatorial library of compounds made for use in PACT.
88 89 90 91
92 82 93
"N"
94
95 81 96
Figure 41. Library of compounds made for use in PACT (all counter ions are Br").
series of cationic compounds have been made for use in PACT. An additional three 
>mpounds were provided by Dr. R. Hudson and are shown in figure 42. Compounds 97 
id 99 have cationic charges, although the groups surrounding the cationic centres differ. 
Dmpound 98 however, I believe to be the neutral compound shown in figure 43, hence it
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may not have any biological activity. The electrospray mass spectrum of compound 98 
shows a lone peak at 1065.0 (TvT) which suggests that the compound is not charged, due 
to the lack of any (M4*), (M + Br)3+, or (M + 2Br)2+ peaks shown for all of the other tetra 
cationic porphyrins.
97 R = 98 R = 99 R =
Figure 42 Compounds supplied by Dr. R. Hudson for use in PACT.
was now possible to compare the structure-activity relationships for the PDI of bacteria 
om nitrogen, phosphorous and arsenic cations and analyse these using standard 
 ualitative Structure Activity Relationship (QSAR) methods.
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Figure 43. Alternative structure of compound 98.
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Chapter 3. Compounds with greater than 4 cationic charges.
Cationic porphyrins have been utilised for PACT, the most studied being 5,10 IS, 20- 
tetra-(4-N-methylpyridyl) porphyrin 22 or related compounds derived from this porphyrin 
core. Spesia et al [52] showed that the PDI of E. coli increases with increasing positive 
charge, using compounds with between 1 and 4 cationic charges. To explore mis 
hypothesis further it was decided to investigate the use of photosensitizers with greater 
than four cationic charges. This would then allow for the comparison of bacterial PDI for 
bom the octa- and tetra-cationic compounds.
3.1. Octa-cationic porphyrins.
3.1.1. Attempted synthesis of octa-cationic porphyrins.
Marzilli et al [82] have synthesised an octa-cationic porphyrin, 100, for use in DNA 
binding studies, as shown in figure 44.
Figure 44. 100 made by Marzilli etal for use in DNA binding studies [82]
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Schneider et al [83] have also examined DNA interactions of porphyrins bearing 
ammonium side chains. They investigated cationic ammonium groups spaced at a 
distance from the macrocycle (scheme 10) rather than close to it as with 5, 10, 15, 20- 
tetra-(4-7V-methylpyridyl) porphyrin and 5, 10, 15, 20-tetra-(4-Ar, N, //-trimethyl- 
anilinium) porphyrins.
102 X = N+Me,
103 X = Py*
Scheme 10. Synthesis of compounds with cationic charge at a distance from the macrocycle [83].
Although the compounds shown in scheme 10 and figure 45 are not octa-cationic 
porphyrins, the methodology was adapted to produce octa-cationic compounds.
72
OMe
MeO
Figure 45. Compound 104 made by Schneider etal [83] which could be adapted to produce an octa-
cationic compound for use in PACT.
In an attempt to produce an octa-cationic porphyrin, the following synthesis was 
performed (shown in figure 46):
o
14 105
Figure 46. Synthetic route to 5,10,15,20-tetra-(4-(3-bromopropoxy)phenyl) porphyrin 101. Quaternisation 
to produce octa-cationic compound was unsuccessful.
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The first step in the synthesis was an Adler reaction, producing 5, 10, 15, 20-tetra-(4- 
hydroxyphenyl) porphyrin (106), from 4-hydroxybenzaldehyde (105) and pyrrole. This 
was then converted to 5,10,15,20-tetra-(4-(3-bromopropoxy)phenyl) porphyrin (101) by 
the method reported by Momenteau et al [83]. Namely 5, 10, 15, 20-tetra-(4- 
hydroxyphenyl) porphyrin was dissolved in dry dioxane with potassium carbonate. The 
reaction was heated to 100°C and 1, 3-dibromopropane was added drop wise. The 
reaction was stirred at 100°C for 4 days and allowed to cool to room temperature. It was 
then filtered and the filtrate evaporated in-vacuo. Quaternization was then attempted 
using N, N, N', JVT-tetramethylethylene diamine (107) or N, N, N', JV-tetramethyl-p- 
phenylene diamine (108). The Quaternization, however, proved problematic. It was found 
that the diamine reacted with the 5, 10, 15, 20-tetra-(4-(3-bromopropoxy)phenyl) 
porphyrin, to form a cross-linked polymer, rather than the desired product. To overcome 
this problem methyl iodide was added slowly to a solution of ice cold chloroform. N, N, 
N', .AT-tetramethylethylene diamine was added in a 1:1 ratio. This ratio was used to 
attempt to quaternize one of the amine functionalities whilst leaving the other free for 
further reaction, as described by Schneider et al [82]. Unfortunately TLC revealed that 
both ends were quaternized simultaneously, leaving the reaction mixture with either 
doubly quaternized amine or doubly free amines (shown in scheme 11).
MeL
^N >|
107
Scheme 1 1 . Quaternization with methyl iodide resulted in di-quatemized product rather than mono-
quaternized product.
3.1.2. Retrosynthesis of an octa-cationic porphyrin
Figures 47 and 48 show the retrosynthetic analysis of the octa-cationic 5, 10, 15, 20- 
tetra-(4-(dimethylamuio-ethyl-trimethylamino)methylphenyl) porphyrin (108). Route 1
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was chosen as the preferred synthetic route due to the complications involved in 
quaternizing one end of the diamine without quaternizing the other as shown in scheme
11. The synthetic route used for the synthesis is shown in scheme
12.
Route 1
HX- V V * 8r'
Figure 47. Route 1. Retrosynthetic analysis of 5,10,15,20-tetra-(4-(dimethylammo-e1iiyl- 
trimethylamino)methylphenyl) porphyrin (108).
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Route 2
Continues as per Route 1
Figure 48. Route 2. Retrosyntfaetic analysis of 5,10,15,20-tetra-(4-(dimethylarnino-ethyl- 
trimethylamino)methylphenyl) porphynn (108).
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108 110
Scheme 12. Synthetic route used for octa-cationic poiphyrin.
3.1.3. Octa-cationic compounds - synthesis attempted.
Synthesis of a series of octa-cationic compounds for screening against bacteria was 
attempted as shown in figure 49. They vary in chain length between the nitrogen atoms, 
namely C2,C3 and C6.
77
112
Figure 49. Octa-cationic compounds made for use in PACT.
The intermediate 5, 10, 15, 20-tetra-(4-(bromomethyl)phenyl) porphyrin (83) was reacted 
with a Boc-protected diamine, purchased from Aldrich, then deprotected using 5%TFA in 
DCM. The resulting octa-amine porphyrin (113) was purified by dialysis and 
quaternization was attempted. However problems arose on quaternization of the amino
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groups with methyl iodide because the reaction did not go to completion, even on 
heating, and hence purification proved problematic.
3.2. Dendritic porphyrins.
3.2.1. Dendrimers.
Dendrimers are monodisperse macromolecules with a regular and highly branched three 
dimensional architecture. They are produced in an iterative sequence of reaction steps 
leading to higher generations. The first example of a dendrimer was produced by Vogtle. 
There are two ways to make dendrimers, by divergent or convergent synthesis. In 
divergent synthesis the dendrimer is grown from the core in a stepwise manner and many 
reactions are performed on a single molecule as shown in figure 50.
X^N^X __ 1
^ x^N-
x
Generation 1.
Generation 3.
X X 
Figure 50. Example of divergent dendrimer synthesis.
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The opposite of divergent synthesis is convergent synthesis, in which the molecule is 
synthesised from the periphery, in towards the core. This method allows a lower number 
of reaction sites per step and is shown in figure 51.
X
I
Core
v y
f T X ^ ^ N s"^-^^I ^ X\X/XM/\X'N\^^K,^\/ ^^ NV^ j-X^sSt * jJ n N I; ** C.-CT ^ ^ S
s " ,_/x
Generation 3. 
x
Figure 51. Convergent dendrimer synthesis.
Buhleir et al [84] reported the first dendritic structure to be synthesised via a divergent 
synthesis in 1978. They treated a primary amine with acrylonitrile in a conjugate addition 
reaction to form the desired dinitrile (scheme 13). This was then reduced by using cobalt 
(II) chloride hexahydrate and sodium borohydride, in methanol, to produce the diamine. 
The process was then repeated in order to generate the hepta-amine. However, more 
recent repetition of the reduction conditions, have proven them to be unreliable and 
diisobutyl aluminium hydride [85] or hydrogenation using Raney nickel on cobalt 
catalyst [86] have been used in its place.
80
red
red
Scheme 13. Vdgtle etal's divergent synthesis to a hepta-amine.
Shortly after the report of Vogtle et al [87], came another from Denkewalter in 1981 [88]. 
He reported the first divergent preparation of dendritic polypeptides using the protected 
amino acid N, AT-bis(tert-butoxycarbonyl)-L-lysine as a building block (scheme 14).
81
H,N
Scheme 14. Denkewalter's divergent synthesis of dendritic polypeptides [88].
>ince then many other dendrimers have been reported with multiple generations and they 
lave been utilised for a wide range of purposes including drug delivery, energy/ light 
arvesting, ion sensing, catalysis, information storage, immuno-diagnostic agents, 
ibricants, diagnostic reagents, vaccines against bacteria, viruses, parasites, modification 
f gene expression and PDT [89, 90, 91].
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3.2.2. Porphyrin dendrimers.
Examples of porphyrin dendrimers exist and porphyrin dendrimers with cationic charges 
on the periphery are of particular interest for use in PACT as they are single, discrete, 
molecules with a known molecular weight. Another reason for interest in cationic 
dendrimers is that the number of cationic charges increases per generation and hence it 
would be possible to find the optimum amount of cationic charge needed for use in the 
PDI of Gram negative and Gram positive bacteria.
3.2.2.1. Target porphyrin dendrimers.
Three target porphyrin dendrimers were identified which bore cationic charges on the 
periphery and the synthesis was undertaken with varying degrees of success. The 
structures of the first generation compounds are shown in figures 52, 53 and 54.
Figure 52. Porphyrin dendrimer (114).
83
115
Figure 53. Porphyrin dendrimer (135).
116
Figure 54. Porphyrin dendrimer (143).
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3.2.2.2. Synthesis of porphyrin dendrimer 114.
Retrosynthesis of porphyrin dendrimer 114 showed a number of different routes, to this 
compound, the first of these is shown in figure 55.
Figure S3. Retrosynthesis of porphyrin dendrimer 114.
The synthetic route used for the attempted synthesis of porphyrin dendrimer 114 is shown 
in scheme 15.
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114
Scheme 15. Synthetic route to porphyrin dendrimer 114.
Prior to synthesising this compound using the porphyrin core, it was decided to test the 
methodology using benzylamine, as shown in scheme 16. The reaction yielded the mono- 
substituted product 121, with a small fraction of di-substituted product 122. It was
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therefore decided not to attempt this synthetic route using the porphyrin, due to the 
possibility of multiple products occurring. This would cause problems with purification 
and extensive purification would be needed, resulting in low yields.
Na2CO
120 117
122
Scheme 16. Synthesis attempted using benzylamine instead of the porphyrin core to test the feasibility of
the reaction.
The retrosynthesis of an analogous compound (123), with one less carbon atom in the 
alkyl chain, was attempted. This is shown in figure 56.
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123
IH2
Figure 56. Retrosynthesis using analogous compound, porphyrin dendrimer (123).
The synthetic route followed is shown in scheme 17. Again, the synthetic route was 
tested prior to using the porphyrin, and this is shown in scheme 18.
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Generation 2
Scheme 17. Synthetic route to porphyrin dendrimer 123.
89
120 124 127
SchemelS. Synthetic route used for test reaction.
The main problem which occurred using this route was that the reduction of the nitrile 
groups to amino groups did not work despite using several methods. The methods 
attempted included LiAlRt, borane-THF complex and hydrogenation with palladium on 
carbon. It was therefore decided to look at an alternative route, where the reduction of the 
nitrile group was not required. The retrosynthesis of this is shown in figure 57.
90
128
Figure 57. Retrosynthesis of 123.
The methodology for the synthetic route was again, tested using benzylamine instead of 
the porphyrin core. The synthetic route used is shown in scheme 19.
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NHBOC
134 133 132
Scheme 19.
Firstly, chloropropylamine hydrochloride (130) was Boc-protected using the method 
described by Kohl et al [91]. Namely, chloropropylamine hydrochloride and di-tert- 
butyldicarbonate (131) were dissolved in THFAVater (50/50 v/v) and the pH was adjusted 
to 8.5 with 4% aqueous NaOH, the reaction was then stirred overnight. The solution was 
acidified to pH 2 using 0.1M HC1 and the product extracted into chloroform. The product 
129 was reacted with benzylamine in the presence of base, deprotected and quaternized 
using methyl iodide. However this was not attempted on a porphyrin due to problems 
encountered synthesising 5,10,15,20-tetra-(4-(aminomethyl)phenyl) porphyrin (70).
3.2.2.3. Synthesis of porphyrin dendrimer 135.
Hamblin et al [59] have shown that polylysine conjugated to a chlorin e6 molecule is 
active against bacteria. However polylysine is not a single discrete molecule, as is 
desirable for a good PDT agent. It was thus decided to attempt the synthesis of a 
porphyrin dendrimer containing a known number of lysine units and hence with a known 
molecular weight. The retrosynthesis of this and the synthetic route are shown in figure 
58 and scheme 20 respectively.
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NHBoc NHBoc
NHBoc NHBoc
Figure 58. Retrosynthesis of porphyrin dendrimer 135.
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NH.
NHj NH2
139
Scheme 20. Synthetic route to porphyrin dendrimer 135.
The lysine (136) was Boc-protected via the methodology of Kohl et al [91]. Following 
aqueous work up, the doubly protected lysine (137) was produced with a free carboxylic 
acid group for attachment to the porphyrin core. A test reaction, shown in scheme 21, was 
carried out using benzylamine in place of the porphyrin core. DCC [92] was used to 
couple the Boc-protected lysine to benzylamine and the product was then deprotected and 
quaternized using methyl iodide.
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NHBoc
140
O
142
Scheme 21. Synthesis testing the methodology of porphyrin dendrimer 135.
However, problems occurred producing the porphyrin core as previously stated in section 
2.1, and hence it was not possible to make porphyrin dendrimer 135.
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$.2.2.4. Synthesis of porphyrin dendrimer 143.
7igure 59 shows the retrosynthesis of porphyrin dendrimer 143.
NH,
H/4
Figure 59. Retrosynlhesis of porphyrin dendrimer 143
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The dendritic wedge (145) for porphyrin dendrimer 143 was prepared via a method 
described by Dupraz et al [93] and Dayan et al [94], and is shown in scheme 22.
-CN
r— OH
^~^OH
OH
144 124
Scheme 22. Synthetic route to the dendritic wedge.
To a vigorously stirred solution of tris (144), acrylonitrile (124) and BmNBr in DCM, 
40% NaOH was added whilst controlling the temperature between 10°C and 20°C. This 
was stirred overnight and following aqueous work up the desired product was recovered.
HC
146
Scheme 23. Coupling dendritic wedge to porphyrin core.
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Attempts were then made to couple 145 to 5, 10, 15, 20-tetra-(4-(carboxy)phenyl) 
porphyrin (146) (scheme 23) via a variety of coupling conditions as reviewed by Han et 
il [94]. These included the methodologies of Dandhker et al [96] (DCC, HOBt, THF), 
Vinogradov et al [97] (DCC, pyridine, THF), Gradl et al [98] (oxalyl chloride, DMF in 
DCM) and Dourtoglou et al [99] (HBTU, HOBT, N-methyl morpholine). However all 
ittempts to couple the dendritic wedge to 5, 10, 15, 20-tetra-(4-(carboxy)phenyl) 
)orphyrin proved unsuccessful. In some attempts it was possible to see, by TLC, that one 
>r two of the wedges had reacted with the carboxylic acid group of porphyrin 146. These 
lowever were not isolated from the reaction mixture, due to the extensive 
;hromatography that would be needed and low yields of either cis or trans isomers that 
vould be produced. It is believed that the bulky size of amine wedge 145, caused steric 
lindrance to occur, preventing the attachment of all four amines to the porphyrin core.
t was decided to investigate the use of photosensitizers with greater than four cationic 
barges to allow the comparison of bacterial PDI for both the tetra-cationic compounds 
ad compounds with greater than four cationic charges, however various problems were 
ticountered with the syntheses. The main problem encountered in the synthesis of the 
cta-cationic porphyrins was purification of the products. This was also the case for the 
sndritic porphyrins which did not go to completion. An additional problem was 
icountered in the synthesis of the starting porphyrin, 5, 10, 15, 20-tetra-(4- 
minomethyl)phenyl) porphyrin (70), Several synthetic routes to this porphyrin were 
tempted without success as discussed in chapter 2.1.3.
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Chapter 4. Bacterial assay development.
4.1. Bacterial assay.
Several different assays exist in the literature for use in PACT, however many of these 
suffer from problems including the use of white light, not washing cells, inconsistent 
light doses and not using single, discrete molecules for assays against bacteria. For this 
reason it was decided to develop a new bacterial assay to avoid all of these problems and 
find the optimum conditions needed for assays used in PACT.
4.1.1 Compound used for assay development.
For this study it was decided to use 5, 10, 15, 20- tetra-(4-Ar, N, 7V-trimethyl-anilinium) 
porphyrin (23) for the development of the bacterial assay because it has been widely used 
in the literature (See chapter 2) and has been shown to cause an effective PDI of Gram 
positive and Gram negative bacteria. The compound is also commercially available, thus 
ensuring consistency between batches.
4.1.2 Bacterial strains used.
A Gram positive and a Gram negative bacterium were used for the development of the 
bacterial assay so that it would be possible to compare and contrast the differences 
between the two types of bacteria. All organisms were obtained from Hull Royal 
Infirmary Microbiological services. The Gram negative bacterium used was E. coli 
NCTC and the Gram positive bacterium used was MRSA (see 4.2.2 for sensitivities), as 
this is a major cause of hospital acquired infection, especially in the elderly or 
immunocompromised patients.
4.1.3. Drug concentrations.
The initial drug concentration range used was from 0 to 50 fiM. This was in order to gain 
an understanding of the amount of compound needed for the PDI of bacteria and so 
accurate dose response curves could be plotted. Thus the optimum concentration of drug 
needed for the PDI of bacteria using this compound could be identified and used as a
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 eference point for future assays. All drug concentrations were performed in triplicate to 
dlow a statistical estimate of accuracy.
1.1.4. Overnight Culture preparation.
Bacteria were grown over night in Luria-Bertani media [3]. lOul of this was then diluted 
jither lin 1000, 1 in 10,000 or 1 in 100,000. lOOul of this diluted culture was then spread 
>ver agar plates and left to incubate over night. The colony forming units were then 
;ounted and the number of cells per lOul of the undiluted overnight culture was 
;alculated. The number of cells used in each well was calculated to be 3.5*108 per well.
1.1.5. Initial Protocol followed.
"assays were performed in 96-well conical bottomed plates. The initial protocol was as 
ollows: overnight culture (lOul), drug solution (lOul) and Luria-Bertani (LB) media 
190ul) were placed in each well. The plates were left to incubate at 37°C for 4 hours, 
ifter incubation the plates were washed twice (centrifuged for ten minutes (1500 g, 
0°C), then re-suspended in fresh media). The contents of the wells were re-suspended in
 esh media and transferred to 96-well flat bottomed plates. Two plates were used in the 
ssay, one to be kept in the dark as a control and the other to be irradiated. The plate was 
radiated for 10 minutes using a panel of red light emitting diodes (Omnilux®), with a 
laximal output at 633 nm ± 3 nm. After irradiation the cells were incubated overnight 
id the absorbance read at 630nm from both the dark control and the irradiated plate.
1.6 Initial results.
lie initial assay results for the commercially available 5, 10, J5, 20-tetra-(4-Ar, N, N- 
methylanilinium) porphyrin (23) against MRSA and E. coli are shown in figures 60 and 
respectively.
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Initial assay results for MRSA.
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Figure 60. Initial assay results for MRSA using 5,10, 15, 20- tetra-(4-N, N, 7V-trimethyl-anilinium)
porphyrin (23).
Initial assay results for E. coli.
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Figure 61. Initial assay results for£. coli using 5,10,15,20- tetra-(4-N, N, TV-trimethyl-anilinium)
porphyrin (23). 
cell kill was seen for either the Gram positive MRSA or the Gram negative E. coli.
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4.2. Protocol optimisation.
4.2.1. Higher drug concentrations.
No cell kill was seen for drug concentrations between 0 - 50uM so it was decided to try 
higher drug concentrations of up to 200uM. The results of this showed no cell kill for 
either MRSA or E. colt.
4.2.2. Bacterial viability assay
No cell death had been observed for the assays using 5, 10, 15, 20-tetra-(4-A/, N, N- 
trimethyl-anilinium) porphyrin despite literature sources reporting that it was effective in 
killing bacteria. Therefore it was decided to check that the cell lines were still viable by 
issaying them against gentamycin. Overnight culture (lOul) and LB media (190ul) were 
Dlaced in each well and gentamycin was added, at concentrations from 0-20 uM. The 
;ells were incubated for 5 hours and 24 hours respectively and the absorbance was read at 
>30nm. The results, shown in figures 62 and 63, show a significant decrease in 
tbsorbance after both 5 and 24 hours for both MRSA and E. coll. Therefore it was 
lecided that both cell lines were still viable for use in the assay.
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Results for gentamycin assay against MRSA.
10 
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Figure 62. Dose response curve for gentamycin against MRSA
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Figure 63. Dose response curve for gentamycin against E. coh.
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It was decided to test the sensitivities of the MRSA used against a number of other 
antibiotics using a disc diffusion test, the results of which are shown in table 7.
Name of Anitbiotic
Flucloxacillin
Penicillin
Clarithromycin
Fusidic acid
Vancomycin
Gentamycin
Linezolid
Ciprofloxacin
Mupirocin
Trimox
Neomycin
Rifampin
Tetracycline
Type of Antibiotic
P-lactam
P-lactam
Macrolide
Cholestadienes
Glycopeptide
Aminoglycoside
Oxazolidinone
Fluoroquinolone
Polyketide
P-lactam
Aminoglycoside
Semi-synthetic. 
Inhibits RNA synthesis
Tetracycline
Resistant or sensitive
R
R
R
S
S
S
S
R
S
S
S
S
S
Table 7. Antibiotic sensitivities of MRSA.
{.2.3 Possible problems with reading absorbance.
t was thought that the colour of the porphyrins in the media may have been affecting the 
esults. The plates were read at 630nm with only porphyrin and media at drug 
:oncentrations of 0-50 uM. It was found that there was no significant change in 
bsorbance with increasing drug concentration and hence the colour of the solution was 
ot adversely affecting the results.
.2.4. Varying fluence.
L light dose of 40 I/cm2 had been used up to this point and it was decided to increase the 
ght dose in order to ascertain if this had any effect on the results. An increased light 
ase of 80 J/cm2 was used and the results are shown in figure 64 and 65. Again no 
;crease in absorbance was seen for either MRSA or E. coli.
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Results for gentamycin assay against E. coli.
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7 igure 64. Results of increased light dose on MRSA, where series 1 is a light dose of 40 J/cm2, series 2 is a 
light dose of 80 J/cm2 and series 3 is the dark control.
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jure 65. Results of increased light dose for,E. coli, where series 1 is a light dose of 40 J/cm2, series 2 is a 
light dose of 80 J/cm2 and series 3 is the dark control.
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4.2.5. Alternative method for determining cell viability.
It was decided at this point that reading the absorbance of the wells on a plate reader may 
not be accurate enough for determining cell death. The MTS assay was therefore used in 
order to achieve a stronger absorbance per well. The MTS assay involves the use of the 
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
sulfophenyl)-2H-tetrazolium, inner salt; MTS) and the electron-coupling reagent, 
phenazine methosulfate (PMS) [99]. MTS is chemically reduced by cells into formazan, 
which is soluble in tissue culture medium. The measurement of the absorbance of the 
formazan can be carried out using 96-well microplates. The assay measures 
dehydrogenase enzyme activity found in metabolically active cells. Since the production 
of formazan is proportional to the number of living cells, the intensity of the produced 
colour is a good indication of the viability of the cells. Unfortunately this assay was 
difficult to use due to the number of bacteria present per well making all wells very dark, 
and hence it was not possible to read the difference in absorbance per well. It was 
decided to plate out the bacteria from the wells and count the number of colony forming 
units (CPU's) per well in order to determine a more accurate picture of what was 
happening. The assay was performed as previously with the exception that after 
irradiation and incubation overnight the cells were serially diluted by a factor of Iff4 or 
10~5 and spread onto agar plates. The plates were then incubated overnight and the CPU's 
were counted. It was found that diluting the wells 10"4 gave too many CPU's to count and 
diluting them 10~5 showed no cell kill for either MRSA or E. coli. This method was used 
for optimisation of assay conditions, however it was very time-consuming and hence not 
appropriate for screening the library of compounds.
4.2.6. Determining bacteriostatic vs. bacteriocidal activity.
It was hypothesised that the protocol may have been inducing bacteriostasis, as opposed 
to cell death, and the bacteria were re-growing after 18 hours. Therefore it was decided to 
plate out the bacteria 30 minutes after incubation, after 60 minutes and after 18 hours to 
enable us to determine if any re-growth had occurred. The results show no significant 
diminution in CPU's for any of the time points after incubation, so it was concluded that 
no initial cell knockdown and re-growth had occurred.
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4.2.7. Effects of washing cells.
Cell washing steps were added to the initial protocol so that only porphyrin either taken 
up by or bound to the cell was irradiated. It was decided to remove the cell washing step 
in order to determine whether the porphyrin was indeed capable of killing the cells. The 
results of this showed that the porphyrin can kill bacteria although there is no difference 
between the light and dark toxicities so this cell kill was not due to a PDT effect.
4.2.8. Fractionating light dose.
The next hypothesis tested was that there is only a limited amount of oxygen in the wells 
and, upon irradiation, this is depleted. Therefore, it was decided to fractionate the light 
lose with 30 minutes in a shaking incubator between doses in order to allow oxygen 
evels to replenish. The light dose was split into two doses of 40 J/cm2 with 30 minutes 
ncubation between doses. The results, as shown in figures 66 and 67, show a significant 
;ell kill after irradiation with a fractionated light dose although again there is no 
iifference between light and dark controls.
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Results of fractionating light dose for dark control
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average 1-5 
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'igure 66. Results of fractionating light dose show a decrease in cell growth for dark controls using MRSA 
Results of fractionating light dose for irradiated cells.
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Figure 67. Results of fractionating light dose show a decrease in cell growth for irradiated cells using
MRSA.
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1.2.9. Importance of incubation time.
The cells have previously been shown to be killed independently of whether they were 
rradiated or kept in die dark as a control. This could be due to self-promoted uptake of 
he drug during the 4 hour incubation time. Self-promoted uptake, as described in chapter 
I, is the process whereby poly-cationic compounds replace the divalent cations from the 
mtside of the cell membrane and, due to their bulky size, create gaps in the membrane 
vhich allow additional drug molecules to enter the cell. It was hypothesised that if the 
ncubation time was shortened then this process could not occur to such an extent and 
icnce a PDT effect would be observed. This hypothesis was tested by shortening the 
ticubation time to 20 minutes. The results after 20 minutes incubation, shown in figure 
18, show some cell knockdown although no selectivity between light and dark. (uM)
Effects of a 20 min pre incubation on the activity of using 5,10, 
15,20-tetra-(4-/V, N, N -trimethyl-anilinium) porphyrin against
MRSA, using a light dose of 2 x 40 J/cm 2
30 min dark 
30 min light 
60 min dark 
60 min light
10 20 30 
concentration (uM)
40 50
Figure 68. Results of 20 minute incubation time for MRSA.
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It was then decided to reinstate the washing step and reduce the incubation time further to 
5 minutes and this gave the graph showing the dose response curve for MRSA. The 
results, as shown in figure 69, show that there is significant light toxicity after 5 minutes 
incubation, but importantly no dark toxicity.
4.3. Dose response curves 
4.3.1. MRSA.
Figures 69 and 70 show the dose response curve for MRSA using 5, 10, 15, 20-tetra-(4- 
V, N, 7V-trimethyl-anilinium) porphyrin.
Dose response curve for MRSA using 5, 10, 15, 20- tetra-(4-/V, N,
N -trimethyl-anilinium) porphyrin.
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Figure 69. Dose response curve for MRSA using 5, 10,15,20-tetra-(4-A/; N. JV-tntnethyl-anilinium)
porphyrin.
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Dose response curve for MRSA using 5,10,15,20-tetra-(4-N, N, N- 
trimethyl-anilinium) porphyrin shown as percentage viability.
10 20 30 
concentration (pM)
40 50
Figure 70. Dose response curve for MRSA using 5,10,15,20-tetra-(4-W, N, JV-trimethyl-anilinium)
porphyrin shown as percentage viability.
4.3.2. E. cott.
Although the assay was now working for the Gram positive bacteria it was still not 
producing any PDT effect for Gram negative bacteria, as shown in figure 71, for which 
the same method was used as for the MRSA in figure 69. This could be due to the outer 
membrane on the Gram negative bacteria preventing the drug binding to the cell and/or 
the compound not having enough positive charge on the periphery in order to be taken up 
by the cell via self-promoted uptake. Therefore, it could be important to look at 
compounds with more than four cationic charges in order to determine whether they can 
be effective in the PDI of Gram-negative bacteria.
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Results of 5 minute incubation time for E. coli shows no 
significant difference between light and dark toxicities.
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Figure 71. Results from E. coli with 5 minute incubation time.
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Chapter 5. PACT Results and Discussion.
Using the methods developed in chapter 4 we were able to generate, and present in this 
chapter, data showing the activity of a number of synthetic porphyrins tested against S. 
aureus, MRSA and E. coli. In this chapter we also present data in relation to potential 
factors that impact on activity.
5.1 Biological methods. 
5.1.1. General
5.1.1.1. Bacterial cells
The cells used were graciously obtained from Hull Royal Infirmary and the sensitivities 
of the MRSA isolate are shown in chapter 4.2.2. (table 7). They were grown under 
aseptic conditions (see chapter 4.1.4) and stored between 2 - 4°C when not in use. 3 xlO8 
cells were used per well
5.1.1.2. Assay conditions.
Assays were completed in 96 well, conical bottomed plates and the contents were 
transferred to 96 well flat-bottomed plates prior to irradiation. Luria-Bertani (LB) growth 
media was used in the assay.
5.1.1.3. Assay controls.
Two plates were used per assay, one of which was irradiated and the other kept in the 
dark as a control. The assay was conducted in a darkened room to»ensure accurate control 
of the light dose and all drug concentrations were performed in triplicate.
5.1.1.4. Light Source.
The light source used was a panel of light emitting diodes (633 nm) (Omnilux EL1000A 
Phototherapeutics Ltd, Altrincham).
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5.1.1.5. Reading Absorbances.
The plates were read at 630 nm using an MRX II microtitre plate reader (Dynex 
technologies).
5.1.2. Assay protocol.
The optimized method used for the in-vitro phototoxicity assay, was as follows: 
To each well, lOul of an overnight culture of bacteria was added with 180ul of LB 
media. lOjil of drug solution at the appropriate concentration range for each well (made 
up using DMSO) or DMSO (for controls) was then added to each well. The plates were 
incubated for 5 min at 37°C prior to being centrifuged (10 min, 1500g, 20°C). The media 
was removed and fresh media added. The contents of each well were then transferred to 
the 96 well, flat bottomed plate. The plates were irradiated with 40 J/cm2 red light then 
incubated for 30 minutes in shaking incubator. The plates were removed from the 
incubator and were irradiated with a further 40 J/cm2 red light. The plates were then 
returned to the shaking incubator and incubated overnight at 37°C. Absorbances were 
then measured at 630 nm using a microtitre plate reader.
5.2. Partition coefficients - method used.
The method used for calculating partition coefficients was that developed by 
Cunderlikova et al [101]. Namely, 15 ml phosphate buffered saline (PBS) (pH 7.43) and 
15 ml 1-octanol were agitated for 2 minutes then centrifuged (1500G, 10 min, room 
temp). Porphyrin (3 mg) was added to 10 ml octanol and 0.3 ml of the resulting solution 
was added to 1.35 ml PBS and 1.35 ml octanol. This solution was agitated for 4 rains 
then centrifuged. 1 ml of each layer was analysed by UV7Vis» absorption at 514 nm. 
Partition coefficients were calculated by equation 1 where [octanol] and [PBS] are me 
concentrations of drug in the octanol and PBS layer respectively.
[octanol]
P = -———— equation 1 
[PBS]
To determine the concentration of drug in each layer, the extinction coefficients (£) for 
octanol and PBS must be calculated using Beer's law. Serial dilutions of known
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concentrations of drug solution were taken and the absorbance read at 514 nm. The 
wavelength was measured at 514 nm rather than at the Soret band due to the peak being 
less affected by aggregation at this wavelength (broader peaks would mean less accurate 
readings at the concentrations used). From this it was possible to calculate Oct8 and PBS£ 
for each compound using Beer's law, 8 = A/Cb, where C is concentration A is 
absorbance read at 514 nm, and b is the cell path length in centimeters.
5.3. Statistics.
5.3.1. Data Analysis.
The LD50 and LD90 values were calculated by graphical analysis, using MS Excel, 
however this method does not easily allow for statistical differences between the results 
to be determined. . Standard deviations were calculated from the data and give some 
indication as to significance however we also used probit regression analysis (SPSS for 
windows, v!4). This analysis gives median concentration values for the LDso, with 95% 
confidence limits on those as an indication of the accuracy of the output. Probit analysis 
was initially carried out on results from irradiated cells only. In addition to deriving 
regression equations from which endpoints (LD50, LD90) can be calculated, probit 
analysis also gives a chi-square (%2) statistic as an indication of the goodness of fit of the 
regression model. Table 8 shows the results of the analysis using SPSS and the problems 
associated with this method for our data set. The majority of data is included to show 
how difficult the statistical analysis was using our data set. Note the negative values 
produced, using this method, for compounds 89 and 92. These values are clearly 
impossible and highlight that special care must be taken when interpreting the statistics. 
Due to the small data set and the small values of some of the data it was not possible to 
perform meaningful statistical analysis on these data, however simple standard deviations 
were generated for all of the values and these are presented in table 9 for the same data 
set.
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Compound 
number
88
89
90
91
92
82
93
94
LDso
93.537
-9.118
14.074
17.744
-763.637
73.236
7.578
3.710
Lower 
bound
NG
NG
8.042
10.173
NG
NG
0.333
NG
Upper 
bound
NG
NG
29.240
33286
NG
NG
15.137
NG
LD,«.
226.102
15029
27979
30.712
1456504
160707
25.131
22.614
Lower 
bound
NG
NG
18751
21.266
NG
NG
16.886
NG
Upper 
bound
NG
NG
67.885
67.210
NG
NG
53.104
NG
x2
4.076
13.384
26.265
15.629
0.839
4661
23.495
15.476
P
1.000
0.818
0.240
0.407
1.000
1.000
0862
0.079
Table 8 Mean LD50 and LDgo for MRSA for irradiated cells Calculated using SPSS. NG=not given. This 
table shows the limitations of this method of analysis, the highlighted values are clearly not accurate
Compound 
number
88
89
90
91
92
82
93
94
LD50.
-
2.5
8
19
-
-
4
4.5
Lower 
bound
-
1.87
7.2
16.72
-
-
3.76
4.18
Upper 
bound
-
2.83
8.8
21.28
-
-
4.24
4.82
LDw.
-
3.5
18
24
-
-
9
9.5
Lower 
bound
-
3.04
16.2
21.12
-
-
6.75
5.41
Upper 
bound
-
3.96
19.8
26.88
-
-
11.25
13.59
Table 9. Mean LD50 and LDgo for MRSA for irradiated cells Calculated using Excel. This table shows the 
advantages of using this method compared to using SPSS. (- = no cell kill).
5.3.2. Statistical analysis.
Statistical testing between compounds was carried out by one way analysis of variance 
(ANOVA) followed by a posteriori comparison of means. All data were tested for 
homogeneity of variance and in cases where this assumption was seriously violated,
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attempts were made to transform the data or the appropriate non-parametric test (Kruskal-
Wallis) was carried out. Post-hoc testing of such data was carried out using the Gamess
and Howell test.
The results from the one way ANOVA tests are shown in appendix 1.
However due to the limitations of this analysis (small sample size and values outside the
limits of this test, the data generated was of little use, as shown in tables 8 and 9. With the
data from the irradiated cells being of little use it was decided not to continue this
analysis using the dark control values.
5.4. Structure activity relationships.
5.4.1. The effect of chain length.
Compounds 88 to 91 (shown in figure 72) vary in chain length. The chain lengths used 
are methyl, ethyl, propyl or butyl, and these surround a phosphorus cation. The dose 
response curves for MRS A are shown in figures 73 to 76. The LDso and LDw values of 
each compound were calculated, from assay results for both irradiated cells and dark 
control and the results for MRS A are compared in table 10.
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Figure 72. Compounds 88 to 91 vary in aliphatic chain length around the phosphorus cation.
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Compound 88. MRSA.
10 20 30
concentration
40
Figure 73. Dose response curve for compound 88, for MRSA
Compound 89. MRSA
20 30
concentration (pM)
40
rf 
50
Figure 74. Dose response curve for compound 89, for MRSA
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Compound 90. MRSA
10 20 30 
concentration (|jM)
40
Figure 75. Dose response curve for compound 90, for MRSA
Compound 91. MRSA
10 20 SO
concentration (uM)
40 50
Figure 76. Dose response curve for compound 91, for MRSA
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Compound 
number
88
89
90
91
Partition 
coefficient
0.057
0.02
0.97
N/A
LD50 Light 
(±SD)
-
2.5 (0.33)
8 (0.8)
19 (2.28)
LDcjo Light 
(±SD)
-
3.5 (0.46)
18(1.8)
24 (2.88)
LD50 Dark 
(±SD)
-
-
18 (7.0)
-
LDwDark 
(±SD)
-
-
40 (15.6)
-
Table 10. Data observed from dose response curves for MRS A. Values shown are in uM (N/A = no 
absorption in PBS). N.B. Extinction coefficients were determined in homogeneous solution for each
compound and were used to determine P.
It can be seen from these results that the optimum aliphatic chain length around a 
phosphorus cation is two carbon atoms. Increasing the carbon chain length decreases the 
activity of the compounds whilst decreasing the carbon chain length to methyl groups gives 
no activity. Interestingly, significant dark toxicity was detected as the chain length increased 
from two to three however this effect was not observed for the next compound in the series. 
Figure 77 shows the nitrogen analogues of these compounds, figures 78 to 81 show the 
dose response curves for MRSA and table 11 gives the tabulated assay results. It can be 
seen that, in moving from phosphorus to a nitrogen centred cation, there is a shift in 
optimum chain length from 2 to 3 carbons atoms. The data from the partition coefficients 
shows no correlation between P values and LD90 values. This is highlighted by looking at 
compounds 89 and 90, where the LD<x> values are 3.5 and 18 respectively, with P values 
being 0.02 and 0.97 respectively. Unfortunately there are not enough data within this set 
to be more precise. Interestingly neither compound 91 or 94 partitioned into the aqueous 
phase, but both still exhibited photodynamic activity against bacteria.
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Figure 77. Compounds 92, 82,93 and 94 vary in aliphatic chain length around the nitrogen cation.
122
Compound 92. MRSA
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Figure 78. Dose response curve for compound 92, for 
MRSA
Compound 82. MRSA
10 20 30 40
concentration (uM)
50 60
Figure 79. Dose response curve for compound 82, for MRSA
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Compound 93. MRSA
20 30 
concentration (uM)
40 50
Figure 80. Dose response curve for compound 93, for MRSA
Compound 94. MRSA
10 20 30
concentration (pM)
Figure 81. Dose response curve for compound 94, for MRSA
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Compound 
number
92
82
93
94
Partition 
coefficient
0.71
0.037
0.177
N/A
LD50 Light 
(±SD)
-
-
4 (0.24)
4.5 (0.32)
LD9o Light 
(±SD)
-
-
9 (2.25)
9.5 (4.09)
LDso Dark 
(±SD)
-
-
8.5 (0.60)
9.5 (0.57)
LDswDark 
(±SD)
-
-
9.5 (0.95)
22 (5.5)
Table 11. Data observed from dose response curves for MRS A. Values shown are in uM (N/A = no 
absorption in PBS). N.B. Extinction coefficients were determined in homogeneous solution for each
compound and were used to determine P.
5.4.2. Aliphatic vs. Aromatic
It was found that, in general, the compovmds with aromatic groups surrounding the cation 
had less activity when compared with those having aliphatic groups surrounding the 
cation. Partition coefficients for compounds 98,95, 81, and 96 could not be calculated as 
we were unable to detect drug in the aqueous phase. However compounds 97,99 and 96 
gave good biological results and the structures and activities of these are shown in figures 
82-85 and table 12 respectively.
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99
96
Figure 82. Aromatic R groups which gave good activity.
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Compound 97. MRSA
10 20 30 
concentration (uM)
SO
Figure 83. Dose response curve for compound 97, for MRSA
1.600
1.400
Compound 99. MRSA
to 20 30
concentration (uM)
Figure 84. Dose response curve for compound 99, for MRSA
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Compound 96. S.aureus
10 4020 30
concentration (pM)
Figure 85. Dose response curve for compound 96, for S. aureus.
50
Comp
97
99
96
97
99
96
Bacterial 
strain
MRSA
MRSA
MRSA
S. aureus
S. aureus
S. aureus
LD50 Light 
(±SD)
3.5 (0.24)
4 (0.64)
-
4.5 (0.27)
20(1.8)
8(1.12)
LD90 Light 
(±SD)
4 (0.4)
15(4.2)
-
7.5 (0.23)
-
20(1.2)
LD50 Dark 
(±SD)
-
-
-
-
-
-
LDgo Dark 
(±SD)
-
-
-
-
-
-
Table 12. Activities of compounds 97,99 and 96 expressed in uM for MRSA and 5. aureus. Calculated
using Excel.
Although compound 96 gave good activity with S. aureus there was no activity for the 
analogous triphenyl phosphoniumyl compound, 81, and possible reasons for this are
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discussed in section 5.4.6. For compound 96 there was no measurable distribution into 
the aqueous phase, making meaningful comparisons of Partition coefficients difficult. 
Tables 10 and 11 suggest that P is not a good predictor for activity. A graph of log P 
vs.l/C, which would normally be a good model for structure-activity relationships, is not 
possible in this case due to the small data set. The size of the available data set is 
primarily due to compounds not distributing to any significant degree into the aqueous 
phase, therefore rendering P values meaningless or, alternatively, lack of activity of 
compounds, hence negating the 1/C value. A similar conclusion was reached by Banfi et 
al [102] who investigated structure activity relationships of 7 different cationic 
porphyrins and were unable to find an unambiguous relationship between the PS's 
lipophilicity and activity. The reason why the compounds appear not to follow any 
observable trends in hydrophobicity vs. activity could be due to interaction of the cationic 
porphyrin with the bacterial cell wall. The porphyrins are flat, relatively rigid molecules 
and they are therefore limited in the number of orientations in which the cations can 
approach and bind to the membrane. It may therefore be possible that charge distribution 
around the cationic sites, rather than simple hydrophilic / lipophilic character, could be 
important in determining photosensitiser-bacteria interactions. It was decided therefore to 
investigate different representations of each compound to determine whether the 
molecular models and Mulliken charges [103] could be used to construct a hypothesis of 
how the charge on each cation would interact with the membrane. Mulliken charges 
provide model representation of charge distribution within a molecule and are a means of 
estimating partial atomic charges via computational chemistry methods [104]. The 
Mulliken charges were calculated using the GAMESS function of Chem3D. The 
porphyrin ring was excluded from this process due to programme limitations, and as it 
could essentially be assumed to remain constant for all compounds due to its rigid 
aromatic framework, hence only the charges on the various R groups were calculated. 
Initially each structure around the cationic centres were minimised using MM2 
(molecular mechanics force field method) to give an overall steric energy. Other 
conformations were then attempted as starting points and the MM2 was minimised and 
compared to the energies with the lowest values being the most stable conformer. Once 
the minimised structure was obtained the GAMESS calculation of charges was carried
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out and produced as a text file. The results of this are shown in table 13. It was 
unfortunately not possible to calculate the Mulliken charges for the 
tribenzylphosphoniumyl, rriphenylphosphiumyl or triphenylarsiniumyl moieties due to 
the computer programme limitations.
Table 13 compares the different compounds with their activities against MRS A and 
Mulliken charges on either the phosphorus or nitrogen atoms. From this it can be seen 
that there is no correlation between the activity and Mulliken charge on the P or N atom.
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R group
"V 
I
ip
_/
 /
V N"
^N
w
-(
^
N ^^"^
r 6^N
LD50 (Light) (±SD)
-
2.5 (0.33)
8 (0.8)
19 (2.28)
-
-
4 (0.24)
4.5 (0.32)
3.5 (0.24)
4 (0.64)
-
Mulliken charge
2.16
1.797
1.809
1.779
-0.747
-0.733
-0.752
-0.753
-0.889
-0.955
-0.893
We 13. Comparison of R groups with analogous compounds activity in jiM and Mulliken charge values 
>ted for charges on either nitrogen or phosphorus atom, calculated using GAMESS function in ChemSD.
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Two methods were used to determine the relationship between the variables of Mulliken 
charge and LDso The Pearson and Spearman's rank correlation coefficient were both 
used as we were unsure of the frequency distribution of the variables. However it can be 
seen from tables 14 and 15 that neither indicated any correlation between activity and 
Mulliken charge given for the cation.
Pearson Correlation
LDSO
mulliken
Correlation co efficient
Sig. (2-tailed)
N
Correlation coefficient
Sig. (2-tailed)
N
LDSO
1
15
.096
.734
15
mulliken
.096
.734
15
1
15
Table 14. Shows correlations between LD50 values against MRS A and Mulliken charge on either the N or P atom.
Spearman's rank correlation coefficient
LDSO
mulliken
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
LDSO
1.000
15
.364
.182
15
mulliken
.364
.182
15
1.000
-
15
Table 15. Shows non-parametric correlations between LD^ values against MRS A and Mulliken charge on either the N
or P atom.
5.4.3. MRSA vs S. aureus.
Although antibiotic-resistant bacteria are able to survive in the presence of the antibiotic, 
this resistance comes at a price. When there is no antibiotic present they take longer to 
grow and take up vital nutrients. MRSA and S. aureus have many similarities in their 
phenotype but do contain some subtle differences. Majcherczyk et al [105] showed that 
matrix-assisted laser desorption ionization-time of flight mass spectrometry (MADLI-
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TOF-MS) can successfully differentiate between isogenic strains of bacteria. They tested 
isogenic strains of MRSA and methicillin-sensitive S. aureus (MSSA) isolates and 
determined that this technique may facilitate identification of surface components altered 
by expression of antibiotic resistance. It is possible that the differences in the surface 
components of MRSA and S. aureus are responsible for the differences in results between 
the two strains in this study and this may impact on their sensitivity to the different 
compounds. Tables 16 and 17 show the results for MRSA and S. aureus respectively.
Compound
88
89
90
91
92
82
93
94
97
98
99
95
81
96
LD50 Light
(±SD)
-
2.5 (0.33)
8 (0.8)
19 (2.28)
-
-
4 (0.24)
4.5 (0.32)
3.5 (0.24)
-
4 (0.64)
-
_
-
LDoo Light 
(±SD)
-
3.5 (0.46)
18(1.8)
24 (2.88)
-
-
9 (2.25)
9.5 (4.09)
4 (0.4)
-
15(4.2)
-
-
LDso Dark 
(±SD)
.
.
18 (7.0)
-
-
-
8.5 (0.60)
9.5 (0.57)
-
-
-
-
-
-
LDso Dark 
(±SD)
-
.
40(15.6)
-
-
-
9.5 (0.95)
22(5.5)
-
-
-
-
-
-
Table 16. Results of assays for MRSA in
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Compound
88
89
90
91
92
82
93
94
97
98
99
95
81
96
LDso Light 
(±SD)
-
3.5 (0.42)
4.5 (0.67)
15.5 (1.08)
-
-
3.75 (0.3)
3(0.3)
4.5 (0.27)
-
20(1.8)
-
-
8(1.12)
LD9« Light 
(±SD)
-
_
13(3.7)
23.5 (8.9)
_
-
8(1.12)
10(1.5)
7.5 (0.22)
.
_
_
_
20(1.2)
LDso Dark
(±SD)
.
_
13 (0.52)
.
.
-
5.75 (0.3)
19(4.0)
.
-
-
.
_
-
LD9o Dark 
(±SD)
-
.
19(4.37)
.
-
-
50 (27)
31 (5.58)
-
-
-
-
-
-
Table 17. Results of assays forS. aureus in
It can be seen from tables 16 and 17 that S. aureus was generally more susceptible to 
PDT than MRSA for most compounds although they produced similar trends in results 
when comparing groups of compounds, with the exception of compound 96.
5.4.4. E. coli.
The assay produced no cell kill for E. coli with the exception of compounds 90, 93 and 
97. The structures and activities of these compounds are shown in figure 86, figures 87- 
89 and table 18 respectively.
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Figure 86. Structures of compounds showing activity against E. coli.
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Compound 90. E coli
-Light I 
Dark ,
20 30
concentration (|jM)
40 50
Figure 87. Dose response curve for compound 90 forE. coli
Compound 93. £ coli
10 20 30
concentration (|jM)
50
Figure 88. Dose response curve for compound 93 for E. coli
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Compound 97. E. coli
1.400
to 20 30 40
Concentation (|jM)
Figure 89. Dose response curve for compound 97 for E. coli
Comp
90
93
97
LDso Light 
(±SD)
8(1.68)
4 (0.48)
50 (5.0)
LD90 Light 
(±SD)
18(4.14)
9 (3.9)
-
LDso Dark 
(±SD)
34 (3.74)
-
-
LD9o Dark 
(±SD)
-
-
-
Table 1 8. Compounds with activity against E. coli. Concentration values given in (J.M.
It can be seen, from table 18, that although compound 97 has an LDso of 50 uM, this is 
the MIC for this compound. Compounds 90 and 93, the phosphoras and nitrogen cations 
respectively, contain R groups consisting of propyl chains and both have relatively low 
LD50 and LDgo values which differ by a factor of two. These are clearly interesting, 
having very similar structures and activities against both Gram positive (MRSA and S. 
aureus) and Gram negative (E. coli) bacteria. It is suggested that these compounds have a 
broader spectrum of activity compared with the other compounds tested. This makes
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them extremely interesting candidates for use in PACT, as wounds generally consist of 
multiple bacterial strains and hence these compounds could be expected to perform 
significantly better in eradicating all of the bacteria in a wound.
5.4.5. Compound 96. Arsenium cation.
Compound 96 was active against 5. aureus but not against E. coli or MRSA The assay 
results for compound 96 against S. aureus are shown in figure 90.
Compound 96. S. aureus
10 20 30
concentration (|jM)
40
Figure 90. Results of assay for compound 96 for S. aureus.
There are two possible reasons why this difference in activity between compound 96 and 
compound 81 (the analogous phosphorus compound) occurs, and why there is a 
difference between the activities of S. aureus and MRSA.
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Arsenic resistance is known to exist in both E. coli and S. aureus. Lowered net 
accumulation of arsenic is achieved via an active efflux pump [106,107]. In E. coli this is 
encoded via plasmid R773 and in S. aureus it is encoded by plasmid pI258. This 
resistance is plasmid mediated so it is possible that the E. coli and MRSA in this study 
contain the plasmids for arsenate resistance, and hence pump out the drug, whilst the S. 
aureus does not contain the plasmid therefore a PDT effect is shown for S. aureus and 
not for the other two organisms. The presence of arsenic has increased the activity over 
the analogous phosphorus compound (compound 81) which gave no cell kill in either the 
light or dark control. Compound 96 does show a PDT effect in that there is cell kill in the 
irradiated cells but not in the dark controls. It is possible that the differences in activity 
between compounds 81 and 96 are due to compound 96 showing a combined effect of 
both arsenic poisoning and PDT. If the membrane is damaged photolytically this could 
inactivate the efflux pump and allow the build-up of arsenic to toxic levels. However this 
theory is somewhat controversial in that the arsenic resistance mechanisms are usually 
associated with inorganic arsenic. A second theory as to the cause of these results is that 
lysis occurs on irradiation of the porphyrin to produce triphenylarsine which is a toxic 
compound. However if this was the reason for compound 96 having toxicity when 
compound 81 does not then this should have been seen in all bacteria, with no difference 
in activity expected between S. aureus said MRSA. Although these theories have some 
data to both support and contradict them, there is not enough data on this compound to 
give an accurate idea of what is happening and hence further tests on a broader range of 
bacteria would have to be carried out in order to be able to determine the mechanism by 
which the differences in cell killing occurs.
The data presented in this chapter highlights some interesting results. We were able to 
observe that both MRSA and S. aureus showed similar, but not identical, activities with 
the PDT agents tested. Also three compounds that showed good activity with Gram 
positive bacteria also showed activity with E. coli - this is an unusual finding as a number 
of PDT agents show no or little activity against Gram negative organisms due to the 
presence of the outer membrane which makes Gram negative bacteria less susceptible to 
attack [102].
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lowever, we were unable to establish any clear SAR/QSAR with the compounds tested. 
Although only two physiochemical parameters were examined, it is likely that the 
lability to correlate this with photodynamic activity is in part due to the small sample 
et. From my data I feel that it is likely that compounds with greater specificity for 
articular groups can be synthesised but more importantly it would seem to be possible to 
reduce compounds with a broad spectrum of activity - which may be of greater benefit 
)r the control of more complex infections such as those found in ulcers and wounds.
.5. Summary
i summary, from this range of compounds differential activity can be seen and some 
lea of an optimum structure derived, with compounds 90 and 93 being the most active 
ver a broad spectrum.
iterestingly, there is a difference between S. aureus and MRSA, possibly due to 
fferent surface structures, with some compounds even showing activity against E. coli. 
he results in this thesis show that porphyrins can be synthesised and optimized for the 
lling of bacteria. It has also been shown that relatively subtle differences in structure 
in yield either strain-specific or broad spectrum drugs for use in Photodynamic 
ntimicrobial Chemotherapy.
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Chapter 6. Experimental 
6.1. General
  'H and 13C NMR spectra were recorded on either a JEOL JNM-LA400 or JEOL 
JNM-GX270 NMR spectrometer. Chemical shifts (8) are quoted in ppm relative 
to SiMe4 signal as internal standard. Coupling constants are given in Hz.
  UV-Visible spectra were measured on an Agilent 8453 diode array spectrometer.
  TLC was performed with Merck aluminium plates coated with silica gel 60 F2 54 
and visualised under UV light. Chromatography was performed using Fluorochem 
silica gel 35-70n 60A or ICU silica gel 32-63 n 60A.
  THF was distilled from sodium and benzophenone.
  Low resolution mass spectra were recorded on either a SHIMADZU GCMS- 
QP5050 or a Bruker Reflex IV mass spectrometers. Electrospray mass spectra 
were obtained from EPSRC National Mass Spectrometry Service centre, 
University of Wales, Swansea.
  Compounds 81, 82, 88, 89, 90, 91,92, 93,94, 95, and 96, due to the limitations of 
the resolution of the mass spectrometer, do not show the isotopomers clearly 
resolved as one would normally expect. The data does support the presence of 
isotopomers, showing them as a shoulder on the main peak, however these are not 
fully resolved. The theoretical data on peak shape received from Swansea matches 
that of the actual data in all cases.
  HPLC analysis was recorded on a high pressure liquid chromatography system 
with UV/visible multi-wavelength detector from JASCQ,(UK) LTD, (Jasco PU- 
1580 intelligent HPLC pump, HG-1580-32 dynamic mixer, MD-1515 
multiwavelength detector, AS-1555 intelligent sampler).
  All reagents were purchased from commercial companies and used without 
further purification unless otherwise specified.
  Compounds 97, 98 and 99 were synthesised by Dr.R.Hudson.
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6.2. Synthesis.
5,10,15,20-tetra-(4-pyridyl)porphyrin (53) [62]
Pyridine-4-carboxaldehyde (15.4ml, 0.127mol) was dissolved in propionic acid (250ml) 
and heated to reflux. Pyrrole (8.82ml, 0.127mol) was added drop wise and the reaction 
refluxed for 30 mins. Upon cooling the fine purple precipitate was collected by filtration 
and washed with propionic acid then water. The crystals were dried under vacuum 
overnight to give compound 53. (1.98g, 10%), *H NMR [400MHz, CD3 C13] 5-2.92 (2H, 
br s, N-fl) 68.16 (8H, d, J = 4 Hz, Ar-3,5-#), 58.87 (8H, s, p-#), 59.06 (8H, d, J = 4 Hz, 
Ar-2,6-fl); 13C NMR [100MHz,CDCl3] 577.00, 77.32, 76.67, 129.30,148.44; UV/Vis 
(CH2C12, nm) X^ 416,512, 547, 586; MS (MALDI) m/z 619.5 (M + H).
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5,10,15,20-tetra-((4-dimethylamino)phenyI)porphyrin (23) [108]
4-Dimethylaminobenzaldehyde (18.9Sg, 0.127mol) was dissolved in propionic acid 
(250ml) and heated to reflux. Pyrrole (8.82ml, 0.127mol) was added drop wise and the 
reaction refluxed for 30 mins. Upon cooling the fine purple precipitate was collected by 
filtration and washed with propionic acid then water. The crystals were dried under 
vacuum overnight to give compound 23. (2.29g, 9%); 1H NMR [400MHz, (CDs^SOJ 5- 
2.82 (2H, br s, N-#) 83.36 (24H, s, NC#3), 87.52 (8H, d, 3J = 8Hz, Ar-3,5-fl), 8.35 (8H, 
s, p-H), 8.53 (8H, d, 3J = 8Hzs Ar-2,6-H); UV/Vis (MeOH, nm) >,« 419, 515, 547, 587, 
646; MS (MALDI) m/z 787.8 (M + H).
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5,10,15,20-tetra-(4-cyanophenyl)porphyrin (71) [26]
4-Cyanobenzaldehyde (6.22g, 0.0474mol) was dissolved in propionic acid (250ml) and 
heated to reflux. Pyrrole (3.29ml, 0.0474mol) was added drop wise and me reaction 
refluxed for SOmins. Upon cooling the fine purple precipitate was collected by filtration 
and washed with propionic acid then water. The crystals were dried under vacuum 
overnight to give compound 71 a fine purple solid. (1.31g, 15%); 'H NMR [400MHz, 
CD3OD] 8-3.00 (2H, br s, Nfl), 58.18 (8H, d, 3J = 8 Hz, Ar-3,5-fl), 58.35 (8H, d, 3J= 8 
Hz, Ar-2,6-#), 58.79 (8H, s, p-#); UV/Vis (MeOH, nm) X^ 420, 514, 549, 590, 644; 
MS (MALDI) m/z 715 (M +H).
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5,10,15,20-tetra-(4-carbomethoxyphenyl)porphyrin (87) [109]
OMe
Methyl 4-formylbenzoate (lO.OOg, 0.061mol) was dissolved in propionic acid (250ml) 
and heated to reflux. Pyrrole (4.23ml, 0.061mol) was added drop wise and the reaction 
refluxed for SOmins. Upon cooling the fine purple precipitate was collected by filtration 
and washed with propionic acid then water. The crystals were dried under vacuum 
overnight to give 87 as lustrous purple needles. (2.39g, 18%), R/" =0.14 (silica, 
5%MeOH/CH2Cl2); JH NMR [400MHz, CDC13] 5-2.81 (2H, br s, N#), 54.11(12H, s, 
CO/s), 58.30 (8H, d, 3J = 8 Hz, Ar-3,5-ff), 58.45 (8H, d, 3J = 8Hz, Ar-2s6-W), 58.81 
(8H, s, p-#); 13C NMR [100MHz, CDC13] 5 52.46, 119.38, 127.98, 129.77, 134.51, 
146.61, 167.24; UV/Vis (MeOH, nm) X^ 427, 515, 550, 590, 645; MS (MALDI) m/z 
846.7 (M + H)
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5,10,15,20-tetra-(4-(hydroxymethyl)phenyl)porphyrin(73) [109]
A solution of compound 87 (l.OOg, l.lSmmol) in freshly distilled THF (250ml) was 
cooled to 0°C under a nitrogen atmosphere. Lithium aluminium hydride (4.47g, O.lSmol) 
was added and the reaction was stirred in the dark for 18 hours at room temperature. 5% 
H2SC>4 (100ml) was added drop wise and the product was extracted into ethyl acetate 
(3* 100ml). The combined organic layer was washed with saturated aqueous sodium 
hydrogen carbonate (200ml), water (200ml) and brine (200ml). The organic layer was 
dried over MgSC>4, filtered and the solvent removed in vacuo to give 73 as lustrous purple 
needles (0.77g, 88%); R^= 0.65 (silica, 20%MeOH/CH2Cl2); 'H NMR [400MHz, 
(CD3)2SO] 8-2.91 (2H, br s, N#), 84.84 (8H, d, 3J = 8 Hz, C#2), 85.50 (4H, t, 3J =6Hz, 
OH), 87.74 (8H, d, 3J =8 Hz, Ar-3,5-fl), 88.14 (8H, d, 3J =8Hz, Ar-2,6-H), 88.80 (8H, s, 
p-#); UVA^is (MeOH, nm) X^ 423, 515, 557, 598, 626; MS (MALDI) m/z 735.8 (M + 
H).
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5,10,15,20-tetra-(4-(bromomethyl)phenyl)porphyrin (83) [109]
,Br
To a solution of 73 (0.150g, 0.2mmol) in freshly distilled dioxane (10ml), under a 
nitrogen atmosphere, was added phosphorous tribromide (1.00ml, lO.OOmmol) and the 
reaction was stirred overnight at room temperature in the dark. MeOH (5ml) was added 
drop wise and the reaction stirred for a former 5 minutes. CH2Cl2 (50ml) was added and 
the organic layer was washed with saturated sodium hydrogen carbonate (3*50ml) and 
brine (3*50ml). The organic layer was dried over MgSO4, filtered and the solvent was 
removed in vacua. The purple solid was adsorbed onto silica and purified by gravity 
percolation chromatography (silica, eluent: CH2C12). Relevant fractions were combined 
and the solvent removed in vacua to yield compound 83 as a fine purple solid (0.138g, 
70%); R/= 0.86 (silica, CH2C12); 'H NMR [400MHz, CDC13] 5-2.81 (2H, br s, Nfl), 
84.86 (8H, s, C#2Br), 87.84 (8H, d, 3J =8Hz, Ar-3,5-fl), 88.24 (8H, d, 3J = 8Hz, Ar-2,6- 
H), 88.84 (8H, s, p-fl); 13C NMR [100MHz,CDCl3 ] 533.48, 119.54, 127.48, 134.92, 
137.40, 142.21; UV/Vis (CH2C12, nm) ^^ 420, 516, 552, 592, 647; MS (MALDI) m/z 
987 (M + H).
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5,10,15, 20-tetra-(4-(phthalimidomethyl)phenyl)porphyrin (74)
3 a solution of 73 in dry THF (100ml) was added triphenyl phosphine (0.098g, 
37mmol) and potassium phthalimide (0.069g, 0.37mmol). The reaction was cooled to 
C and stirred for 15 minutes. Diethylazodicarboxylate (0.072ml, 0.37mmol) was added 
id the reaction was stirred at room temperature for 48 hours. Column chromatography 
ilica, eluent: 5% MeOH in CH2 C12) afforded 74 as a purple solid. (0.067g, 79%), ] H 
MR [400MHz, (CD3 )2 SO] 8-2.79 (2H, br s, N#), 64.97 (8H, s, CH2), 8 7.65 (8H, d, 3J = 
fa, Ar-3,5-H), 5 7.69 (8H, d, 3J = 8Hz, Ar-2,6-#), 5 7.76 (8H, q, J = 8Hz) 8 7.87 (8H, q, 
= 8Hz), 88.81 (8H, s, p-//); UV/Vis (MeOH, nm) X^ 417, 515, 545, 594, 637; MS
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5,10,15, 20-tetra-(4-((triphenylphosphonJumyl)methyI)phenyl)porphyrin
tetrabromide(81)[109]
To a flame dried flask under a nitrogen atmosphere was added compound 83 (20mg, 
0.02mmol) and triphenylphosphine (3g). The mixture was heated to 110°C and was 
stirred for 48 hours effecting reaction solvolysis. On cooling the solid was ground up and 
methanol added (5ml). The suspension was stirred for 5 minutes and the unreacted 
riphenylphosphine was collected by microfiltration (Millipore®) and washed with 
nethanol. The recovered filtrate was added to 50ml diethyl ether. The resultant 
precipitate was collected by microfiltration (Millipore®) and this process was repeated 
wice. The purple solid was dried under vacuum to give compound 81. (0.022g, 63%); 
H NMR [400MHz, (CD3)2 SO] 8-3.12 (2H,br s, NH), 5.53 (8H, d, 2J=15.2 Hz, CH2P), 
7.41(8H, dd, 4J=2.24Hz, 3J=8.44Hz, 5,10,15,20-Ar-3,5-H), 7.91-8.02 (64H, m 
>verlapping, 5,10,15,20-Ar-2,6-H & ortho, meta, para-Ai-H), 8.75 (8H, s, p-H); UV/Vis 
H2O, nm) 3^ 416, 520, 557, 587, 643; MS (ES) m/z 429 (M4*), 599 (M + Br)3+, 938
M + 2 Br)2+ . HPLC tr = 17.3 min (flow rate= lml/min;eluent A, H2O and 0.1%TFA; 
Juent B, methanol; gradient Omin,0%B; lOmin, 75% B; 15min, 75% B; 18min 0% B; 
9min 0% B; column, Phenomenex Luna 5u C18(2) 250*4. 6mm
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5,10,15,20-tetra-(4-((triethylamino)methyI)phenyI)porphyri]] tetrabromide (82)
[109]
Br
To a flame dried flask under a nitrogen atmosphere was added a solution of 83 (20mg, 
0.02mmol) in DMF (10ml). To this solution was added triethylamine (O.llml, 
O.SOmmol). The reaction was allowed to proceed for 24 hours at room temperature in the 
dark. Upon completion of the reaction the solvent was removed in vacua to yield a crude 
purple solid. The solid was dissolved in 2ml MeOH and this was added to 50ml diethyl 
ether. The resultant precipitate was collected by microfiltration (Millipore®) and this 
process was repeated twice. The purple solid was dried under vacuum to give compound 
82. (0.0178g, 86%) ] H NMR [400MHz, (CDs^SO] 5-2.96 (2H, br s, Nff), 1.47 (36H, t, 3J 
= 8 Hz, C/73), 2.47-2.49 (24H, m, NCfli), 4.83 (8H, s, PhC/f2), 7.95 (8H, d, J = 8 Hz, Ar- 
3,5-fl), 8.34 (8H, d, J = 8 Hz, Ar-2,6-fl), 8.90 (8H, s, 0-fl); UV/Vis (octanol, nm) TW 
420, 515, 549, 592, 649; MS (ES) m/z 268 (NT), 383 (M + Br)3+, 615 (M + 2 Br)2+; 
HPLC tr = 4.00 min (flow rate= lml/min;eluent A, H2O and 0.1%TFA; eluent B, 
methanol; gradient Omin,0%B; lOmin, 75% B; 15min, 75% B; 18min 0% B; 19min 0% 
B; column, Phenomenex Luna 5u C18(2) 250*4.6mm
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5,10,15,20-tetra-(4-((trimethylphosphoniumyl)methyl)phenyi)porphyrin
tetrabromide (88)
To a flame dried flask under a nitrogen atmosphere was added a solution of 83 (20mg, 
0.02mmol) in DMF (10ml). To this solution was added trimethyl phosphine (0.08ml, 
O.SOmmol). The reaction was allowed to proceed for 24 hours at room temperature in the 
dark. Upon completion of the reaction the solvent was removed in vacuo to yield a crude 
purple solid. The solid was dissolved in 2ml MeOH and this was added to 50ml diethyl 
ether. The resultant precipitate was collected by microfiltration (Millipore®) and this 
process was repeated twice. The purple solid was dried under vacuum to give compound 
88. (0.0048g, 27%), ! H NMR [400MHz,(CD3)2SO] 5-2.96 (2H, br s, N#), 82.03 (36H, 
d,3J = 16 Hz C#3), 54.12 (8H, d, J=16 Hz, PhC#2), 57.74 (8H, d, J= 8 Hz, Ar-3,5-#), 
58.25 (8H, d, J=8 Hz, Ar-2,6-#), 58.90 f8H, s, p-fl); UV/Vis (Octanol, nm) X *- 414,
517, 549, 585, 620; MS (ES) m/z 243 (M"), 351 (M + Br)3*, 565 (M + 2 Br)i+; HPLC tr 
= 8.40 min (flow rate= lml/min;eluent A, H20 and 0.1%TFA; eluent B, methanol; 
gradient Omin,0%B; lOmin, 75% B; 15min, 75% B; 18min 0%B; 19min 0%B; column, 
Phenomenex Luna 5u C18(2) 250*4.6mm.
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5,10,15,20-tetra-(4-((triethylphosphoniumyl)methyI)phenyl)porphyrin
tetrabromide (89)
To a flame dried flask under a nitrogen atmosphere was added a solution of 83 (20mg, 
0.02mmol) in DMF (10ml). To this solution was added triethyl phosphine (0.12ml, 
O.SOmmol). The reaction was allowed to proceed for 24 hours at room temperature in the 
dark. Upon completion of the reaction the solvent was removed in vacuo to yield a crude 
purple solid. The solid was dissolved in 2ml MeOH and this was added to 50ml diethyl 
ether. The resultant precipitate was collected by microfiltration (Millipore®) and this 
process was repeated twice. The purple solid was dried under vacuum to give compound 
89. (0.0056g, 38%) ] H NMR [400MHz, (CE^SO] 8-2.95 (2H, br s, N#), 51.27 (t, 3J = 
8Hz, overlapping with 81.32 (t, 3J =8 Hz, 60H CH2CH3 + CH2C#3), 84.19 (8H, d, J = 16 
Hz, PhC#2), 57.81 (8H, d, J= 4 Hz, Ar-3,5-#), 88.25 (8H, d, J = 4 Hz, Ar-2,6-//), 88.87 
(8H, s, |3-#); UV/Vis (octanol, nm) A * 424, 517, 558, 590, 624; MS (ES) m/z 285 
(M4*), 407 (M + Br)3+, 649 (M + 2 Br)2+; HPLC tr = 4.38 min (flow rate= lml/min;eluent 
A, H2O and 0.1%TFA; eluent B, methanol; gradient Omin,0%B; lOmin, 75% B; 15min, 
75% B; 18min 0% B; 19min 0% B; column, Phenomenex Luna 5u C18(2) 250*4.6mm
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5,10,15,20-tetra-(4-((tripropylphosphoniumyl)methyl)phenyl)porphyrin
tetrabromide(90)[109]
To a flame dried flask under a nitrogen atmosphere was added a solution of 83 (20mg, 
0,02mmol) in DMF (10ml). To this solution was added tripropyl phosphine (0.16 ml, 
O.SOmmol). The reaction was allowed to proceed for 24 hours at room temperature in the 
dark. Upon completion of the reaction the solvent was removed in vacua to yield a crude 
purple solid. The solid was dissolved in 2ml MeOH and this was added to 50ml diethyl 
ether. The resultant precipitate was collected by microfiltration (Millipore®) and this 
process was repeated twice. The purple solid was dried under vacuum to give compound 
90. (0.019g, 72%) *H NMR [400MHz, (CD3)2SO] 8-2.98 (2H, br s, NH), 51.08 (36H, t, 
3J= 6 Hz, CH3\ 51.64-1.60 (24H, m, C#2CH3), 62.38-2.30 (24H, m, PC#2), 54.13 (8H, d, 
J = 16 Hz, PhCH2), 57.76 (8H, d, J = 8 Hz, Ar-3,5-fl), 58.22 (8H, d, J = 8 Hz, Ar-2,6-fl), 
58.79 (8H, s, P-//); UV/Vis (octanol, nm) A^ 426, 515, 549, 591, 648 ; MS (ES) m/z 
327 (M4*), 463 (M 4- Br)3+, 734 (M + 2 Br)2+; HPLC tr = 9.52 min (flow rate= 
lml/min;eluent A, H2O and 0.1%TFA; eluent B, methanol; gradient Omin,0%B; lOmin, 
75% B; 15min, 75% B; 18min 0% B; 19min 0% B; column, Phenomenex Luna 5u 
C18(2) 250*4.6mm
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5,10,15,20-tetra-(4-((tributylphosphoniumyl)methyQphenyI)porphyrin
tetrabromide(91)[109]
To a flame dried flask under a nitrogen atmosphere was added a solution of 83 (20mg, 
0.02mmol) in DMF (10ml) and the solution was stirred at 80°C for five minutes. To this 
solution was added tributyl phosphine (0.197ml, O.SOmmol). The reaction was allowed to 
proceed for three days at 80°C in the dark. Upon completion of the reaction the solvent 
was removed in vacua to yield a crude purple solid. The sglid was dissolved in 2ml 
MeOH and this was added to 50ml diethyl ether. The resultant precipitate was collected 
by microfiltration (Millipore®) and this process was repeated twice. The purple solid was 
dried under vacuum to give compound 91. (0.0219g, 74%); *H NMR 
[400MHz,(CD3)2SO] 5-2.95 (2H, br s, N//), 60.99 (36H, t, 3J= 8 Hz, C#3), 51.53-1.48 
(m, C#2CH3 overlapping with 81.62-1.58 (m, C#2CH2CH3,48H), 52.49-2.48 (24H, m, 
PC#2), 54.18 (8H, d, J= 16Hz, PhC#2), 57.81 (8H, d, J= 8 Hz, Ar-3,5-#), 8 26 (8H, d, J= 
8 Hz, Ar-2,6-#), 58.82 (8H, s, p-fl); UV/Vis (Octanol, nm) X^ 424, 517, 548, 593, 650; 
MS (ES) m/z 369 (M4+), 519 (M + Br)3+, 818 (M + 2 Br)2+; HPLC tr = 13.7 min flow 
rate= lml/min;eluent A, H2O and 0.1%TFA; eluent B, methanol; gradient Omin,0%B; 
lOmin, 75% B; 15min, 75% B; 18min 0% B; 19min 0% B; column, Phenomenex Luna 
5uC18(2)250*4.6mm
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5,10,15,20-tetra-(4-((trimethylamino)methyl)phenyl)porphyrin tetrabromide (92)
Br
Br
Br
To a flame dried flask under a nitrogen atmosphere was added a solution of 83 (20mg, 
0.02mmol) in DMF (10ml). To this solution was added trimethylamine hydrochloride 
(0.076g, O.SOmmol) and DBU (0.119ml, 0.8mmol). The reaction was allowed to proceed 
for 24 hours at room temperature in the dark. Upon completion of the reaction the solvent 
was removed in vacua to yield a crude purple solid. The solid was dissolved in 2ml 
MeOH and this was added to 50ml diethyl ether. The resultant precipitate was collected 
by microfiltration (Millipore®) and this process was repeated twice. The purple solid was 
dried under vacuum to give compound 92. (0.007g, 39%) *H NMR [400MHz, (CDs^SO] 
5-2.94 (2H, br s, N#), 52.17 (36H, s, C#3), 54.94 (8H, s, PhC#2), 58.00 (8H, d, J= 8 Hz, 
Ar-3,5-#), 68.35 (8H, d, J = 8 Hz, Ar-2,6-ff), 58.93 (8H, s, pV/); MS (ES) m/z 226 
(M4"), 327 (M + Br)3+, 531 (M + 2 Br)2+; UV/Vis (octanol, nm) X^ 421, 516, 549, 593, 
650; HPLC tr = 7.72 min (flow rate= lmymin;eluent A, H2O and 0.1%TFA; eluent B, 
methanol; gradient Omin,0%B; lOmin, 75% B; 15min, 75% B; 18min 0% B; 19min 0% 
B; column, Phenomenex Luna 5u C18(2) 250*4.6mm
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5,10,15,20-tetra-(4-((tripropylamino)metbyl)phenyl)porphyrin tetra bromide (93)
To a flame dried flask under a nitrogen atmosphere was added a solution of 83 (20mg, 
0.02mmol) in DMF (10ml). To this solution was added tripropylamine (0.15ml, 
O.SOmmol). The reaction was allowed to proceed for 24 hours at room temperature in the 
dark. Upon completion of the reaction the solvent was removed in vacua to yield a crude 
purple solid. The solid was dissolved in 2ml MeOH and this was added to 50ml diethyl 
ether. The resultant precipitate was collected by microfiltration (Millipore®) and this 
process was repeated twice. The purple solid was dried under vacuum to give compound 
93. (0.0106g, 44%), JH NMR [400MHz, (CD3)2SO] 8-3.01 (2H, br s, N#), 60.99 (36H, 
t, 3J = 8Hz, C#3), 81.97-1.85 (24H, m, C#2CH3), 82.63-2.60 (24H,m, NC#2), 84.84 (8H, 
s, PhC#2), 87.87 (8H, d, 3J = 8 Hz, Ar-3,5-//),88.32 (8H, d/J = 8 Hz, Ar-2,6-#), 88.87 
(8H, s, p-fl); UV/Vis (octanol, nm) X^ 415, 515, 549, 591, 648 ; MS (ES) m/z 310 
(M4^), 440 (M + Br)3+, 670 (M + 2 Br)2+; HPLC tr = 10.7 min (flow rate= lml/min;eluent 
A, H2O and 0.1%TFA; eluent B, methanol; gradient Omin,0%B; lOmin, 75% B; 15min, 
75% B; 18min 0% B; 19min 0% B; column, Phenomenex Luna 5u C18(2) 250*4.6mm
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5,10,15,20-tetra-(4-((tributyIamino)methyl)phenyl)porphyrin tetrabromide (94)
[109]
To a flame dried flask under a nitrogen atmosphere was added a solution of 83 (20mg, 
0.02mmol) in DMF (10ml) and the solution was stirred at 80°C for five minutes. To this 
solution was added tributyl amine (0.191ml, O.SOmmol). The reaction was allowed to 
proceed for three days at 80°C in the dark. Upon completion of the reaction the solvent 
was removed in vacua to yield a crude purple solid. The solid was dissolved in 2ml 
MeOH and this was added to 50ml diethyl ether. The resultant precipitate was collected 
by microfiltration (Millipore®) and this process was repeated twice. The purple solid was 
dried under vacuum to give compound 94. (0.0208g, 74%); 'H NMR [400MHz, 
(CD3)2SO] 5-2.96 (2H, br s, N#), 61.03 (36H, t, 3J = 8Hz, CH3), 51.48-1.40 (24H, m, 
C#2CH3), 51.96-1.83 (24H, m, C//2CH2CH3), 52.51-2.48 (24H, m, NC#2), 54.88 (8H, s, 
PhC#2), 67.92 (8H, d, J= 8Hz, Ar-3,5-#), 58.35 (8H, d, J= 8Hz, Ar-2,6-#), 68.89 (8H, s, 
p-fl); UV/Vis (octanol, nm) Jw 429, 515, 550, 592, 648; MS (ES) m/z 352 (M4*), 496 
(M + Br)3+; HPLC tr = 14.8 min (flow rate= lml/min;eluent A, H2O and 0.1%TFA; 
eluent B, methanol; gradient Omin,0%B; lOmin, 75% B; 15min, 75% B; 18min 0% B; 
19min 0% B; column, Phenomenex Luna 5u C18(2) 250*4.6mm
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5,10,15,20-tetra-(4-((tribenzylphosphoniumyl)methyl)phenyl)porphyrui
tetrabromide (95)
To a flame dried flask under a nitrogen atmosphere was added a solution of S3 (20mg, 
0.02mmol) in DMF (10ml). To this solution was added tribenzyl phosphine (0.24g, 
O.SOmmol). The reaction was allowed to proceed for 72 hours at room temperature in the 
dark. Upon completion of the reaction the solvent was removed in vacua to yield a crude 
purple solid. The solid was dissolved in 2ml MeOH and this was added to 50ml diethyl 
ether. The resultant precipitate was collected by microfiltration (Millipore®) and this 
process was repeated twice. The purple solid was dried under vacuum to give compound 
95. (0.0242g, 56%); ] H NMR [400MHz, (CD3)2 SO] 8-2.99 (2H, br s, N#), 52.32 (24H, 
d, 3J = 16Hz, PCtf2Ph), 84.01 (8H, d, 3J=12, Ctf2P), 87.41 (8H, d, 3J = 8Hz, 5,10,15,20- 
Ar-3,5-H), 88.12-8.28 (68H, m overlapping, 5,10,15,20-Ar-2,6-H & ortho, meta, para- 
Ar-H), 88.98 (8H, s, p-H); UV/Vis (octanol, nm) l^ 415, 516 550, 593, 649; MS (ES) 
m/z 471 (M4*), 655 (M + Br)3+; HPLC tr = 17.1 min (flow rate= lml/min;eluent A, H2O 
and 0.1%TFA; eluent B, methanol; gradient Omin,0%B; lOmin, 75% B; ISmin, 75% B; 
18min 0% B; 19min 0% B; column, Phenomenex Luna 5\n C18(2) 250*4.6mm
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5,10,15, 20-tetra-(4-((triphenylarsonium)methyl)phenyI)porphyrin tetrabromide
(96)
To a flame dried flask under a nitrogen atmosphere was added compound 83 (20mg, 
0.02mmol) and triphenylarsine (3g). The mixture was heated to 110°C and was stirred for 
48 hours effecting reaction solvolysis. On cooling the solid was ground up and methanol 
added (5ml). The suspension was stirred for 5 minutes and the, unreacted triphenylarsine 
was collected by microfiltration (Millipore®) and washed with methanol. The recovered 
filtrate was added to 50ml diethyl ether. The resultant precipitate was collected by 
microfiltration (Millipore®) and this process was repeated twice. The purple solid was 
dried under vacuum to give compound 96. (0.0089g, 60%) 'H NMR [400MHz, 
(CD3)2 SO] 5-2.94 (2H,br s, N//), 64.86 (8H, s, C#2As), 87.41 (8H, d, 3J= 8Hz, 
5,10,15,20-Ar-3,5-H), 7.87-7.96 (64H, m overlapping, 5,10,15,20-Ar-2,6-H & ortho, 
meta, pam-Ar-H), 58.71 (8H, s, pVH); UV/Vis (octanol, nm) ^ 423, 515, 550, 592,648; 
MS (ES) m/z 472 (M4*), 657 (M + Br)3+, 1025 (M + 2 Br)2+; HPLC tr = 18.4 min (flow 
-ate= lml/min;eluent A, H2O and 0.1%TFA; eluent B, methanol; gradient Omin,0%B; 
lOmin, 75% B; 15min, 75% B; 18min 0% B; 19min 0% B; column, Phenomenex Luna 
>uC18(2)250*4.6mm
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5,10,15, 20-tetra-(4-hydroxyphenyI)porphyrin (106)
4-Hydroxybenzaldehyde (15.51g, 0.127mol) was dissolved in propionic acid (250ml) and 
heated to reflux. Pyrrole (8.82ml, 0.127mol) was added drop wise and the reaction 
refluxed for SOmins. Upon cooling the fine purple precipitate was collected by filtration 
and washed with propionic acid then water. The crystals were dried under vacuum 
overnight to give compound 106. (2.51g, 11%) R/=0.54 (silica, 10% EtOH/CHCl3); ] H 
NMR [400MHz, CD3 OD] 57.22 (8H, d, J= 8 Hz, Ar-3,5-//), 88.02 (8H, d, J= 8 Hz, Ar- 
2,6-H), 68.90 (8H, br s, p-fl); UV/Vis (MeOH, nm) Jw 413, 517, 554, 593, 650. MS 
(MALDI) m/z (M+) 680.
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5,10,15, 20-tetra-(4-(3-bromopropoxy)phenyl)porphyrin (101) [83]
Br
Compound 106 (0.5g, 0.737mmol) was dissolved in dry dioxane (100ml). K2CO3 (1.02g, 
0.737mmol) was added and the reaction was heated to 100°C. 1,3 Dibromopropane 
(0.0368mol, 14.74ml) was dissolved in 35ml dry dioxane and this was added drop wise to 
the reaction mixture. The reaction was stirred at 100°C for 4 days in the dark then it was 
cooled to room temperature and filtered to remove the potassium carbonate. The filtrate 
was concentrated in vacuo and the crude product was adsorbed onto silica and purified by 
gravity percolation chromatography (silica, eluent: 1% MeOH in DCM), the relevant 
fractions were combined and the solvent removed in vacuo to give 101 as fine purple 
crystals. (0.89g, 18%) ] H NMR [400MHz, CDC13 ] 5-2.76 (2H, br s, N-H), 8 2.60-2.48 
:8H, m, CH2C#2CH2 ), 53.80 (8H, t, 3J = 8Hz, Br-CH2), 54.41 (8H, t, 3J = 8Hz, OCH3 ), 
57.29 (8H, d, 3J= 8Hz, Ar-3,5-H) 58.12 (8H, d, 3J = 8 Hz, Ar-2,6-#), 88.86 (8H, s, p-H). 
LJV/Vis (MeOH, nm) Jw 423, 519, 555, 594, 651; MS (MALDI) m/z (M + /H) 1165.
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5,10,15, 20-tetra-(4-carboxyphenyl)porphyrin (146) [110]
4-Carboxybenzaldehyde (19.06g, 0.127mol) was dissolved in propionic acid (250ml) and 
heated to reflux. Pyrrole (8.82ml, 0.127mol) was added drop wise and die reaction 
refluxed for 30 mins. Upon cooling the fine purple precipitate was collected by filtration 
and washed with propionic acid then water. The crystals were dried under vacuum 
overnight to give compound 21. (9.46g, 38%) *H NMR [400MHz, CD3OD] 5-3.00 (2H, 
br s, N#), 68.36 (8H, d, 3J = 8 Hz, Ar-3,5-//), 88.40 (8H, d, 3J = 8 Hz, Ar-2,6-//), 58.86 
(8H, s, p-fl), 512.00 (4H, bs, O#); UV/Vis (CH2C12 , nm) A^ 420, 517, 551, 595, 650; 
MS (MALDI) m/z 791.61(M + H).
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121 4-BenzyIaminobutanenitrile 
127 4-(N-Benzyl-N-(3-cyanopropyl)amino)butanenitriIe
121 127
Benzylamine (O.Olmol, 1.09ml), chlorobutanenitrile (0.022mol, 2.10ml) and Na2CO3 
(O.Olmol, 1.0599g) were dissolved in butanol (50ml) and stirred for 48 hours. No product 
was seen so the reaction was refluxed for 24 hours. The Na2CC«3 was removed by 
filtration and the solvent removed in vacua. TLC in 2%MeOH in DCM showed 2 spots 
(rf = 0.177 and 0.84). Column chromatography (2% MeOH in DCM) afforded both 
compound 121 and compound 127.
Compound 121. (0.62g, 36%) ! H NMR [400MHz, CDC13] 51.34 (1H, bs, N-H), 51.73 
(2H, quint, J = 3Hz, CH2-C#2-CH2), 52.36 (2H, t, 3J = 5Hz, C#2-CN), 52.69 (2H, t, 3J = 
6Hz, N-C#2-CH2), 53.71 (2H, s, Ar-C#2), 57.25 (5H, m, Ar-fl); MS (ES) m/z 174.
Compound 127. (0.54g, 22%) *H NMR [400MHz, CDC13 ] 51.72 (4H, quint, J = 3Hz, 
CH2-C#2-CH2), 52.28 (4H, t, 3J = 5Hz, C/f2-CN), 52.49 (4H, t, 3J = 6Hz, N-C//2-CH2), 
53.47 (2H, s, Ar-C//2), 57.25 (5H, m, Ar-fl); MS (ES) m/z 241.
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t-Butyl N-(3-chloropropyl)carbamate (129) [92]
3- Chloropropylamine hydrochloride (2.31g,22.91mmol) and di-tert-butyl di-carbonate 
(5g, 22.91mmol) were dissolved in 1:1 THF/H2O and the pH was adjusted to 8.5 using 
4% aqueous NaOH. The reaction was stirred overnight and the pH was adjusted 2 using 
0.1M HC1. The product was extracted into chloroform and dried over MgSO4. The 
solvent was removed in vacuo to give 129 (3.26g, 73%); JH NMR [400MHz,CDCl3] 
81.41 (9H, s, C#3), 61.93 (2H, quint, 3J = 5Hz, ClCH2C//2), 53.25 (2H, t, 3J = 8Hz, 
NHC#2), 83.56 (2H, t, 3J = 4Hz, C#2C1); MS (ES) m/z 194,196 (3:1) (M + H).
NV^-Diff-butoxycarbonyl) lysine (137) [91]
V
HN
-"\ 11^^
OH
O
To a solution of lysine (lOmmol, 1.826g), triethylamine (ISmmol, 2.09ml) in 50% aq 
lioxane (14ml) was added BOC-ON (22mmol, 5.41 g). The reaction was stirred for 2 
lays. Water was added to the reaction mixture and 2-hydroxyimino-2-phenylacetone was 
;xtracted into diethyl ether (50ml). The ether layers were washed with water to ensure the 
>roduct remained in the aqueous layer. The aqueous layer was acidified using 5% aq 
;itric acid and the product extracted into EtOAc. The organic layer was dried over 
vlgSO4 , filtered and the solvent removed in vacuo to produce 137 as a foam. (2.64g; 
'6%). 'H NMR [400MHz, CDC13] 81.37 (9H, s, C#3 ), 81.40 (9H, s, C#3), 81.66-1.64 
2H m, NHCH2CH,), 51.73-1.70 (2H, m, CHCH2C//2 ), 51.87-1.83 (2H, m, CHC//2), 
3.01 (2H, t, 3J= 8Hz, NHC//2), 64.30-4.28 (2H, m, C//); MS (ES) m/z 347 (M + H).
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140 Na,NE-Di(|-butoxycarbonyl) lysine N-benzylamiiie
AP-AP-diboc-lysine (137) (4.6mmol, 1.607g) and benzylamine (4.6mmol, 0.5ml) were 
dissolved in DCM (30ml). HOBt (9.2mmol, 1.24g) was added and the reaction was 
cooled to 0°C. DCC (4.6mmol, 0.95g) in DCM (10ml) was added and the reaction was 
stirred under nitrogen for 24 hours. The reaction mixture was filtered to remove the 
precipitate and the solvent was removed in vacuo. The product was adsorbed onto silica 
and purified by gravity percolation chromatography (silica, eluent: 2% MeOH in DCM) 
to afford 140. (1.93g, 97%) MS (ES) m/z 436 (M + H).
141 Lysine N-benzylamide
O
140 (l.OOg, 2.29mmol) was dissolved in 1:1 DCM:TFA (20ml) and stirred for 2 hours. 
The solvent was removed in vacuo. The product was washed with DCM and filtered to 
give 141 as white crystals. (0.47g, 88%) *H NMR [400MHz, D2O] 51.51-1.32 (2H, m, 
CHCH2C#2), 81.72-1.62 (2H, m, CHC/fc), 51.88-1.80 (2H, m, NH2CH2Cft), 53.00-2.92 
(2H, t, 3J = 8Hz, NH2Cft), 53.33-3.30 (2H, m, CHjfo) ,63.83-3.72 (1H, m, CH), 57.34- 
7.27 (5H, m, Ph); MS (ES) m/z 235(M+).
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142 2,6- Bis-trimethylamino-hexanoic acid benzylamide
141 (0.4g, 1.7mmol) was dissolved in dry dioxane (20ml) and Mel (15ml) was added. 
The reaction was refluxed overnight and the solvent and excess Mel were removed in 
vacuo to give 142 (0.23g, 42%) ] H NMR [400MHz, D2O] 51.51-1.33 (2H, m, 
CHCH2O/2), 81.73-1.62 (2H, m, CHC#2), 51.88-1.80 (2H, m, N*CH2C/fc), 83.33-3.30 
(4H, m, frTCJfc and C#2Ph overlapping), 53.35 (9H, s, CH3), 83.37 (9H, s, CHS), 63.99- 
3.87 (1H, m, CH), 57.34-7.27 (5H, m, Ph); MS (ES) m/z 160.7 (M2+).
3-(3-Amino-2,2-bis-(2-cyano-ethoxymethyl)-propoxy)-propionitrUe (145) [94]
To a vigorously stirred solution of tris (hydroxymethyl) methylamine (9.99g, 0.0825mol), 
acrylonitrile (18.43ml, 0.28mol) and NBmBr (5.32g, 0.0165mol) in 100ml DCM was 
added NaOH (25g) in H2O(lOOml). The reaction was stirred tetween 5 and 10°C for 3 
days. The organic layer was separated and dried over MgSO4 . This was filtered and the 
filtrate evaporated in vacuo. The crude sample was purified by chromatography (silica, 
5%MeOH in DCM) and relevant fractions were combined and evaporated in vacuo to 
give 145 as a white solid. (14.62g; 60%). ] H NMR [400MHz, CDC13] 51.67 (2H, s, N#2), 
82.56 (6H, t, 3J= 6Hz, C#2CN), 83.38 (6H, s, CC//2O), 53.63 (6H, t, 3J = 6Hz, 
OO/2CH2). MS (ES) m/z 294(M+).
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Phenylcarboxy(3-(3-amino-2,2-bis-(2-cyano-ethoxymethyl)-propoxy)-propioiiitrile
(148)
145 (0.25g, O.Smmol), benzole acid (0.1089g, O.Smmol) and HOBt (0.241g, 1.78mmol) 
were dissolved in DCM (10ml). The solution was cooled to 0°C and N-N'- 
diisopropylcarbodiimide (DIG) (0.139ml, O.Smmol) was added. The reaction was stirred 
under nitrogen for 24 hours and the solvent removed in vacua. Column chromatography 
(silica, EtOAc) afforded the product. (0.12g, 37%) *H NMR [400MHz, CDC13] 62.61 
(6H, t, 3J= 6Hz ,C#2CN), 83.72 (6H, t, 3J = 6Hz, OC#2CH2), 64.01 (6H, s, CC//2O), 
86.52 (1H, s, Nfl), 87.49-7.42 (3H, m, Ar-3,4,5-/0, 87.77-7.76 (2H, m, Ar-2,6-W); MS 
(ES)w/z399(M + H).
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Appendix 1. Statistics.
1.1 Probit Analysis 
1.1.1. MRSA
1.1.1.1. Compound 88. MRSA
Parameter Estimates
Parameter
PROBIT3 Cone 
Intercept
Estimate
-.010 
.904
Std. Error
.015 
.353
Z
-.635 
2.561
Sig.
.526 
.010
95% Confidence Interval
Lower Bound
-.040 
.551
Upper Bound
.020 
1.257
a. PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
4.076
df3
19
Sig.
1.000
a Statistics based on individual cases differ from statistics based on 
aggregated cases.
b. Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Cone
2.000
3.000
4.000
5.000
10.000
25.000
50.000
1.000
2.000
4.000
5.000
10.000
25.000
50.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Expected 
Responses
1.088
1.084
1.081
1.077
1.059
1.000
.889
1.100
1.096
1.089
1.085
1.067
1.007
.895
1.072
1.068
1.065
1.061
1.043
.985
.875
Residual
-.033
.255
-.157
.175
.119
.040
-.038
.118
-.515
-.469
.142
.088
.062
-.037
-.290
.191
.155
.078
.157
.029
-.067
Probability
.812
.809
.807
.804
.790
.746
.663
.814
.812
.807
.804
.790
.746
.663
.812
.809
.807
.804
.790
.746
.663
Confidence Limits
ProbabWtv
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
900
910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
334.176
305.979
288.088
274.630
263.682
254.364
246.194
238.879
232.226
226.102
200.747
180.595
163.307
147.782
133.395
119.744
108.536
93.537
80.539
67.331
53.680
39.293
23.768
6.479
-13.672
-39.027
-45.151
-51.804
-59.120
-67.290
-76.608
-87.555
-101.013
-118.904
-147.102
Lower 
Bound Upper Bound
.
,
.
Probit Transformed Responses
o
8
000 20.00 40.00
Cone
1.1.1.2. Compound 89. MRSA
Parameter Estimates
Parameter
PROBIT* Cone 
Intercept
Estimate
-.053 
-.484
Std. Error
.038 
.365
Z
-1.409 
-1.324
Sig.
.159 
.185
95% Confidence Interval
Lower Bound
-.127 
-.849
Upper Bound
.021 
-.119
a. PROBIT model: PROBlT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
13.384
df9
19
Sig.
b 
.818
a. Statistics based on individual cases differ from statistics based on 
aggregated cases.
b. Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Cone
.000
1.000
3.000
4.000
5.000
10.000
25.000
50.000
3.000
4.000
5.000
10.000
25.000
50.000
.000
3.000
4.000
5.000
10.000
25.000
50.000
Number of 
Subjects
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
2
1
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
Expected 
Responses
.484
.455
.401
.374
.349
.239
.054
.001
.343
.321
.299
.205
.046
.001
.421
.348
.326
.304
.208
.047
.001
Residual
1.053
.359
-.052
-.313
-.306
-.176
.066
.049
-.250
-.229
-.254
-.135
-.032
.051
.915
-.258
-.245
-.258
-.034
.022
.004
Probability
.314
.296
.260
.243
.227
.155
.035
.001
.260
.243
.227
.155
.035
.001
.314
.260
.243
.227
.155
.035
.001
Confidence Limits
ProbabWv
PROBIT .010 
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% C
Estimate
34.715 
29.579
26.320
23.869
21.875
20.177
18.689
17.357
16.145
15.029
10.411
6.740
3.591
.763
-1.857
-4.344
-6.750
-3.118
-11.485
-13.891
-16.378
-18.998
-21.826
-24.975
-28.646
-33.265
-34.380
-35.592
-36.924
-38.413
-40.110
-42.104
-44.556
-47.814
-52.951
onfidence Limits for Cone
Lower Bound Upper Boimd
Probit Transformed Responses
2-\
H
g
Q.
-H
0§ 
°8
o 
8
0.00 20.00 •40.00
Cone
1.1.1.3. Compound 90. MRSA
Parameter Estimates
Parameter
PROSIT8 Cone 
Intercept
Estimate
-.092 
1.297
Std. Error
.031 
.381
Z
-2.967 
3.406
Sig.
.003 
.001
95% Confidence Interval
Lower Bound
-.153 
.916
Upper Bound
-.031 
1.678
a. PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
26.265
of
22
Sig.
b
.240
a. Statistics based on individual cases differ from statistics based on 
aggregated cases.
b- Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Cone
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
1
1
0
0
0
1
1
1
1
1
0
0
0
1
1
1
1
1
1
0
0
Expected 
Responses
1.215
1.188
1.159
1.128
1.094
.886
.215
.001
1.180
1.133
1.106
1.076
1.044
.845
.205
.001
1.169
1.145
1.117
1.087
1.054
.853
.207
.001
Residual
.031
.064
-.062
-.117
.047
-.824
-.152
.071
.127
.139
.151
.109
.068
-.757
-.143
.069
.146
.056
.164
.207
.263
-.017
-.056
.052
Probability
.886
.867
.846
.823
.799
.646
.157
.000
.903
.867
.846
.823
.799
.646
.157
.000
.886
.867
.846
.823
.799
.646
.157
.000
Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
330
.300
.350
.400
.450
.500
.550
.600
JBSO
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
570
.980
.990
95% Confidence Limits for Cone
Estimate
39.316
36.358
34.481
33.069
31.921
30.944
30.087
29.319
28.622
27.979
25.320
23.206
21.393
19.764
18.255
16.823
15.438
14.074
12.711
11.325
9.893
8.384
6.756
4.942
2.829
.169
-.473
-1.171
-1.939
-2.796
-3.773
-4.921
-6.333
-8.210
-11,167
Lower Bound
26.054
24.184
22.987
22.081
21.339
20.704
20.143
19.639
19.178
18.751
16.954
15.482
14.176
12.956
11.773
10.585
9.356
8.042
6.588
4.921
2.939
.505
-2.553
-6.450
-11.509
-18.395
-20.116
-22.008
-24.103
-26.466
-29.184
-32.403
-36.390
-41 .731
-50.217
Upper Bound
100818
92.190
86.726
82.622
79.288
76.454
73573
71.754
69.738
67.885
60243
54212
49.062
44.521
40.349
36.454
32.768
29.240
25-855
22.604
19.504
16.582
13.860
11.321
8.878
6.324
5.765
5.178
4.551
3.873
3.122
Z265
1.242
-.077
-2,090
Probit Transformed Responses
OO o
o o
o 
o
-2H
20.000.00 40.00
Cone
1.1.1.4. Compound 91. MRSA
Parameter Estimates
Parameter
PROBCP Cone 
Intercept
Estimate
-.099 
1.754
Std. Error
.033 
.552
z
-3.010 
3.178
Sig.
.003 
.001
95% Confidence Interval
Lower Bound
-.163 
1.202
Upper Bound
-.034 
2.305
a PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
15.629
df3
15
Sig.
b 
.407
a Statistics based on individual cases differ from statistics based on 
aggregated cases.
b- Since the significance level is greater than . 150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Cone
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
3.000
25.000
50.000
.000
4.000
5.000
10.000
25.000
50.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
1
1
1
0
0
1
0
0
1
1
1
1
0
0
Expected 
Responses
1.369
1.354
1.336
1.314
1.290
1.120
.341
.001
1.298
.331
.001
1.364
1.296
1.272
1.105
.336
.001
Residual
.055
.079
.027
.016
.013
.034
-.296
.070
.078
-.236
.081
.052
.120
.052
-.220
-.289
.054
Probability
.951
.940
.927
.913
.896
.778
.237
.001
.927
.237
.001
.960
.913
.896
.778
.237
.001
Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
41.284
38.525
36.775
35.459
34.388
33.476
32.677
31.962
31.311
30.712
28.232
26260
24.569
23.050
21.643
20.308
19.016
17.744
16.473
15.181
13.845
1£438
10319
9.228
7.257
4.776
4.177
3.527
Z811
Z012
1.100
.029
-1.287
-3.037
-5.796
Lower Bound
28.429
26.614
25.447
24.560
23.831
23.205
22.651
22.150
21.692
21.266
19.461
17.964
16.621
15.354
14.113
12.859
11.559
10.173
8.658
6.961
5.010
2.716
-.048
-3.462
-7.829
-13.775
-15.270
-16.913
-18.742
-20.809
-23.193
-26.026
-29.547
-34.281
-41.835
Upper Bound
96.748
88.967
84.078
80.396
77.407
74.869
72.649
70.665
68.864
67510
60.405
55.059
50.531
46.526
4Z882
39.499
36.315
33.286
30.387
27.599
24.913
22.322
19.814
17.367
14.881
12.217
11.632
11.016
10.361
9.653
8.873
7.988
6.939
5.597
3.576
Probit Transformed Responses
2-
o o 
o
o
o
2
Q.
O 
O
0-
-2-
0.00 20.00
O
o
Cone
40.00 8
1.1.1.5. Compound 92. MRSA
Parameter Estimates
Parameter
PROBIP Cone 
Intercept
Estimate
.002 
1.412
Std. Error
.029 
.640
z
.064 
2.205
Sig.
.949 
.027
95% Confidence Interval
Lower Bound
-.055 
.772
Upper Bound
.058 
2.052
a. PROBITmodel: PROBIT(p) = Intercept* BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
.839
df9
14
Sig.
b 
1.000
a- Statistics based on individual cases differ from statistics based on
Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Cone
.000
.500
2.000
3.000
10.000
20.000
30.000
40.000
.000
20.000
50.000
.000
1.000
2.000
20.000
50.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed
Responses
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Expected 
Responses
.881
.882
.882
.882
.884
.886
.889
.891
.828
.833
.839
.879
.879
.879
.884
.891
Residual
.076
-.036
.016
-.017
-.136
-.067
-.027
-.010
.071
-.023
.050
.075
.065
-.060
-.025
.048
Probability
.921
.921
.922
.922
.924
.926
.929
.931
.921
.926
.934
.921
.921
.922
.926
.934
Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
-2021.915
-1874.471
-1780.923
-1710.550
-1653.307
-1604.585
-1561.864
-1523.614
-1488.826
-1456.804
-1324.224
-1218.854
-1128.456
-1047.275
-972.050
-900.668
-831.605
-763.637
-695.669
-626.606
-555.224
-479.999
-398.818
-308.420
-203.050
-70.470
•38.448
-3.660
34.590
77.311
126.033
183.276
253.649
347.197
494.640
Lower Bound Upper Bound
.
.
.
,
,
.
.
Probit Transformed Responses
2.1-
O 
O
2 
I
1.8-
15-
1.2-
09-
0.00 20.00 40.00
Cone 10
1.1.1.6. Compound 82. MRSA.
Parameter Estimates
Parameter
PROBIP Cone 
Intercept
Estimate
-.015 
1.073
Std. Error
.012 
.318
Z
-1.185 
3.375
Sig.
.236 
.001
95% Confidence Interval
Lower Bound
-.039 
.755
Upper Bound
.010 
1.391
a. PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
4.661
df9
28
Sig.
1.000
Statistics based on individual cases differ from statistics based on 
aggregated cases.
. Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Cone
.000
.500
1.000
2.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
Number of 
Subjects
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Expected 
Responses
1.297
1.294
1.292
1.287
1.282
1.276
1.271
1.243
1.182
1.113
1.038
.957
1.239
1.225
1.220
. 1.215
1.188
1.130
1.064
.992
.914
1.233
1.219
1.214
1.209
1.183
1.124
1.059
.987
.910
Residual
.214
.212
.208
.204
.059
-.346
-.247
.008
-.236
-.193
-.065
.116
.205
.110
-.235
.127
.049
-.178
-.127
.353
.063
.204
.112
-.264
-.184
-.111
-.170
-.080
.052
.129
Probability
.858
.857
.855
.852
.848
.845
.841
.823
.782
.737
.687
.633
.858
.848
.845
.841
.823
.782
.737
.687
.633
.858
.848
.845
.841
.823
.782
.737
.687
.633
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Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
232.019
213.413
201.608
192.728
185.504
179.356
173.965
169.138
164.748
160.707
143.977
130.680
119.273
109.029
99.536
90.528
81.813
73.236
64.659
55.944
46.936
37.443
27.199
15.792
2.495
-14.235
-18.276
-22.666
-27.493
-32.884
-39.032
-46.256
-55.136
-66.941
-65.547
Lower Bound Upper Bound
.
,
Probit Transformed Responses
3.0-
2S-
2.0-
o
o
1.0- o o
05- O8° 
o
0 o
o 
o
0.0-
—I—
0.00
—I—
20.00 40.00
Cone 12
1.1.1.7. Compound 93. MRSA
Parameter Estimates
Parameter
PROBIT* Cone 
Intercept
-.073 
.553
Std. Error
.022 
.274
Z
-3.284 
2.018
Sta.
.001 
.044
95% Confidence Interval
Lower Bound
-.117 
.279
Upper Bound
-.029 
.828
a. PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
23.495
df3
32
Sig.
.862"
a. statistics based on individual cases differ from statistics based on 
aggregated cases.
b. Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
Cone
.000
.500
1.000
2.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.500
1.000
2.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.000
500
1.000
2.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
1
1
0
0
0
0
0
0
1
1
1
1
0
0
0
0
0
0
0
1
1
1
1
1
1
1
0
0
0
0
0
Expected 
Responses
.902
.886
.869
.836
.766
.730
.546
.231
.065
.011
.001
.976
.958
.921
.883
.844
.805
.602
.255*
.071
.013
.001
.966
.948
.931
.895
.858
.820
.782
.585
248
.069
.012
.001
Residua)
.366
.326
.228
-.112
.064
-.482
-.493
-.180
-.007
.058
.073
.312
.348
-.192
-.086
-.689
-.652
-.552
-.199
-.006
.059
.073
.394
.346
"Mid
.ODD
.188
.430
.249
.007
-.526
-.196
-.009
.051
.071
Probability
.710
.697
.684
.658
.603
.575
.430
.182
.051
.009
.001
697
.684
.658
.631
.603
.575
.430
.182
.051
.009
.001
.710
.697
.684
.658
.631
.603
.575
.430
182
.051
.009
.001
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Confidence Limits
Probebility
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.650
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
39.440
35.707
33.338
31.556
30.107
28.873
27.791
26.822
25.942
25.131
21.774
19.105
16.816
14.761
1Z856
11.048
9.300
7.578
5.857
4.109
Z301
.396
-1.659
-3549
-6.617
-9.974
-10.785
-11.666
-12.634
-13.716
-14.950
-16.399
-18.181
-20.550
-24.284
Lower Bound
26.522
24.069
22.497
21.304
20.325
19.484
18.742
18.071
17.456
16.886
14.459
12.426
10.568
8.761
6.916
4.950
2.781
.333
-2.454
-5.619
-9.187
-13.198
-17.730
-22.947
-29.176
-37.157
-39.101
-41.219
-43.554
-46.168
-49.157
-52.677
-57.015
-62.797
-71.937
Upper Bound
87.916
78.772
72.986
68.644
65.121
62.129
59.512
57.174
55.052
53.104
45.103
38.848
33.596
29.018
24546
21.298
18.035
15.137
12.578
10.311
8.265
6.358
4.505
Z612
.554
-1.893
-Z468
-3.086
-3.760
-4.506
-5.349
-6.331
-7.528
-9.104
-11561
Probit Transformed Responses
2-
o go o
o 
oo
-2-
——I— 
0.00 3000
Cone
40.00
14
1.1.1.8. Compound 94. MRSA
Parameter Estimates
Parameter
PROBFP Cone 
Intercept
Estimate
-.068 
.251
Std. Error
.038 
.594
Z
-1.779 
.424
Si9-
.075 
.672
95% Confidence Interval
Lower Bound
-.142 
-.342
Upper Bound
.007 
.845
a. PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
15.476
df9
9
Sig.
.079
a- Statistics based on individual cases differ from statistics based on 
aggregated cases.
. Since the significance level is less than .150, a heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
Cone
.000
10.000
20.000
50.000
.000
10.000
20.000
50.000
10.000
20.000
50.000
Number of 
Subjects
2
2
2
2
1
1
1
1
2
2
2
Observed 
Responses
2
0
0
0
1
0
0
0
0
0
0
Expected 
Responses
.899
.502
.202
.001
.875
.489
.197
.001
.529
.213
.001
Residual
.601
-.457
-.142
.058
.583
-.433
-.133
.099
-.193
-.163
.043
Probability
.599
.335
.135
.001
.599
.335
.135
.001
.335
.135
.001
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Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits tor Cone
Estimate
38.027
34.005
31.454
29.535
27.974
28.645
25.480
24.437
23.488
22.614
18.999
16.125
13.659
11.445
9.394
7.447
5.564
3.710
1.856
-.027
-1.974
-4.026
-6.240
-8.705
-11.579
-15.195
-16.068
-17.017
-18.060
-19.225
-20.554
-22.115
-24.034
-26.586
-30.607
Lower Bound
.
a- A heterogeneity factor is used.
Probtt Transfonned Responses
20.00 40.00
Cone 16
1.1.1.9. Compound 97. MRSA.
Parameter Estimates
Parameter
PROBIT* Cone 
Intercept
Estimate
-.010 
-.347
Std. Error
.016 
.359
z
-.633 
-.967
Sig.
.526 
.333
95% Confidence Interval
Lower Bound
-.042 
-,705
Upper Bound
.021 
.012
a. PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
12.296
df3
16
Sig.
b 
.723
a Statistics based on individual cases differ from statistics based on 
aggregated cases.
b- Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Cone
1.000
2000
3.000
4.000
5.000
10.000
25.000
50.000
4.000
5.000
10.000
25.000
50.000
3.000
5.000
10.000
25.000
50.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
0
0
0
0
0
0
0
0
0
1
1 «
0
0
1
0
Expected 
Responses
.516
.510
.505
.499
.494
.467
.391
.279
.426
.421
.398
.333
.238
.469
.459
.434
.363
.259
Residual
.706
.698
.829
-.423
-.445
-.410
-.306
-.053
-.375
-.345
-.334
-.228
.301
.682
-.393
-.373
.384
.078
Probability
.361
.357
.353
.349
.345
.327
.273
.195
.349
.345
.327
.273
.195
.353
.345
.327
.273
.195
17
Confidence Limits
Probabilitv
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
192.842
166.286
149.438
136.763
126.453
117.678
109.984
103.095
96.829
91.062
67.184
48.206
31.925
17.304
3.755
-9.101
-21.540
-33.781
-46.023
-58.461
-71.318
-84.866
-99.487
-115.768
-134.746
-158.625
-164.392
-170.657
-177.547
-185.241
-194.016
-204.326
-217.000
-233.849
-260.404
Lower Bound Upper Bound
Probit Transformed Responses
°0
I a.
o 
o
O
o
2000
Cone
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1.1.1.10. Compound 98. MRSA.
Parameter Estimates
Parameter
PROBIT3 Cone 
Intercept
Estimate
-.017 
1.631
Std. Error
.017 
.447
z
-1.009 
3.649
Sig.
.313 
.000
95% Confidence Interval
Lower Bound
-.051 
1.184
Upper Bound
.016 
2.078
PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
1.875
df9
20
Sig.
1.000
Statistics based on individual cases differ from statistics based on 
aggregated cases.
Since the significance level is greater than . 150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Cone
4.000
5.000
10.000
25.000
50.000
.000
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
Number of 
Subjects
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
Observed 
Responses
1
1
1
1
1
1
1
1
1
1
1
1
1 .
1
2
1
1
1
1
1
1
1
Expected 
Responses
1.336
1.333
1.317
1.257
1.107
1.423
1.420
1.417
1.414
1.411
1.408
1.391
1.328
1.169
1.442
1.436
1.433
1.430
1.427
1.410
1.345
1.185
Residual
.032
.050
-.081
-.055
.099
.073
.001
-.006
.004
-.025
.030
.045
-.334
-.064
.078
.037
.028
.054
.036
-.229
.014
.211
Probability
.941
.939
.928
.885
.779
.949
.947
.945
.943
.941
.939
.928
.885
.779
.949
.945
.943
.941
.939
.928
.885
.779
19
Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
229.951
214.110
204.059
196.498
190.348
185.114
180.524
176.414
172.677
169.236
154.992
143.671
133.958
125.236
117.154
109.485
102.065
94.762
87.460
80.040
72.371
64.288
55.566
45.854
34.533
20.289
16.848
13.111
9.001
4.411
-.823
-6.974
-14.534
-24.585
-40.426
Lower Bound Upper Bound
Probit Transformed Responses
ao-
25-
20-
fa.
o
o
o 
o
o 
o
0.5-
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0.00 2000
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1.1.1.11. Compound 99. MRSA.
Parameter Estimates
Parameter
PROBIT8 Cone 
Intercept
Estimate
-.052 
.507
Std. Error
.021 
.298
z
-2.471 
1.701
Sig.
.013 
.089
95% Confidence Interval
Lower Bound
-.094 
.209
Upper Bound
-.011 
.805
a- PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
10.296
df3
22
Sig.
b 
.983
a Statistics based on individual cases differ from statistics based on 
aggregated cases.
b. Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Cone
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
Number of 
Subjects
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
0
1
0
0
0
1
1
1
1
1
0.
0
0
1
1
1
1
1
0
0
0
Expected 
Responses
1.027
.998
.968
.938
.908
.751
.323
.027
.878
.853
.828
.802
.776
.642
.276
.023
.937
.886
.860
.833
.806
.667
.287
.024
Residual
.405
.334
-.157
-.608
-.373
-.640
-.260
.046
.315
.137
.254
-.121
.344
-.431
-.167
.227
.410
.351
.213
.002
.020
-.510
-.129
.116
Probability
.675
.656
.637
.617
.597
.494
.213
.018
.675
.656
.637
.617
.597
.494
.213
.018
.694
.656
.637
.617
.597
.494
.213
.018
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Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
54.304
49.079
45.764
43.271
41.242
39.516
38.002
36.646
35.414
34.279
29.581
25.847
22.643
19.767
17.101
14.571
12.124
9.715
7.307
4.859
2.330
-.336
-3.213
-6.416
-10.150
-14.848
-15.983
-17.216
-18.571
-20.085
-21.812
-23.840
-26.334
-29.649
-34.874
Lower Bound
32.947
29.894
27.938
26.452
25.234
24.188
23.264
22.429
21.663
20.952
17.923
15.371
13.009
10.660
8.153
5.269
1.671
-3.127
-9.605
-17.913
-27.848
-39.218
-52.073
-66.786
-84.232
-106.436
-111.826
-117.690
-124.148
-131.371
-139.619
-149.322
-161.267
-177.166
-202.263
Upper Bound
231.002
205.888
189.974
178.015
168.298
160.036
152.800
146.328
140.448
135.042
112.744
95.166
80.258
67.100
55_235
44.483
34.888
26.701
20.196
15.310
11.608
8.608
5.955
3.398
.715
-2.409
-3.136
-3.917
-4.766
-5.705
•6.764
-7.996
-9.495
-11.467
-14.537
Probit Transformed Responses
2-
S
Q.
0-
o
00y
oo
00
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2000 4000
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1.1.2. S. aureus
1.1.2.1. Compound 88. S.aureus
Parameter Estimates
Parameter
PROBIT8 Cone 
Intercept
Estimate
-.016 
1.374
Std. Error
.015 
.368
Z
-1.071 
3.729
Sig.
.284 
.000
95% Confidence Interval
Lower Bound
-.046 
1.005
Upper Bound
.014 
1.742
a. PROBIT model: PROBIT(p) = Intercept •*• BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
1.181
df
22
Sig.
b 
1.000
Statistics based on individual cases differ from statistics based on 
aggregated cases.
Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Cone
1.000
2.000
4.000
5.000
10.000
25.000
50.000
.000
1.000
2.000
4.000
5.000
10.000
25.000
50.000
.000
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Expected 
Responses
1.314
1.311
1.303
1.299
1.277
1.199
1.024
1.287
1.283
1.280
1.272
1.268
1.247
1.171
1.000
1.327
1.323
1.320
1.316
1.312
1.308
1.286
1.207
1.031
Residual
-.006
-.018
-.058
.011
.028
-.132
.020
.119
-.119
.067
-.221
.021
.063
.066
.020
.121
.016
-.063
.038
-.070
.041
.096
-.043
.000
Probability
.913
.910
.905
.902
.887
.833
.711
.915
.913
.910
.905
.902
.887
.833
.711
.915
.913
.910
.907
.905
.902
.887
.833
.711
23
Confidence Limits
ProbabiBv
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
226.208
209.544
198.970
191.017
184.547
179.040
174.211
169.888
165.956
162.337
147.352
135.443
125.226
116.050
107.548
99.480
91.674
83.992
76.310
68.504
60.436
51.934
42.759
32.541
20.632
5.647
Z028
-1.904
-6.227
-11.056
-16.563
-23.033
-30.986
-41.560
-58.224
Lower Bound Upper Bound
.
.
Probit Transformed Responses
3.0 H O
25H
2.<H
±! 
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I
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1.1.2.2. Compound 89. S.aureus
Parameter Estimates
Parameter
PROBIT3 Cone 
Intercept
Estimate
-.018 
.610
Std. Error
.013 
.282
z
-1.374 
2.162
S'9
.170 
.031
95% Confidence Interval
Lower Bound
-.045 
.328
Upper Bound
.008 
.893
a. PROBIT model: PROBIT(p) = Intercept* BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
7.325
df»
22
Sig.
b 
.999
a- Statistics based on individual cases differ from statistics based on 
aggregated cases.
b. Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Cone
.000
1.000
3.000
4.000
5.000
10.000
25.000
50.000
.000
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
.000
3.000
4.000
5.000
10.000
25.000
50.000
Number of
Subjects
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed
Responses
1
1
1
0
1
0
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
Expected 
Responses
1.094
1.085
1.066
1.056
1.047
.998
.839
.567
1.072
1.063
1.054
1.045
1.035
1.026
.978
.823
.556
1.050
1.023
1.014
1.005
.958
.806
.544
Residual
.404
.302
-.056
-.612
.005
-.526
-.083
.366
.393
.339
.316
.034
-.392
.068
-.194
-.679
.091
.385
.000
-.256
-.029
-.112
.062
.132
Probability
.729
.723
.711
.704
.698
.665
.560
.378
.729
.723
.717
.711
.704
.698
.665
.560
.378
.729
.711
.704
.698
.665
,560
.378
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Confidence Limits
Probability
PROBIT .010 ——
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
159.449
144.648
135.258
128.194
122.448
117.558
113.269
109.430
105.938
102.724
89.415
78.838
69.764
61.616
54.064
46.899
39.967
33.144
26.322
19.389
12.224
4.673
-3.476
-12.550
-23.127
-36.435
-39.649
-43.141
-46.981
-51.269
-56.160
-61.906
-68.970
-78.360
-93.160
Lower Bound Upper Bound
o 
o
Probit Transformed Responses
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1.1.2.3. Compound 90. S.aureus
Parameter Estimates
Parameter
PROSIT8 Cone 
Intercept
Estimate
-.083
.750
Std. Error
.034 
.370
Z
-2.419 
2.027
Sifl.
.016 
.043
95% Confidence Interval
Lower Bound
-.150 
.380
Upper Bound
-.016 
1.120
a. PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
28.000
df3
20
Sig.
b 
.109
a- Statistics based on individual cases differ from statistics based on 
aggregated cases.
b- Since the significance level is less than .150, a heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Cone
2.000
3.000
5.000
10.000
25.000
50.000
.000
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
0
0
0
1
1
1
1
1
1
o.
0
0
1
1
1
0
0
0
0
Expected 
Responses
.864
.830
.757
.562
.111
.000
.951
.920
.886
.851
.814
.776
.576
.114
.000
.944
.906
.867
.827
.613
.121
.000
Residual
.309
.214
.238
-.368
-.059
.054
.275
.298
.291
.338
.036
-.123
-.283
-.064
.055
.313
-.104
-.362
-.739
-.553
-.065
.056
Probability
.720
.692
.631
.468
.093
.000
.773
.748
.720
.692
.662
.631
.468
.093
.000
.720
.692
.662
.631
.468
.093
.000
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Confidence Limits
Probability
PROBIT» .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
37.070
33.785
31.701
30.133
28.858
27.772
26.820
25.966
25.193
24.480
21.526
19.178
17.164
15.355
13.679
12.089
10.550
9.036
7.522
5.983
4.393
2.717
.908
-1.106
-3.454
-6.407
-7.121
-7.896
-8.748
-9.700
-10.785
-12.061
-13.629
-15.713
-18.998
Lower Bound Upper Bound
- A heterogeneity factor is used.
Probit Transformed Responses
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1.1.2.4. Compound 91. S.aureus
Parameter Estimates
Parameter
PROBIP Cone 
Intercept
Estimate
-.095 
1.613
Std. Error
.027 
.365
Z
-3.445 
4.416
Sia.
.001 
.000
95% Confidence Interval
Lower Bound
-.149 
1.248
Upper Bound
-.041 
1.978
a. PROBITmodel: PROBIT(p) = Intercept* BX
Chf-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
14.732
df3
24
Sig.
.928
a Statistics based on individual cases differ from statistics based on 
aggregated cases.
b Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
Cone
.000
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
.000
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
1.000
2.000
3.000
4.000
5.000
10.000
25.000
50.000
Number of
Subjects
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
Observed 
Responses
2
2
1
1
1
1
1
0
0
2
2
2
1
1
1
1
0
0
2
1
1
1
1
1
0
0
Expected 
Responses
1.524
1.506
1.486
1.462
1.435
1.405
1.203
.362
.001
1.552
1.534
1.513
1.489
1.462
1.431
1.226
.369
.001
1.459
1.439
1.417
1.391
1.362
1.166
.351
.001
Residual
.084
.081
-.020
.002
-.006
.047
.017
-.313
.055
.084
.086
-.004
.000
-.059
.021
.101
-.321
.107
.068
.054
-.042
-.017
-.064
-.028
-.304
.069
Lprobability
.947
.936
.923
.908
.891
.873
.747
.225
.001
.947
.936
.923
.908
.891
.873
.747
.225
.001
.936
.923
.908
.891
.873
.747
.225
.001
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Confidence Limits
Probability
PRbBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
41.590
38.712
36.886
35.512
34.395
33.444
32.610
31.864
31.185
30.560
27.972
25.915
24.151
2Z.5S6
21.098
19.705
18.357
17.030
15.704
14.356
12.962
11.494
9.910
8.145
6.088
3.501
2.876
2.197
1.450
.616
-.335
-1.452
-2826
-4.651
-7.529
Lower Bound
28.866
28.953
25.731
24.808
24.053
23.407
22.839
22.328
21.861
21.430
19.625
18.161
16.877
15.696
14.571
13.468
12.360
11.218
10.013
8.705
7.241
5.544
3.498
.926
-2.466
-7.246
-8.469
-9.821
-11.333
-13.050
-15.038
-17.409
-20.366
-24.352
-30.728
Upper Bound
85.66S
79.060
74.891
71.753
69.205
67.038
65.141
63.446
61.903
60.486
54.640
50.023
46.090
42.586
39.369
36.353
33.475
30.694
27.976
25.296
22.643
19.999
17.359
14.714
12.024
9.154
8.526
7.873
7.177
6.428
5.605
4.672
3.567
2.154
.021
3- O
O
2-
Probit Transformed Responses
*•
t Ha. o 8
-2-
0.00 20.00
Cone
40.00
30
1.1.2.5. Compound 92. S.aureus
Parameter Estimates
Parameter
PROBFP Cone 
Intercept
Estimate
-.008 
1.778
Std. Error
.027 
.652
z
-.288 
2.726
Sig.
.773 
.006
95% Confidence Interval
Lower Bound
-.061 
1.126
Upper Bound
.045 
2.431
a. PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
.825
df3
18
Sig.
1.000b
a Statistics based on individual cases differ from statistics based on 
aggregated cases.
b Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Cone
.000
5.000
40.000
.000
.500
3.000
4.000
5.000
20.000
40.000
50.000
.000
.500
1.000
2.000
3.000
5.000
20.000
30.000
40.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Expected 
Responses
.885
.882
.854
.991
.991
.989
.988
.988
.976
.957
.945
.991
.991
.991
.990
.989
.988
.976
.967
.957
Residual
.030
.016
.000
.038
.013
.015
-.007
.017
.030
-.055
.070
.036
.005
-.013
.008
-.127
-.026
-.051
.054
-.053
Probability
.962
.959
929
.962
.962
.960
960
.959
.948
.929
.917
.962
.962
.962
.961
.960
.959
.948
.939
.929
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Confidence Limits
Probability
PROBIT .010 
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
525.270 
490.388
468.256
451.607
438.064
426.537
416.430
407.380
399.150
391.574
360.208
335.279
313.892
294.686
276.889
260.001
243.662
227.582
211.502
195.163
178.275
160.478
141.272
119.885
94.956
63.590
56.014
47.784
38.734
28.627
17.100
3.557
-13.092
-35.224
-70,106
Lower Bound Upper Bound
3JH
o 
o
00°
Probtt Transformed Responses
15H O 
O
0.00 20.00 40.00
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1.1.2.6. Compound 82. S.aureus
Parameter Estimates
Parameter
PROBIT8 Cone 
Intercept
Estimate
-.014 
1.090
Std. Error
.012
.317
z
-1.153 
3.443
Sig.
.249
.001
95% Confidence Interval
Lower Bound
-.038 
.773
Upper Bound
.010 
1.406
a. PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
5.161
df"
28
Sig.
b
1.000
a Statistics based on individual cases differ from statistics based on 
aggregated cases.
b Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Cone
.000
.500
2.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.000
.500
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.500
2.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
Observed 
Responses
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Expected 
Responses
1.224
1.222
1515
1511
1.206
1.201
1.177
1.122
1.061
.994
.922
1.319
1.317
1.299
1.294
1.268
1.209
1.143
1.071
.993
1599
1.292
1.287
1.282
1.277
1.251
1.193
1.128
1.057
.980
Residual
.193
.155
.130
.177
-.165
-.210
.128
-.114
-.057
-.036
.281
.211
.037
-.331
-.473
.097
.125
.245
-.097
.331
.066
.065
-.012
-.230
.096
.073
.058
-.152
-.431
-.161
Probability
.862
.861
.856
.853
.849
.846
.829
.790
.747
.700
.649
.862
.861
.849
.846
.829
.790
.747
.700
.649
.861
.856
.853
.849
.846
.829
.790
.747
.700
.649
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Commence Limits
ProbabiBv
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
241.757
222.466
210.226
201.018
193.529
187.154
181.564
176.560
172.008
167.818
150.472
136.685
124.857
114.236
104393
95.054
86.017
77.125
68.232
59.196
49.856
40.013
29.392
17.564
3.778
-13.569
-17.759
-22.310
-27.315
-32.905
-39.280
-46.769
-55.977
-68.217
-87.508
Lower Bound Upper Bound
.
-
-
15-
Probit Transformed Responses
o 
o
0.5-
o oo o o
00-
-0.5-
——1—— 
0.00 20.00 4000
Cone 34
1.1.2.7. Compound 93. S.aureus
Parameter Estimates
Parameter
PROBIP Cone 
Intercept
Estimate
-.077 
.463
Std. Error
.024 
.272
Z
-3.168 
1.702
Sig.
.002 
.089
95% Confidence Interval
Lower Bound
-.124 
.191
Upper Bound
-.029 
.736
a PROBITmodel: PROBIT(p) = Intercept* BX
Cni-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
27.908
df9
31
Sig.
b 
.626
a. Statistics based on individual cases differ from statistics based on 
aggregated cases.
b- Since the significance level is greater than .150, no heterogeneity 
factor is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
Cone
.000
.500
1.000
2.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.000
1.000
2.000
3.000
4.000
5.000
10.000
20.000
30.000
40000
50.000
1.000
2000
3.000
4.000
5.000
10.000
20000
30.000
40.000
50.000
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
1
1
1
1
0
0
0
0
0
1
1
1
1
1
0
0
0
0
0
0
1
1
1
1
0
0
0
0
0
0
Expected 
Responses
1.011
.990
.969
.926
.883
.838
.793
.568
.212
050
.007
.001
.984
.943
.902
.859
.815
.771
.352
.207
.048
.007
.001
.930
.889
.847
.804
.761
.545
.204
.048
.007
.001
Residual
.477
.474
.327
-.195
.152
.117
-.165
-.519
-.162
.003
.050
.060
.466
.423
-.019
.018
-.172
-.572
-.503
-.156
.006
.051
.056
.467
.186
.118
-272
-.507
-.495
-.153
.003
.051
.056
Probability
.678
.665
.651
.622
.592
.562
.532
.381
.143
.033
.005
.000
.678
.651
.622
.592
.562
.532
.381
.143
.033
.005
.000
.651
.622
.592
.562
.532
.381
.143
.033
.005
.000
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Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimste
36.408
32.850
30.593
28.895
27.514
26.338
25.308
24.385
23.545
22.772
19.573
17.031
14.850
12.891
11.076
9.353
7.687
6.047
4.407
2.740
1.018
-.797
-2.756
-4.937
-7.480
-10.679
-11.451
-12.291
-13.214
-14.245
-15.420
-16.801
-18.499
-20.757
-24.314
Lower Bound
24.241
21.933
20.453
19.329
18.406
17.613
16.912
16.278
15.696
15.155
12.849
10.900
9.095
7.311
5.447
3.411
1.112
-1.520
-4.523
-7.906
-11.674
-15.859
-20.543
-25.895
-32.250
-40.360
-42.332
-44.479
-46.845
-49.492
-52.517
-56.078
-60.464
-66.308
-75.539
Upper Bound
85.362
76.140
70.306
85.927
62.374
59.357
56.718
54.360
52.222
50.258
42.198
35.907
30.643
26.080
22.061
16.516
15.414
12.731
10.420
8.402
6.589
4.891
3.227
1.510
-.374
-2.631
-3.163
-3.736
-4.362
-5.055
-5.840
-6.755
-7.871
-9.343
-11.641
o 
o
Probit Translonned Responses
s°
o o
0.00
Cone
40-00 36
1.1.2.8. Compound 94. S.aureus
Parameter Estimates
Parameter
PROBIP Conc2 
Intercept
Estimate
-.069 
.290
Std. Error
.037 
.563
Z
-1.899 
.515
Sifl.
.058 
.606
95% Confidence Interval
-.141 
-.273
.002 
.853
a- PROBIT model: PROBIT(p) = Intercept* BX
Chi-Square Tests
PROBIT Pearson 
Goodness-of-Fit Test
Chi-Square
16.878
of
9
Sig.
b 
.051
a. Statistics based on individual cases differ from statistics based on 
aggregated cases.
b. Since the significance level is less than .150, a heterogeneity factor 
is used in the calculation of confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
Conc2
.000
10.000
20.000
50.000
.000
10.000
20.000
50.000
10.000
20.000
50.000
Number of 
Subjects
2
2
2
2
2
2
2
2
2
2
2
Observed 
Responses
2
0
0
0
2
0
0
0
0
0
0
Expected 
Responses
1.019
.570
.226
.001
1.056
.591
,235
.001
.577
.229
.001
Residual
.640
-.171
-.159
.084
.659
-.531
-.164
.042
-.528
-.118
.086
Probability
.614
.343
.136
.001
.614
.343
.136
.001
.343
.136
.001
37
Confidence Limits
Probabiltv
PROBfP .010 ——
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
350
.300
350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
96% Confidence Limits for Conc2
Estimate
37.740
33.807
31.313
29.436
27.909
26.610
25.470
24.450
23523
22669
19.133
16.323
13512
11.747
9.741
7,837
5.995
4.182
Z370
528
-1.376
-3.382
-5.547
-7.958
-10.768
-14.304
-15.158
-16.086
-17.106
-18.245
-19.544
-21.071
-22.948
-25.443
-29.375
Lower Bound
.
.
.
.
.
.
a A heterogeneity factor is used.
Probit Transformed Responses
o 
o
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0.00
o 
o
2000
O 
O
40.00 38
Conc2
1.1.3E. co/f.
1.1.3.1. Compound 93 £. Co//
Parameter Estimates
Parameter
PROBIT( Cone 
a> Intercept
Estimate
-.043 
.288
Std. Error
.014 
.267
Z
-3.021 
1.078
Sig.
.003 
.281
95% Confidence Interval
Lower Bound
-.072 
.021
Upper Bound
-.015 
.556
a PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROSIT Pearson Goodness-of- 
Fit Test
Chi-Square
16.388
df(a)
37
Sig.
.999(b)
a Statistics based on individual cases differ from statistics based on aggregated cases.
b Since the significance level is greater than .150, no heterogeneity factor is used in the calculation of
confidence limits.
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Cone
.000
.500
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.500
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.000
.500
Number of 
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
0
1
1
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
1
1
1
0
0
0
0
0
1
1
Expected 
Responses
.748
.738
.687
.666
.645
.539
.342
.189
.090
.036
.696
.647
.627
.608
.508
.323
.178
.085
.034
.705
.627
.608
.508
.323
.178
.085
.034
.773
.762
Residual
.472
-.528
.515
.067
-.253
-.479
-.278
-.123
.126
.047
-.300
.474
.267
-.498
-.350
-.182
-.078
.248
.085
.440
.062
.009
-.446
-.262
-.079
.280
.059
.486
.471
Probability
.613
.605
.563
.546
.528
.442
.281
.155
.074
.030
.605
.563
.546
.528
.442
.281
.155
.074
.030
.613
.546
.528
.442
.281
.155
.074
.030
.613
.605
39
30
31
32
33
34
35
36
37
38
39
1.000
2.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
.752
.731
.709
.687
.666
.557
.354
.195
.093
.037
.470
.468
.154
-.260
-.471
-.506
-.301
-.131
.025
.073
.597
.580
.563
.546
.528
.442
.281
.155
.074
.030
Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
60.169
53.896
49.916
46.921
44.486
42.413
40.596
38.968
37.488
36.126
30.485
26.002
22.156
18.702
15.502
12.465
9.527
6.635
3.743
.805
-2.232
-5.433
-8.886
-12.732
-17.215
-22.856
-24.218
-25.699
-27.326
-29.143
-31.216
-33.652
-36.646
-40.626
-46.899
Lower Bound
39.901
35.902
33.333
31.379
29.771
28.388
27.162
26.051
25.028
24.075
19.963
16.394
12.952
9.351
5.335
.686
-4.705
-10.809
-17.534
-24.812
-32.650
-41.139
-50.474
-61.008
-73.411
-89.136
-92.949
-97.096
-101.661
-106.766
-112.595
-119.451
-127.889
-139.121
-156.850
Upper Bound
150.359
132.696
121.521
113.137
106.334
100.559
95.509
91.001
86.913
83.161
67.796
55.884
46.045
37.719
30.683
24.845
20.090
16.209
12.948
10.079
7.431
4.868
2.276
-.470
-3.549
-7.301
-8.193
-9.156
-10.211
-11.382
-12.712
-14.266
-16.166
-18.677
-22.610 40
Probit Transformed Responses
4-
3-
2-
1-
0-
-1-
-2-
O
o
o
O O0
o o 
o o 
8
8 
o 
o
0.00 20.00 40.00
Cone
1.1.3.2. Compound 90. E. coli
Parameter Estimates
Parameter
PROBIT( Cone 
a> Intercept
Estimate
-.084 
1.102
Std. Error
.021 
.352
Z
-3.953 
3.133
Sig.
.000 
.002
95% Confidence Interval
Lower Bound
-.125 
.750
Upper Bound
-.042 
1.454
a PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson Goodness-of- 
FrtTest
Chi-Square
21.424
df(a)
32
Sig.
.922(b)
a Statistics based on individual cases differ from statistics based on aggregated cases.
b Since the significance level is greater than .150, no heterogeneity factor is used in the calculation of
confidence limits.
41
Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
Cone
.000
2.000
3.000
10.000
20.000
30.000
40.000
50.000
2.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
2.000
3.000
4.000
5.000
10.000
20.000
30.000
40.000
50.000
.000
2.000
5.000
10.000
20.000
30.000
40.000
50.000
Number of
Subjects
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
0
0
0
0
0
1
1
1
1
1
0
0
0
0
1
1
1
1
0
0
0
0
0
1
1
1
0
0
0
0
0
Expected 
Responses
1.098
1.048
1.019
.768
.360
.101
.016
.001
1.106
1.075
1.043
1.009
.810
.380
.106
.017
.001
1.073
1.043
1.012
.979
.786
.369
.103
.016
.001
1.090
1.040
.949
.762
.357
.100
.016
.001
Residual
.172
.014
.240
-.472
-.308
-.040
.050
.073
.161
.241
.253
.109
.001
-.329
-.047
.049
.068
.112
.245
.288
-.170
-.452
-.314
-.042
.044
.070
.165
-.009
.067
-.538
-.302
-.036
.046
.068
Probability
.865
.825
.803
.604
.284
.079
.012
.001
.825
.803
.779
.753
.604
.284
.079
.012
.001
.825
.803
.779
.753
.604
.284
.079
.012
.001
.865
.825
.753
.604
.284
.079
.012
.001
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Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for Cone
Estimate
40.949
37.693
35.627
34.073
32.809
31.733
30.790
29.945
29.177
28.470
25.542
23.216
21.219
19.427
17.766
16.189
14.664
13.163
11.663
10.137
8.561
6.900
5.107
3.111
.784
-2.143
-2.850
-3.618
-4.463
-5.407
-6.482
-7.746
-9.300
-11.366
-14.622
Lower Bound
30.164
27.855
26.374
25.248
24.325
23.532
22.831
22.199
21.619
21.080
18.798
16.902
15.195
13.574
11.978
10.358
8.672
6.881
4.949
2.837
.503
-2.107
-5.069
-8.509
-12.660
-18.035
-19.352
-20.790
-22.378
-24.160
-26.201
-28.610
-31.585
-35.560
-41.859
70.735
64.409
60.412
57.416
54.987
52.927
51.125
49.518
48,061
46.723
41.241
36.966
33.379
30.245
27.435
24.875
22.517
20.327
18.278
16.345
14.499
12.704
10.911
9.057
7.037
4.647
4.089
3.489
2.837
2.117
1.305
.361
-.785
-2.289
-4.626
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Probit Transformed Responses
2-
•2 
2
Q.
0-
-2-
0 
O
O 
O
8 8
8 
o
0.00 20.00 40.00
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1.1.3.3. Compound 97. E. coli
Parameter Estimates
Parameter
PROBIT( cone 
a) Intercept
Estimate
.130 
.648
Std. Error
.821 
1.495
Z
.158 
.433
Sig.
.874 
.665
95% Confidence Interval
Lower Bound
-1.479 
-.847
Upper Bound
1.739 
2.143
a PROBIT model: PROBIT(p) = Intercept + BX
Chi-Square Tests
PROBIT Pearson Goodness-of- 
Fit Test
Chi-Square
.264
df(a)
5
Sig.
.998(b)
a Statistics based on individual cases differ from statistics based on aggregated cases.
b Since the significance level is greater than .150, no heterogeneity factor is used in the calculation of
confidence limits.
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Cell Counts and Residuals
Number
PROBIT 1
2
3
4
5
6
7
cone
1.000
2.000
1.000
2.000
3.000
1.000
2.000
Number of 
Subjects
1
1
1
1
1
1
1
Observed 
Responses
1
1
1
1
1
1
1
Expected 
Responses
.696
.728
.813
.851
.884
.680
.712
Residual
.005
-.032
-.003
-.135
.095
.098
-.029
Probability
.782
.818
.782
.818
.850
.782
.818
Confidence Limits
Probability
PROBIT .010
.020
.030
.040
.050
.060
.070
.080
.090
.100
.150
.200
.250
.300
.350
.400
.450
.500
.550
.600
.650
.700
.750
.800
.850
.900
.910
.920
.930
.940
.950
.960
.970
.980
.990
95% Confidence Limits for cone
Estimate
-22.913
-20.813
-19.481
-18.479
-17.663
-16.969
-16.361
-15.816
-15.321
-14.865
-12.976
-11,476
-10.188
-9.032
-7.060
-6.944
-5.960
-4.992
-4.024
-3.040
-2.024
-.952
.204
1.491
2.992
4.880
5.336
5.832
6.377
6.985
7.679
8.494
9.497
10.829
12.929
Lower Bound Upper Bound
.
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Probit Transformed Responses
1.50-
1.25-
1.00-
0.75- 8
0.50-
1.00 1.50 2.00
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2.50 3.00
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1.2. Comparison.
compound 88. 
S.aureus.
compound 89. 
S.aureus
compound 90.
S.aureus
compound 91. 
S.aureus
compound 82. 
S.aureus
compound 93. 
S.aureus
compound 94. 
S.aureus
compound 90. 
MRSA
compound 91.
MRSA
compound 82.
MRSA
compound 93. 
MRSA
compound 94. 
MRSA
compound 99. 
MRSA
Total
N
3
3
3
3
2
3
2
3
3
3
3
2
3
36
Mean
86.0833
37.8190
8.3387
16.9720
64.8850
5.7180
7.3065
14.1717
17.4003
79.9297
6.9573
5.6135
10.3050
27.9638
Std. 
Deviation
11.82083
12.20855
5.95364
1.12332
26.84460
1.91459
1.72605
3.61418
.89802
19.80112
4.79502
.29204
5.19126
30.03156
Std. 
Error
6.82476
7.04861
3.43733
.64855
18.98200
1.10539
1.22050
2.08665
.51847
11.43218
2.76841
.20650
2.99717
5.00526
95% Confidence 
Interval for Mean
Lower 
Bound
56.7188
7.4913
-6.4510
14.1815
-176.3042
.9619
-8.2014
5.1935
15.1695
30.7410
-4.9542
2.9897
-2.5908
17.8025
Upper 
Bound
115.4479
68.1467
23.1283
19.7625
306.0742
10.4741
22.8144
23.1498
19.6311
129.1184
18.8688
8.2373
23.2008
38.1250
Minimum
76.72
24.70
1.46
16.31
45.90
4.16
6.09
11.10
16.39
57.14
1.93
5.41
4.41
1.46
Maximum
99.37
48.85
11.78
18.27
83.87
7.86
8.53
18.16
18.10
92.96
11.48
5.82
14.18
99.37
Table 13.
1.3. Test of Homogeneity of Variances
LD50
Levene 
Statistic
8.291
df1
12
df2
23
Sig.
.000
47
1.4. ANOVA
Between Groups
Within Groups
Total
Sum of
Squares
29272.507
2293.794
31566.301
df
12
23
35
Mean Square
2439.376
99.730
F
24.460
Sig.
.000
1.5. Comparison of compounds.
(1) Compound
compound 88.
S.aureus.
compound 89. 
S.aureus
(J) Compound
compound 89.
S.aureus
compound 90.
S.aureus
compound 91.
S.aureus
compound 82.
S.aureus
compound 93.
S.aureus
compound 94.
S.aureus
compound 90.
MRSA
compound 91.
MRSA
compound 82.
MRSA
compound 93.
MRSA
compound 94.
MRSA
compound 99.
MRSA
compound 88. 
S.aureus.
compound 90.
S.aureus
compound 91.
S.aureus
compound 82. 
S.aureus
compound 93.
S.aureus
compound 94.
S.aureus
compound 90.
MRSA
compound 91.
Mean 
Differe 
nee (I- 
J)
48.264
33(*)
77.744
67(*)
69.111
33C)
21.198
33
80.365
33(*)
78.776
83(*)
71.911
670
68.683
ooo
6.1536
7
79.126
ooo
80.469
83(*)
75.778
33(*)
48.264
33f)
29.480
33
20.847
00
27.066
00
32.101oon
30.512
50
23.647
33
20.418
std. 
Error
8.1539
4
8.1539
4
8.1539
4
9.1163
9
8.1539
4
9.1163
9
8.1539
4
8.1539
4
8.1539
4
8.1539
4
9.1163
9
8.1539
4
8.1539 
4
8.1539
4
8.1539
4
9.1163 
9
8.1539
4
9.1163
9
8.1539
4
8.1539
Sig.
000, \J\J\s
.000
.000
.522
.000
.000
.000
000
95% Confidence 
Interval
Lower 
Bound
18.2781
47.7584
39.1251
-
12.3273
50.3791
45.2512
41.9254
386968~"
1.00
0
.000
.000
.000
.
23.8326
49.1398
46.9442
45.7921
1
.000
.057
.386
.200
.029
.099
.225
.416
78.2506
-.5059
-9.1392
60.5916
2.1148
-3.0131
-6.3389
-9.5676
Upper 
Bound
78.250
6
107.73
09
99.097
6
54.724
0
110.35•ifiID
112.30
25
101.89
79
98.669
2
36.139
9
109.11
22
113.99
55
105.76
46
18.278
1
59.466
6
50.833
2
6.4596
62.087
2
64.038
1
53.633
50.404
48
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67(*)
30.861 
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32.205 
50
27.514 
00
77.744
67p)
29.480 
33
8.6333 
3
-
56.546
33O
2.6206
7
1.0321
7
5.8330 
0
9.0616
7
-
71.591
OOP)
1.3813
3
2.7251
7
1.9663 
3
-
69.111
33P)
-
20.847
00
8.6333
3
-
47.913
OOP)
11.254
00
9.6655
0
2.8003
3
-
.42833
62.957
10.014
67
4
8.1539
4
8.1539 
4
9.1163 
9
8.1539
4
8.1539
4
8.1539 
4
8.1539 
4
9 1 *1 fi3
9
8.1539
4
9.1163
9
8.1539 
4
8.1539 
4
8.1539
4
8.1539
4
9.1163
9
8.1539 
4
8.1539
4
Q 4 (^*5Q
4
8.1539
4
9 -1 •ift'*. 1 1 OO
9
8.1539
4
9.1163
9
8.1539
4
8.1539
4
8.1539 
4
8.1539
4
.002
.040
.068
.093
.000
.057
.996
.000
1.00
0
1.00
0
1.00 
0
.994
.000
1.00
0
1.00
0
1.00 
0
.000
.386
QQfi.990
.001
967
72.0969
.8754
-1.3201
-2.4722
107.730
9
59.4666
38.6196
90.0720
-
27.3656
-
32.4935
35.8192
39.0479
-
101.577
2
-
28.6049
-
30.8005
31.9526
99.0976
50.8332
-
21.3529
81.4386
-
18.7322
QQR.99D
1.00
0
1.00
0
.000
'
23.8601
-
27.1859
-
30.4146
92.9439
-
19.9716
9
12.124
4
60.847 
9
65.731 
1
57.500 
2
47.758
4
.5059
21.352 
9
-
23.020
7
32.606
9
34.557
8
24.153 
2
20.924 
6
-
41.604
8
31.367
6
36.250
8
28.019 
9
-
39.125
1
9.1392
38.619
6
-
14.387
4
41.240
2
43.191
1
32.786
6
29.557
9
32.971 
4
40.000
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33
27.066 
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56.546 
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47.913
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59.167
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50.713 
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47.484 
67(*)
15.044 
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59.271
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54.580
ooo
-
80.365
33O
-
32.101
ooo
2.6206
7
11.254 
00
-
59.167
ooo
1 CQQC .DOOO
0
8.4536
7
11.682
33
74.211
67O
1.2393 
3
.10450
4.5870 
0
78.776
9.1163
9
8.1539
4
9.1163 
9
9.1163 
9
9.1163 
9
9.1163 
9
9.1163 
9
9.9865 
0
9.1163 
9
9.1163 
9
9.1163 
9
9.1163 
9
9.9865 
0
9.1163 
9
8 -m^Q. 1 3O<7
4
8 -it^a . 13*39
4
8.1539
4
8.1539 
4
9 -Me-j. 1 1 wO
9
9.1163
9
8.1539, 
4
8.1539 
4
8.1539 
4
8.1539
4
9.1163 
9
8.1539
4
9.1163
9
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0
.522
.200
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.001
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0
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10.093 
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-
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.34917
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0
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0
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67(*)
-
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0
2.8003 
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-
50.713
33(*)
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7
6.8651
7
3.2286
7
65.758oon
7.2143
3
8.5581
7
3.8666
7
68.683
00(*)
20.418
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9.1163 
9
9.1163 
9
9.1163
9
9.9865 
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9.1163
9
9.1163 
9
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9
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9.1163 
9
8.1539
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0
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0
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-
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.
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8
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36.5241
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9
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-
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-
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-
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-
22.7719
-
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-
26.1196
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50.4049
2
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32.493 
5
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1
20.853 
0
35.114
1
26.660 
5
23.431 
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.
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5
33.874 
8
38.418
5
30.527 
1
41.925
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6.3389
35.819
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17.187
7
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35.771
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.42833
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11.682
33
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3.2286
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62.529
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11.786
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7.0953
3
6.1536
7
42.110 
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71.591
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67O
15.044
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74.211 
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72.623 
17O
65.758
ooo
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33O
72.972 
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74.316
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67O
-
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-
30.861
67O
1.3813 
3
10.014
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-
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3
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4
8.1539
4
9.1163 
9
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4
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9
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4
4
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4
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9
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0
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.999
.
20.9246
-
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81.0103
.
18.3039
.
23.4318
.
26.7576
92.5156
.
19.5432
.
21.7388
.
22.8909
36.1399
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41.6048
32.9714
-
18.4810
44.2254
39.0975
35.7718
32.5431
42.9861
40.7905
39.6384
-
109.112
2
60.8479
31.3676
40.0009
91.4533
-
28.7469
-
33.8748
-
39.047
9
30.414
6
13.959 
0
41.668
6
43.619
5
33.214
9
.
32.543
1
40.429
2
45.312
5
37.081
6
23.832 
6
72.096 
9
101.57 
72
92.943 
9
48.570
3
104.19 
79
106.14 
88
95.744 
2
92.515 
6
102.95 
86
107.84 
18
99.610 
9
-
49.139
8
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28.604 
9
19.971 
6
-
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0
31.225
6
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S.aureus
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3
10.443 
00
72.972
33(*)
1.3438
3
3.3476 
7
80.469
83(*)
32.205 
50
2.7251
7
11.358 
50
59.271 
50(*)
-
.10450
1.6930 
0
8.5581
7
11.786 
83
-
74.316
170
1.3438 
3
4.6915 
0
75.778
33(*)
-
27.514
00
1.9663
3
6.6670
0
54.580
OOH
4.5870
0
2.9985
0
-
4
8.1539 
4
8.1539
4
9.1163
9
8.1539 
4
9.1163
9.1163 
9
9.1163 
9
9.1163 
9
9.9865 
0
9.1163
9
9.9865 
0
9.1163 
9
9.1163 
9
9.1163
9.1163 
9
9.1163 
9
8.1539, 
4
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4
8.1539
4
8.1539 
4
9.1163 
9
8.1539
4
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9
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.000
1.00
0
1.00 
0
.000
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1.00 
0
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.000
1.00
0
1.00 
0
.999
.980
.000
1.00 
0
1.00 
0
.000
.093
1.00
0
1.00 
n°
37.2006
40.4292
102.958
6
-
32.1818
33.3339
113.995
5
65.7311
36.2508
44.8841
95.9970
-
33.6301
38.4185
42.0838
45.3125
-
107.841
8
34.8695
38.2171
105.764
6
57.5002
-
28.0199
36.6532
.000
1.00
0
1.00
0
88.1056
-
25.3992
-
30.5271
1.00
9
19.543 
2
42.986
1
34.869
5
26.638 
6
46.944
2
1.3201
30.800 
5
22.167 
1
22.546 
0
33.421
1
35.032 
5
24.967 
5
21.738 
8
-
40.790
5
32.181 
8
28.834
1
45.792
1
2.4722
31.952
6
23.319 
2
21.054
4
34.573
2
36.524
1
26.119 53
MRSA
compound 91. 
MRSA
compound 82. 
MRSA
compound 93.
MRSA
compound 94.
MRSA
3.8666
7
7.0953 
3
69.624
67(*)
3.3476
7
4.6915
0
4
8.1539 
4
8.1539
4
8.1539
4
9.1163
9
0
QQQ .999
.000
1.00
0
1.00
0
33.8529
37.0816
99.6109
-
26.6386
-
28.8341
6
22.890 
9
39.638
4
33.333
9
38.217
1
* The mean difference is significant at the .05 level.
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Appendix 2. Mulliken Charges.
8
Figure 1. trimethylphosphoniurnyl group.
Trimethytphosphoniumyl group
C(l) -0.222177
C(2) -0.213277
C(3) 0.014848
C(4) -0.276021
C(5) -0.216624
C(6) -0.228538
H(7) 0.277859
H(8) 0.248322
C(9) -1.137709
H(10) 0.213902
H(l 1)0.273105
H(12) 0.279131
H(13) 0.321 121
H(14) 0.320852
P(15) 2.162966
C(16) -1.143236
C(17) -1.161136
C(18) -1.163300
H(19) 0.297914
H(20) 0.304726
H(21) 0.289493
H(22) 0.288541
H(23) 0.306278
H(24) 0.297 168
H(25) 0.290679
H(26) 0.287863
H(27) 0.287248
Table 1. Mulliken charges for atoms of trimethylphosphoniumyl group.
•ifi
Figure 2. Triethyl phosphoniumyl group
Triethylphosphoniumyl group
C(l) -0.226492
C(2) -0.219851
C(3) -0.080802
C(4) -0.228649
C(5) -0.225642
C(6) -0.228908
H(7) 0.272433
H(8) 0.242755
C(9) -0.890940
H( 10) 0.245 140
H(ll) 0.271163
H(12) 0.275542
H(13) 0.299127
H(14) 0.290662
P(15) 1.797111
C(16) -0.885802
C(17) -0.870733
C( 18) -0.887062
H(19) 0.282752
H(20) 0.290687
C(21) -0.599891
H(22) 0.299530
H(23) 0.269272
C(24) -0.601909
H(25) 0.2761 54
C(26) -0.600010
H(27) 0.282371
H(28) 0.265784
H(29) 0.217542
H(30) 0.234254
H(3 1)0.266904
H(32) 0.221 820
H(33) 0.2227 12
H(34) 0.266260
H(35) 0.222676
H(36) 0.234038
Table 2. Mulliken charges for triethyl phosphoniumyl group.
V
Figure 3. Tnpropyi phosphomumyl group.
tripropyl phosphoniumyl group
C(l) -0.227416
C(2) -0.227352
C(3) -0.087249
C(4) -0.221251
C(5) -0.227134
C(6) -0.228636
H(7) 0.269811
H(8) 0.248610
C(9) -0.879826
H( 10) 0.242708
H(l 1)0.270468
H(12) 0.274048
H(13) 0.291789
H(14) 0.289009
P(15) 1.809179
C(16) -0.867403
C(17) -0.863923
C(18) -0.867555
H( 19) 0.290794
H(20) 0.277454
C(21) -0.449273
H(22) 0.292609
H(23) 0.264614
C(24) -0.446750
H(25) 0.272380
C(26) -0.451 595
H(27) 0.273642
H(28) 0.230099
H(29) 0.22 1952
C(30) -0.563331
H(3 1)0.235033
H(32) 0.221499
C(33) -0.561668
H(34) 0.241486
H(35) 0.226282
C(36) -0.562804
H(37) 0.234347
H(38) 0.213653
H(39) 0.2 14628
H(40) 0.234654
H(41) 0.212074
H(42) 0.2 15587
H(43) 0.234438
H(44)0.214615
H(45) 0.2 15704
Table 3. Mulliken charges for tripropyl phosphoniumyl group
46•
Figure 4. Tributyl phosphoniumyl group.
Tributylphosphonfumyl group
P(l) 1.779372
C(2) -0.853854
H(3) 0.267912
H(4) 0.3021 54
C(5) -0.892660
C(6) -0.874856
C(7) -0.885380
H(8) 0.265516
C(9) -0.398465
H( 10) 0.286303
C(ll) -0.076338
H( 12) 0.275583
H(13) 0.264422
C(14) -0.421 117
C(15) -0.21 1756
C(16) -0.228546
C( 17) -0.229595
H( 18) 0.293920
H(19) 0.286240
C(20) -0.2277 16
C(21) -0.228228
H(22) 0.246568
H(23) 0.269571
H(24) 0.273408
H(25) 0.268667
H(26) 0.238864
C(27) -0.395381
H(28) 0.253248
H(29) 0.2 15937
C(30) -0.451282
H(3 1)0.247 123
H(32) 0.255885
C(33) -0.426841
H(34) 0.258352
H(35) 0.223820
C(36) -0.446327
H(37) 0.196221
H(38) 0.217326
C(39) -0.572980
H(40) 0.228692
H(41) 0.221784
C(42) -0.564689
H(43) 0.191861
H(44) 0.213558
C(45) -0.563345
H(46)0.219111
H(47) 0.209647
H(48) 0.197162
H(49) 0.222645
H(50) 0.215558
H(51) 0.206734
H(52) 0.2 19002
H(53) 0.212613
H(54) 0.204579
Table 4. Mulliken charges for tributyl phosphoniumyl
VJi
Figure 5. Trimethyl ammoniumyl group
Trimethylammoniumyl group
C(l) -0.229409
C(2) -0.219067
C(3) -0.105802
C(4) -0.218911
C(5) -0.229400
C(6) -0.221250
H(7) 0.275998
H(8) 0.246496
C(9) -0.212746
H( 10) 0.246663
H(l 1)0.276030
H(12) 0.281493
H( 13) 0.286071
H(14) 0.286108
N(15) -0.747381
H(16) 0.264724
H(17) 0.270278
C(18) -0.398747
C(19) -0.398136
H(20) 0.272719
C(21) -0.398131
H(22) 0.272937
H(23) 0.295684
H(24) 0.270293
H(25) 0.272941
H(26) 0.295891
H(27) 0.264652
Table 5. Mulliken charges for trimethyl ammoniumyl.
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Figure 6. Triethyl ammoniumyl group.
Triethylammoniumyl group
C(l) -0.230182
C(2) -0.222987
C(3) -0.105507
C(4) -0.223731
C(5) -0.230567
C(6) -0.22 1823
H(7) 0.274071
H(8) 0.246256
C(9) -0.230602
H(l 0)0.2461 73
H(ll) 0.273954
H(l 2) 0.279407
H(13) 0.2827%
H(14) 0.282273
N(15) -0.733738
H(16) 0.3021 57
H(17) 0.305109
C(18) -0.215698
C( 19) -0.224766
H(20) 0.268941
C(21) -0.225765
H(22) 0.269127
H(23) 0.258947
C(24) -0.621651
C(25) -0.630892
H(26) 0.258072
C(27) -0.621470
H(28) 0.251006
H(29) 0.239341
H(30) 0.2381 70
H(31) 0.250854
H(32) 0.239532
H(33) 0.237974
H(34) 0.258173
H(35) 0.238342
H(36) 0.238701
Table 6 Muiliken charges for triethyl ammoniumyl group.
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Figure 7. Tripropj'lammoniumyl group.
Trlpropytammoniumyl group
C(l) -0.231974
C(2) -0.22641 7
C(3) -0.1 13841
C(4) -0.21 5822
C(5) -0.231222
C(6) -0.222305
H(7) 0.271425
H(8) 0.254361
C(9) -0.222503
H(10) 0.244526
H(l 1)0.2722%
H(12) 0.277498
H(13) 0.279542
H( 14) 0.286022
N(15) -0.752015
H( 16) 0.293009
H(17) 0.274394
C(18) -0.184551
C( 19) -0.192535
H(20) 0.264727
C(21) -0.186981
H(22) 0.2651 54
H(23) 0.255048
C(24) -0.473621
H(25) 0.241581
C(26) -0.487582
H(27) 0.212702
H(28) 0.285393
H(29) 0.2 13499
C(30) -0.481029
H(3 1)0.240979
C(32) -0.573857
H(33) 0.213005
H(34) 0.233548
H(35) 0.214552
H(36) 0.230949
H(37) 0.241351
H(38) 0.237587
H(39) 0.2 14982
C(40) -0.577901
H(41) 0.2 14601
H(42) 0.230181
C(43) -0.577246
H(44) 0.235733
H(45) 0.252755
Table 7. Mulliken charges for tripropyl ammoniumyl.
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Figure 8 Tributyl ammoniumyl.
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tributyl ammoniumyl
C(l) -0.232137
C(2) -0.226081
C(3) -0.1 13438
C(4) -0.215924
C(5) -0.231304
C(6) -0.222445
H(7) 0.270618
H(8) 0.254799
C(9) -0.221777
H(10) 0.244315
H(ll) 0.271541
H(12) 0.276684
H(13) 0.278584
H(14) 0.285436
N(15) -0.753751
H(16) 0.291 197
H(17) 0.273863
C( 18) -0.1 87635
C(19) -0.194860
H(20) 0.263655
C(21) -0.1 88626
H(22) 0.264213
H(23) 0.253630
C(24) -0.445236
C(25) -0.569292
C(26) -0.459656
H(27) 0.2 15345
H(28) 0.284425
H(29) 0.215412
C(30) -0.452790
H(31) 0.214792
C(32) -0.420377
H(33) 0.218163
H(34) 0.228982
H(35) 0.228680
H(36) 0.204545
C(37) -0.569207
H(38) 0.205960
H(39) 0.2261 81
H(40) 0.228706
H(41) 0.2053 11
C(42) -0.569382
H(43) 0.232601
H(44) 0.205379
H(45) 0.217057
H(46) 0.228003
C(47) -0.424955
H(48) 0.205272
H(49) 0.2 17682
H(50) 0.205342
H(51) 0.225930
C(52) -0.423963
H(53) 0.232007
H(54) 0.248524
Table 8. Mulliken charges for tributyl anvmoniumyl
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Figure 9. Dimethylpyridium
Dimethyl
C(l) -0.180168
C(2) 0.272976
N(3) -0.889321
C(4) 0.263075
C(5) -0.1 80555
C(6) -0.082604
C(7) -0.590071
H(8) 0.350262
C(9) -0.165505
H(10) 0.3 16582
C(ll) -0.590924
H(12) 0.31 1854
H(13) 0.287967
H(14) 0.287919
C(15) -0.150885
C(16) -0.212238
lyridium
C(17) -0.231 171
C(18) -0.223109
C( 19) -0.23 1182
C(20) -0.212317
H(21) 0.254304
H(22) 0.273555
H(23) 0.278223
H(24) 0.274257
H(25) 0.256268
H(26) 0.241 577
H(27) 0.258729
H(28) 0.255585
H(29) 0.240354
H(30) 0.261211
H(3 1)0.2553 53
Table 9. MuHiken charges for dimethylpyridium.
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Figure 10. hydroxypyndinium.
hydroxypyridinium
C(l) -0.332684
C(2) 0.257157
N(3) -0.893708
C(4) 0.262496
C(5) -0.378201
C(6) 0.516539
H(7) 0.341428
H(8) 0.347557
C(9) -0.178728
H(10) 0.343810
H(l 1)0.31 1221
O(12) -0.687797
H(13) 0.287327
H(14) 0.286647
C(15) -0.095387
C(16) -0.222447
C(17) -0.220232
C(18) -0.230004
C(19) -0.219840
C(20) -0.226396
H(21) 0.251433
H(22) 0.274176
H(23) 0.273731
H(24) 0.266309
H(25) 0.228562
H(26) 0.437031
Table 10. Mulliken charges for hydroxypyridinium.
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Figure 11. Quinolinium.
quinolinium
C(l) -0.156473
C(2) 0.444726
N(3) -0.955260
C(4) 0.307199
C(5) -0.358580
C(6) -0.055524
C(7) -0.227608
C(8) -0.202138
C(9) -0.219908
H( 10) 0.336902
H(ll) 0.315554
H(12) 0.323632
H( 13) 0.280956
H( 14) 0.292404
C(15) -0.085644
C(16) -0.219934
C( 17) -0.226161
C(18) -0.226140
C( 19) -0.226345
C(20) -0.222103
H(2 1)0.248331
H(22) 0.267005
H(23) 0.273188
H(24) 0.270946
H(25) 0.248067
C(26) -0.226873
C(27) -0.178754
H(28) 0.287995
H(29) 0.302572
H(30) 0.295984
H(3 1)0.291983
Table 11. Mulliken charges for Quinolinium
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